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ABSTRACT
Retinitis pigmentosa (RP) is a heterogeneous group of genetic disorders characterised by a
progressive pigmentary degeneration of the retina. The disease manifests as night-
blindness, tunnel vision, and often total loss of sight. RP is a common cause of blindness,
affecting around 1 in 4000 of the general population.
RP can be inherited as an autosomal dominant, recessive or X-linked condition, with
autosomal recessive RP (arRP) accounting for at least a third of all cases. RP also occurs as
a feature of several syndromes in association with non-ocular features. One example is the
autosomal recessive condition Bardet-Biedl syndrome (BBS), in which RP is associated
with Polydactyly, mental retardation, hypogonadism and obesity. To date, five genes have
been identified as causing autosomal recessive forms of RP, and linkage to another twelve
chromosomal regions has been established, four of these involving BBS. The aim of this
project was to identify loci for recessive forms of RP by genetic linkage analysis, using
patients with arRP and BBS, and to test for mutations in any resultant candidate genes.
Pedigrees with arRP from south-central Sardinia, an ethnic outlier with a high prevalence of
recessive disease, were studied initially. Linkage analysis was carried out using genome-
wide microsatellite markers, and genetic heterogeneity was identified among the 11 families
studied. Examination of the data revealed potential linkage to D14S80, on chromosome
14q 11, in a subset of families. Fine mapping with further markers in this region identified a
region of homozygosity in one consanguineous family, suggesting identity-by-descent.
A strong candidate gene for RP, coding for the neural retina specific leucine zipper (NRL),
was found to be located within the region of homozygosity. NRL is an evolutionarily
conserved protein which is expressed in all layers of the neural retina, and is thought to
have a role in the transcriptional regulation of retinal genes, including rhodopsin. The NRL
gene was studied in the consanguineous family by direct sequencing and mutation analysis,
but no mutations were identified within the coding region.
A total of 29 BBS pedigrees collected worldwide were studied using markers in regions
where linkage was established during the course of the study. These loci are located on
chromosomes 11 q 13, 16q21, 3pl3-pl2 and 15q22.3-q23. The results revealed significant
genetic heterogeneity, with most families showing linkage to 11 q 13 and 15q22.3-q23, and
others being consistent with linkage to the 16q chromosomal region. Some of the larger
pedigrees could be assigned to specific loci, but many of the smaller families were too
small for a definite assignment. The results of multipoint linkage and haplotype analyses in
these three linked chromosomal regions, especially in consanguineous pedigrees, have
helped to narrow down the region of search for candidate genes, in particular refining the
BBS4 locus from an interval of 4.3 cM to 1.6 cM.
Both of these studies highlight the difficulties of linkage mapping in autosomal recessive
disorders, and the power of homozygosity mapping in genetically heterogeneous conditions.
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Retinitis pigmentosa (RP) is the name given to a set of hereditary progressive pigmentary
disorders of the retina. With a prevalence of around 1 in 4000 in most populations
(Boughman, Conneally and Nance, 1980) and affecting approximately 1.5 million people
worldwide (Kumar-Singh et al, 1993), RP is a major cause of blindness. As the retina has a
limited response to disease the term retinitis pigmentosa covers a genetically very
heterogeneous group of disorders. RP can be inherited as an autosomal dominant,
autosomal recessive or X-linked recessive condition and is often categorised on this basis,
although in many simplex cases the mode of inheritance cannot be determined
(Heckenlively, 1988a). Most cases are thought to be monogenic but there is also a report of
digenic RP inheritance, involving mutations in two separate loci (Kajiwara, Berson and
Dryja, 1994). Much clinical variability exists both between and within each genetic
subgroup, although it is generally accepted that the X-linked and autosomal recessive forms
result in a more severe phenotype (Bird and Jay, 1994). The first symptoms of RP are
usually a progressive deterioration in night vision (night blindness), followed by
constriction of the peripheral visual fields (tunnel vision) due to degeneration of the rod
photoreceptors within the eye. The disease frequently results in loss of central vision
causing total blindness in the middle decades of life. To date, mutations in ten genes have
been shown to cause RP when mutated, but linkage between RP and many other
chromosomal locations has been reported. Identification of more causative genes could
lead to a better understanding of the disease mechanisms involved, and also allow for
genetic counselling for the many families affected by this disorder. This study is concerned
with attempting to map and identify genes responsible for autosomal recessive RP in a
Sardinian population, and for Bardet-Biedl syndrome, an example of an RP syndrome
where other organ systems are also affected (reviewed in Green et al, 1989).
1.1 - THE GENETICS OF RP
Retinitis pigmentosa is usually inherited as an autosomal dominant, autosomal recessive or
X-linked recessive condition, and is frequently classified by its mode of inheritance. It is
often possible to categorise cases of RP on the basis of the family history of the patient, but
commonly there is not sufficient information about the family, or insufficient cooperation
for this to be done, and the genetic type of RP must remain undetermined. There is also the
possibility of maternal inheritance, which occurs when the gene causing RP is present in the
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mitochondrial genome, such as in NARP syndrome (neuropathy, ataxia and retinitis
pigmentosa).
If there is only one affected individual presenting this can make it difficult for the disease to
be classified genetically. Such cases are referred to as "simplex", and many may be due to
autosomal recessive inheritance, but it is important not to presume that this is the case
without sufficient evidence. The term "sporadic" should not be used unless a mutational or
environmental event has been suggested as the cause of the RP in an individual. This can
include rubella or cytomegalovirus infection, or exposure to chloroquine (used to treat
arthritis) or thioridazine (used in the treatment of psychoses) (Heckenlively, 1988a).
RP is generally accepted as being a monogenic disorder, with mutations in only one gene
being responsible in each pedigree. However, Kajiwara, Berson and Dryja (1994) reported
digenic inheritance, involving mutations in two gene loci, in three RP families. This poses
the possibility that RP could in some cases be an oligogenic trait, with more than one gene
influencing the phenotype. This could account for the clinical variability seen within
families, but would greatly complicate the search to identify specific causative genes.
1.2 - CLINICAL SYMPTOMS OF RP
Typical retinitis pigmentosa primarily affects the rod photoreceptors, with the cones only
being involved as the disease progresses (Deutmann, 1977). Ophthalmoscopic examination
reveals progressive pigmentary changes in the retinas of both eyes, with the migration of
pigment-laden cells from the retinal pigment epithelium (RPE) to the mid-periphery of the
retina where many of the rods are found. This pigment often accumulates around the blood
vessels in bone corpuscle-like arrangements as shown in figure 1.1B, but can also be seen
in irregular clumps or spots, or is even absent in some cases (retinitis pigmentosa sine
pigmento). The blood vessels become narrowed but probably only as a secondary feature
of the disease (Deutmann, 1977). As the rod cells act as receptors for dim light, one of the
first symptoms of RP is night-blindness, followed by a narrowing of the visual fields
(tunnel vision) as the rods are also essential for peripheral vision, being more concentrated
in the mid-peripheral retina (Krill, 1972). Central vision is usually preserved until the end
stages of RP. The loss of rod function can be measured by a scotopic electroretinogram
(ERG) which measures electrical activity in the retina in response to flashes of light,
following dark-adaptation of the patient (Heckenlively, 1988a). Photopic (cone) responses
can also be measured in light-adapted conditions. In a typical RP patient, the rod responses
show reduced or absent amplitudes, and may also be temporally delayed. It is sometimes
possible to detect ERG changes in presymptomatic cases of RP (Humphries, Kenna and
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Figure 1.1
A: normal optic disc and retinal vessels
B. RP patient - optic disc pallor and attenuation of retinal vessels, with typical bone spicule
pigmentary deposits
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Farrar, 1992). Other diagnostic tests that can be used include a visual field test,
measurement of visual acuity, a dark adaptation test, fluorescein angiography, and the
electro-oculogram (EOG) which measures the standing potential generated by the RPE
(Heckenlively, 1988b).
As the course of the disease progresses with continuing loss of the rod cells, more extensive
changes take place in the retina, as seen by fundus photography (fig. 1.1). The optic nerve
develops a waxy pallor, the blood supply to the retina diminishes due to the attenuation of
the blood vessels, and the retina visibly thins. The cone cells, which mediate daylight
(colour) and central vision, also begin to die, causing further reduction in visual acuity.
Eventual loss of central visual acuity is usually due to macular involvement, macular cysts
or posterior subcapsular cataracts. These cataracts, characterised by yellow crystalline
changes in the lens, are commonly seen in all types of RP with an overall frequency of
41%, although the cause of their formation is unknown (Heckenlively, 1988b).
1.2.1 - Clinical Classification of Genetic Subgroups
The age of onset, severity and progression of RP varies between the genetic sub-types, with
X-linked RP and autosomal recessive RP usually being more severe than autosomal
dominant RP. However, clinical heterogeneity has also been identified within each of the
three genetic classes. Studies of autosomal dominant RP (adRP) have revealed two broad
subdivisions of the disease with type I, a "diffuse" form, and type II, a "regional" form
(Massof and Finkelstein, 1981; Lyness et al, 1985). Type I shows a widespread loss of rod
function, with night-blindness in childhood and later cone involvement. Type II shows a
regionalised loss of both cone and rod function, with night-blindness onset in adulthood. A
further variant that has been identified with autosomal dominant inheritance is sector RP,
where the dystrophy is restricted to specific parts of the fundus (usually the lower half) and
the progression of the disease is very slow. Sector RP has also been inherited in rare cases
as an autosomal recessive condition, and has been observed in X-linked carriers (Deutmann,
1977). It is worth considering that, as with many dominant conditions, the expressivity of
adRP varies between generations, and Ernst and Moore (1988) have suggested that up to
30% of obligate carriers show only mild symptoms of the disease.
Excluding cases of recessively inherited RP where the disease appears as part of a
syndrome, subtypes of autosomal recessive RP (arRP) have also been identified. One
example is preserved para-arteriolar retinal pigment epithelial RP (PPRPE), a severe early-
onset form of RP (Heckenlively, 1988c). Kaplan et al (1990) have suggested that most
cases of arRP can be subdivided into two main groups, precocious onset (average age 7.5
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years) with severe progression, and later onset (average age 17 years) with mild
progression. A third type, also reported by Grondahl (1987a) and Bonneau et al (1992) is
the "senile" form of arRP, where onset of symptoms does not occur until the fifth or sixth
decade.
A sub-division of X-linked RP (xlRP) has been made based on the clinical symptoms of
female carriers. The presence of a tapetal reflex, a golden metallic sheen seen in the
fundus, and first observed by Falls and Cotterman (1948), has been noted in the
heterozygotes of some families. Linkage studies originally suggested the presence of two
separate xlRP loci, RP2 and RP3 (a third locus, RP15, has now been reported by McGuire
et al, 1995b), and some studies predict that families with a tapetal reflex are linked to the
RP3 locus, recently identified as the RPGR gene (Meindl et al, 1996), as opposed to the
RP2 locus (Nussbaum et al, 1985, Denton et al, 1988, Musarella et al, 1989).
1.3 - PREVALENCE OF RP
Retinitis pigmentosa appears in all ethnic groups with comparable gene frequencies.
Overall prevalence rates have ranged from 1 in 1500, from a study in Birmingham (UK)
(Bundey and Crews, 1984), to 1 in 7000 in Switzerland (Ammann, Klein and Franceschetti,
1965), but generally an average of around 1 in 4000 is reached (figure 1.2).
Many studies have been carried out in an attempt to ascertain the relative proportions that
each genetic subgroup accounts for in the RP population. Results from various studies
differ considerably, and several reasons for this are possible, such as the method of
recruitment used by the researchers; the sampling area covered; the method of
ascertainment used; and the population under consideration (e.g. level of consanguinity, sex
and age distribution). The high degree of variability seen between these figures (figure 1.3)
shows that they can be regarded only as guidelines to the relative proportions of genetic
groups. It is important to discriminate between figures for the number of affecteds as
opposed to the number of probands, or families, as this can introduce a bias into the
analysis of dominant and simplex cases. The large proportion of arRP in some studies may
be attributable to high levels of consanguinity, or inbreeding in the population, as seen in
Sardinia.
Overall, it seems apparent that xlRP is generally the least common form of RP, and that
simplex cases make up the largest proportion of RP patients. While some of the simplex
cases will be due to recessive inheritance in small families, in genetic analyses there still
remains an excess of simplex RP beyond probabilistic expectations (Boughman and
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Author Area Studied Prevalence Rate
Ammann, Klein and Franceschetti
(1965)
Switzerland 1 in 7000
Merin and Auerbach (1976) Israel 1 in 4500
Boughman, Conneally and Nance
(1980)
USA and Canada 1 in 3700
Bundey and Crews (1984) Birmingham, UK 1 in 1500
Bunker et al (1984) Maine, USA 1 in 3544
Hu (1987) China 1 in 4016
Grondahl(1987b) Norway 1 in 4440
Fossarello et al (1993) South-Central Sardinia 1 in 3355
Figure 1.2
Prevalence of retinitis pigmentosa
% % % %
Author Area simplex arRP adRP xlRP
Jay (1982) England 42.1 15.5 24.4 18.0
Hu (1982) China 48.3 33.1 11 7.7
Boughman and Fishman
(1983)
Illinois 50.0 16.0 21.7 9.0
Grondahl (1986) Norway 53 30 15 2
Kaplan et al (1990) France 41.9 21.5 20.4 12.9
Haim (1992) Denmark 43.2 22.6 6.9 10.8
van den Bom, Bergen and
B leeker-Wagemaker
(1992)





53.8 21.5 5 1.3
Figure 1.3
Distribution (in percentages) of genetic subgroups in families with retinitis pigmentosa
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Fishman, 1983; Jay, 1982). Several reasons have been suggested for the high number of
simplex cases:
Some may be phenocopies of RP, or multifactorial in nature
New mutations in dominant RP genes
Reduced penetrance of adRP (mildly affected individuals are not diagnosed)
Simplex females may be xlRP heterozygotes
Simplex males may have xlRP (Pagon, 1988).
It is clear that genetic diagnosis would be greatly aided by the development of genetic tests
for commonly mutated genes. This could in turn allow the refinement of clinical correlates
for specific subtypes of RP and also allow for a more accurate prognosis of the disease.
1.3.1 - arRP in the Sardinian Population
Sardinia is a recognised ethnic outlier among European populations, second only to the
Lapps in genetic isolation (Cavalli-Sforza and Piazza, 1993). The island has been inhabited
for at least 10,000 years, probably initially by a heterogeneous population of settlers, but
isolation from the mainland, low immigration, the mountainous geography, and malaria
have all contributed to genetic drift from the rest of Europe (Workman et al, 1975).
Consanguinity has been comparatively common, even in the middle of this century,
particularly in isolated mountain villages, increasing endogamy within these communities.
Genetic disease is common among the Sardinian population, with high rates of insulin-
dependent diabetes and haemoglobinopathies. In studies of genetic disease among the
Sardinian population, such as (3-thalassaemia, relative genetic homogeneity is observed,
with one specific mutation (P39) accounting for 95% of P-thalassaemic chromosomes
(Rosatelli et al, 1992).
The overall prevalence of RP in south-central Sardinia is 1 in 3,355, with the relative
proportions of each genetic type listed in figure 1.3 (Fossarello et al, 1993). It is likely that
the high proportion of recessive cases of RP is due to the extent of inbreeding and isolation
within the small communities in this part of the island. Furthermore, religion and the rural
economy have favoured large families, making the mode of inheritance easier to establish.
However, this figure is still likely to be an underestimate of the true level of arRP, as many
families may have only one affected child. Interestingly, in a study of adRP in Sardinia, a
single rhodopsin mutation was found to account for RP in three of a total of eight families
(Fossarello et al, 1993). A different rhodopsin defect accounted for RP in another of the
families, so that this one gene alone was responsible for 50% of adRP, a figure much higher
than in other populations, where rhodopsin mutations are thought to cause a quarter of
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adRP cases (Dryja, 1992). This result agrees with previous reports of genetic homogeneity
in the Sardinian population (Figus et al, 1995), and makes it a suitable candidate population
in which to study genetic disease.
1.4 - RP SYNDROMES
Pigmentary retinopathy is a feature common to many human disorders, where other organ
systems are also affected. These syndromes can be subdivided into four general classes:
i) lipid or mucopolysaccharide disorders
ii) syndromes involving the central nervous system
iii) syndromes with muscular involvement
iv) RP in association with deafness
However, the retinopathy observed in such cases is often not "typical RP", and may be
secondary to metabolic disturbances produced by the disease, which can in some cases be
treated (Deutmann, 1977). Also, the spectrum of retinal degeneration seen among patients
may include true RP as well as other types of pigmentary retinopathy. The two most
common RP syndromes, Usher syndrome and Bardet-Biedl syndrome, are discussed, with
reference to genetic linkage studies carried out for each condition.
1.4.1 - Usher Syndrome
This is an example of an autosomal recessive syndrome, with classic RP associated with
deafness. It is the most common RP syndrome with a prevalence of 6-10% among RP
patients, and 3-6% among the deaf population (Heckenlively, 1988d). This highly
heterogeneous disorder is usually seen in two equally prevalent forms, type I with profound
hearing loss, no speech, vestibular ataxia and RP (usually diagnosed pre-puberty), and type
II with milder nonprogressive hearing loss and RP (usually diagnosed post-puberty)
(Kimberling, Weston and Moller, 1994). The clinical distinctions between types I and II
have been established by the identification of six separate loci, four for type I: USH1A at
14q32 (Kaplan et al, 1992), USH1B at 11 q 13.5 (Kimberling et al, 1992), USHJC at
11 p 15.1 -p 14 (Keats et al, 1994) and USH1D at 10q21-q23 (Wayne et al, 1996); and two for
type II: USH2A at 1 q41 (Kimberling et al, 1995) and USH2B, which has not yet been
localised (Kimberling, Weston and Moller, 1994). A third form of Usher syndrome, type
III, involving RP and progressive hearing loss, is estimated to account for 2% of Usher
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patients. Linkage between this condition and 3q21-q25 has been established using Finnish
pedigrees (Sankila et al, 1995).
The gene for Usher type IB on chromosome 11 q was recently identified as the
unconventional myosin, myosin VIIA, after null mutations were seen in this gene in patients
(Weil et al, 1995). This protein is expressed predominantly in the inner cochlea, RPE, lung,
kidney and testis (Hasson et al, 1995). Studies of the mutated myosin VII gene in mice
resulted in congenital deafness, but no retinal degeneration (Gibson et al, 1995), and El-
Amraoui et al (1996) subsequently showed that this protein is expressed only in the RPE,
and not the photoreceptors, of adult mice, but is expressed in both cell types in man. This
suggests that the RP seen in Usher type IB patients is due to the presence of defective
myosin VIIA in human rods and cones.
1.4.2 - Bardet-Biedl Syndrome
Bardet-Biedl syndrome (BBS) is an autosomal recessive condition generally characterised
by the presence of the five cardinal features of retinopathy, post-axial Polydactyly (Figure
1.4), hypogenitalism, obesity and mental retardation. The severe tapetoretinal degeneration
seen is often described as "atypical" retinitis pigmentosa, with early macular involvement,
later pigmentation, and commonly resulting in blindness in the second or third decade
(Riise, 1987, Green et al, 1989). It has been suggested that renal anomalies should also be
added to the diagnostic criteria, as they are a significant cause of death among BBS patients
(Harnett et al, 1988, Green et al, 1989, Odea et al, 1996, Riise, 1996), and that syndactyly
and brachydactyly are more commonly seen than Polydactyly (Green et al, 1989). Green et
al (1989) have further suggested that the apparent mental retardation is often simply due to
visual impairment, and that hypogenitalism is much more pronounced in males. It is
possible that many female cases of BBS are diagnosed as having non-syndromal RP, due to
the lack of obvious hypogenitalism, and the high variability of the other cardinal features.
Other symptoms occasionally associated with the disorder include diabetes mellitus,
hearing impairments, dental anomalies, liver disease and hypertension (R. Riise, personal
communication). However all these symptoms are highly variable, and clinical
heterogeneity is seen both within and between families. This can lead to misdiagnosis of
BBS with overlapping conditions such as Laurence-Moon syndrome, where spastic-
paraplegia is present, but obesity and dysmorphic extremities are absent, or other clinically
similar disorders such as Biemond syndrome type II, Alstrom syndrome or Weiss syndrome
(Schachat and Maumenee, 1982). Obviously, identification of the genetic defect would
greatly aid classification in uncertain cases.
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Figure 1.4
Polydactyly in Bardet-Biedl Syndrome patients.
a). Extra post-axial digit on foot.
b) Scar left following surgical removal of extra post-axial digit on hand.
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The incidence of BBS differs greatly between populations. Particularly high prevalences are
seen among the Bedouin tribes throughout the Middle East (1 in 13,500) (Farag and Teebi,
1989) and in Newfoundland (1 in 17,500) (Green et al, 1989) especially when compared to a
study in Switzerland which found the incidence to be 1 in 160,000 (Amann, 1970). As BBS
is known to be inherited as an autosomal recessive condition, this is probably due to
increased levels of consanguinity in these populations (and possible under-diagnosis in other
populations).
Linkage has been reported to four distinct BBS loci. The first gene to be localised (BBS2)
was mapped, using a large inbred pedigree from the Negev region of Israel, to chromosome
16q21 (Kwitek-Black et al, 1993). However this locus was excluded in another
consanguineous family from a different Bedouin tribe. The second study involved thirty-one
multiplex North American families, and found linkage to 11 ql3 (BBS1) in seventeen of
these, but no evidence of linkage to chromosome 16 in the remaining unlinked families,
indicative of yet another BBS locus (Leppert et al, 1994). The presence of this BBS1 locus
has since been confirmed by homozygosity mapping with two large inbred pedigrees from
Puerto Rico (Cornier et al, 1995). Sheffield et al (1994) then mapped the second of the
Bedouin pedigrees to a ten centiMorgan (cM) interval on chromosome 3pl3-pl2 (BBS3),
and the same group (Carmi et al, 1995a) then used a DNA pooling strategy to identify a
fourth BBS locus (BBS4) at 15q22.3-q23 in a third Bedouin family. This high level of
genetic heterogeneity is unexpected for such a comparatively rare disorder, and as yet none
of the actual genes have been identified. Carmi et al (1995b) have suggested that the
genetic heterogeneity in BBS is at least partially responsible for the clinical variation
observed. However, their study was carried out using a small number of patients, from three
inbred Bedouin kindreds (each linked to BBS2, BBS3 or BBS4), and the suggested
correlations between phenotype and genotype can only be regarded as observations until a
larger population has been studied, and any findings confirmed.
1.5 - MAPPING AND ISOLATION OF RP GENES
1.5.1 - Methods
Two approaches have commonly been used to identify and isolate causative genes for
specific diseases. The first of these is the positional cloning ("reverse genetics") approach,
which initially uses linkage analysis to localise the disease gene to a small region of the
genome. This region can then be examined in more detail by physical mapping, using
techniques such as yeast and bacterial artificial chromosome contig mapping and pulsed
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field gel electrophoresis. The linkage work is ideally carried out in large pedigrees, as
combining data from several small families can be complicated by genetic heterogeneity.
Known cytogenetic rearrangements associated with the disease can also help narrow down
the region of search, as can deletions, or expanded triplet repeats (Bates and Lehrach,
1994). This approach is guaranteed to be successful providing that sufficient samples are
available, and that markers at a suitably high genetic density are studied. Over forty disease
genes have been cloned using this technique (Collins, 1995), including Duchenne muscular
dystrophy (Monaco et al, 1986), cystic fibrosis (Rommens et al, 1989, Riordan et al, 1989,
Kerem et al, 1989) and retinoblastoma (Friend et al, 1986). However, this method is time-
consuming and expensive.
The second method is the candidate gene approach where specific genes of known function
are screened for mutations in patients with the disease. As each patient's DNA is examined
individually for mutations, genetic heterogeneity is not a complication. Also, if a mutation
is found, then deductions can be made concerning the physiology of the disease, as the
function of the gene product is already known. However, a negative result could be due to
limitations of the mutation screening technique used, or perhaps the sample size was not
large enough to include any individuals with defects in that specific gene.
It is becoming increasingly common to use a combination of linkage analysis and candidate
gene screening to identify causative genes - the "positional candidate" approach (Collins,
1995). The initial part of the study involves the use of markers to narrow down the region
of interest within the human genome, and any known candidate genes from this region are
then examined for mutations, or further linkage with the disease. This cuts out the need for
large scale physical mapping projects, where linkage may only have narrowed down the
region of interest to several megabases of DNA. This type of approach has been used to
identify over twenty genes (Collins, 1995), including the RP genes rhodopsin (Dryja et al,
1990) and peripherin/RDS (Farrar et al, 1991)(see fig. 1.5).
1.5.2 - Rhodopsin
The first report of linkage in adRP was from McWilliam et al (1989), who were working
with a large early-onset and severely affected Irish pedigree. They achieved a two-point lod
score of 14.7 between the marker D3S47 and RP (at zero recombination), and this locus on
the long arm of chromosome 3 was designated RP4. In the region of D3S47 there were four
potential candidate genes for RP including two coding for proteins involved in visual
transduction, the alpha subunit of transducin (Blatt et al, 1988), and rhodopsin (Nathans
and Hogness, 1984, Sparkes et al, 1986). Dryja et al (1990) decided to sequence one of
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these candidates, rhodopsin, in 20 North American affecteds, and found 5 patients to be
heterozygous for a point mutation changing a highly conserved proline to a histidine at
residue 23. They then extended their panel of patients to 148, and found this mutation in a
total of 17, but in none of their 102 unaffected controls.
Following this original finding, almost a hundred mutations have been identified in the
rhodopsin gene (Dryja and Li, 1995) among patients in Europe, North America and Japan,
accounting for around a quarter of all cases of adRP. Nearly all cause dominant RP, and are
mostly missense mutations, but three recessive alleles have also been identified, two of
which are "null" mutations, coding for a non-functional protein (Rosenfeld et al, 1992,
Kumaramanickavel et al, 1994). Interestingly, two missense mutations in the rhodopsin
gene have also been identified in patients with autosomal dominant congenital stationary
night blindness, a benign disorder diagnosed by night blindness, reduced visual acuity and
characteristic ERG changes (Dryja et al, 1993, Sieving et al, 1995). Recently, Souied et al
(1996) studied a family with a rhodopsin mutation where three affected members had
retinitis punctata albescens (RPA), a form of RP with white dots deep in the retina, and one
member had "typical" RP. RPA has previously been reported in a family with a
peripherin/RDS mutation (Kajiwara et al, 1993). Souied et al (1996) suggested that the
RPA phenotype may be induced by another genetic, or environmental, factor such as
specific alleles of the apolipoprotein E gene (apoE), as the lipoprotein coded for by this
gene may be involved in the formation of the white deposits seen in RPA. Huq et al (1993)
previously reported an association between certain haplotypes of this gene (E2 and E4) and
the RP phenotype, and the E4 allele of the apoE gene was seen to cosegregate with RPA in
this family, suggesting a possible role for this gene in the RPA phenotype.
Rhodopsin is a major component of rod outer segments, and an intrinsic protein of the disc
membrane. It is composed of two covalently linked molecules, the apoprotein opsin (coded
for by the rhodopsin gene on 3q) and 11 -cis retinal, a vitamin A derivative. Light causes
the 11 -cis retinal to isomerise to all-trans retinal and this photo-excited rhodopsin molecule
activates the G-protein transducin, which then triggers the phototransduction pathway
(Nathans, 1992). It appears that in vitro many of the adRP mutations cause the rhodopsin
protein to accumulate in the rough endoplasmic reticulum (ER), as opposed to being
transported to the cytoplasmic membrane, or alter the opsin molecule so that it is unable to
bind 11 -cis retinal (Sung et al, 1994). Studies on dominant rhodopsin mutations in
Drosophila have suggested that the mutant protein interferes with the wild-type molecules,
perhaps by forming complexes, and prevents them being processed by the ER (Colley et al,
1995). Work with transgenic mice has led Sung et al (1994) to suggest that the carboxy-
terminal region of rhodopsin is required for correct transport of the protein, and that
alteration or loss of this region leads to accumulation of the defective protein in the ER,
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eventually causing cell death. However, unlike the situation in Drosophila, the transport of
the wild-type protein is not impaired, suggesting that mammals have a different mechanism
for transporting the normal newly synthesised opsin molecules.
1.5.3 - Rod cGMP Phosphodiesterase a and (3 Subunits
After the activation of rhodopsin in visual transduction, the G-protein transducin is
stimulated, releasing its GTP-bound alpha subunit, which in turn stimulates the multimeric
protein cGMP phosphodiesterase (PDE). This protein consists of three types of subunits, a,
P and y. The holoenzyme contains one of each of the large catalytic a and P subunits,
which are very similar in structure, and both of these bind a small inhibitory y subunit (Lem
et al, 1992). On stimulation of the protein in response to light, the two y subunits
dissociate, the active aP dimer hydrolyses cyclic GMP, hence reducing the intracellular
level of cGMP, in turn causing the cGMP-gated cation channels to close (Fig. 1.5) (for
review see Palczewski, 1994).
After the discovery that the mouse rd gene, which causes a severe retinal degeneration,
codes for the p subunit of PDE (PDEB) (Lem et al, 1992) this became a strong candidate
gene for human RP. The gene, which comprises 22 exons covering around 43 kb (Weber et
al, 1991), was mapped to the telomeric region of chromosome 4 (4pl6), close to the
Huntington disease gene locus (Altherr et al, 1992). Riess et al (1992a) attempted to
identify mutations in the PDEB gene and its 5' flanking region, using single-stranded
conformation polymorphism (SSCP) analysis in RP families but only identified
polymorphic variants (Riess et al, 1992b).
McLaughlin et al (1993) then used the same technique in a partial screen (7 exons) of the
gene in 99 unrelated arRP patients, and identified four mutations segregating with the
disease, two of which were nonsense mutations. In the same year, Suber et al (1993) also
identified a causative nonsense mutation in the PDEB gene in Irish setter dogs with a
recessive rod/cone dysplasia. The next mutation identified in the PDEB gene was found to
cause autosomal dominant congenital stationary night blindness (CSNB) (Gal et al, 1994),
as seen with some rhodopsin mutations (Dryja et al, 1993). It was suggested that the
missense mutation (His258Asp), occurring in a highly conserved residue, in this form of
CSNB may inhibit the binding of the y subunit to the P subunit, such that about half of the
PDE enzyme is permanently in a partially active state. In a further screen of 92 arRP
patients, McLaughlin et al (1995) identified a total of seven mutations, and this has led to
the suggestion that mutations in PDEB account for approximately 5% of arRP mutations in
the North American population. Bayes et al (1995a) have also identified a tandem
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duplication of 71 base-pairs in exon 1 of the PDEB gene in a Spanish consanguineous arRP
family. As mutations in this gene only accounted for 1 out of 19 pedigrees studied, this
suggests that a similar proportion of arRP could be due to PDEB mutations in European
populations.
Because of the sequence and functional similarities between the (3 subunit and the a subunit
Huang et al (1995) have also examined the a subunit gene, on chromosome 5q31.2-34,
using SSCP analysis. They used DNA from 340 unrelated RP patients (173 arRP patients)
and screened 19 of the 22 exons. A total of three mutations were identified in two recessive
RP patients, two of which were nonsense mutations, and the other of which altered a highly
conserved amino acid.
1.5.4 - Rod cGMP-Gated Cation Channel a Subunit
The hydrolysis of cyclic GMP to 5'GMP by active phosphodiesterase causes the closure of
cGMP-gated cation channels that are located in the plasma membrane of the rod outer
segment. This results in hyperpolarisation of the rod photoreceptor cell, inhibiting the
release of neurotransmitter at the cell synapse (for review see Yau, 1994). The rod cGMP-
gated cation channel protein is made up of two similar subunits, a and (3, although a y
subunit of unknown function has also been identified (Chen et al, 1994). The a subunit
gene has been mapped to human chromosome 4pl4-ql3, and the sequence of its ten exons
determined (Pittler et al, 1992). The SSCP technique was used to screen the entire coding
sequence and exon-intron boundaries of the a subunit cGMP-gated channel (CNCG1) in
173 autosomal recessive and 94 dominant RP patients (Dryja et al, 1995). In addition to
polymorphic changes, they identified five mutations in four arRP pedigrees. Three of these
mutations were null alleles (two nonsense mutations and a large deletion), while the other
two were a missense mutation (Ser316Phe) and a frameshift that should truncate the protein
by 32 amino acids.
In one of the arRP families in which a paternally-derived mutation was identified, Dryja et
al (1995) were unable to find the other mutated allele of the CNCG1 gene, and indeed saw
from polymorphic analysis that both two affected sibs inherited different maternal alleles.
They suggest that the other recessive mutation could be in another gene coding for a protein
that interacts with the product of CNCG1 in some way. This type of digenic inheritance
has previously been proposed for RP with mutations in the peripherin/PDS gene and the
ROM-1 gene being found in three families (Kajiwara, Berson and Dryja, 1994). Another
possibility is that the heterozygous nonsense mutation in the CNCG1 gene in this family
does not cause RP. Interestingly, one of the panel of patients with adRP also carried
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the Ser316Phe missense mutation in heterozygous form. This individual belonged to a
family where a known rhodopsin mutation had previously been found, and there appeared
to be no clear phenotypic difference between individuals in the family who only had the
rhodopsin mutation or both the rhodopsin and the CNCG1 mutation. Also, the unaffected
mother carried only the CNCG1 mutation. It seems likely that the rhodopsin defect is the
cause of RP in this family and that the CNCG1 mutation is a variant with no obvious
phenotypic effect (Dryja et al, 1995).
The CNCG1 gene product has previously been expressed in vitro in human embryonic
kidney (HEK) cells (Dhallan et al, 1992) to measure its channel activity, and Dryja et al
(1995) decided to express the missense Ser316Phe allele and the Arg654(l-bp del) allele in
cultured HEK cells. They detected very low levels of mutant channels in the plasma
membrane, although any found were functional, and found that most of the mutant protein
failed to be incorporated into the plasma membrane. Thus, it seems that a lack of cGMP-
gated channels correlates with the photoreceptor degeneration for these two recessive
mutations. In both of these mutations, and in the null alleles, the cells would be expected to
behave as if exposed to constant light, as there would be few or no channels open, as
happens when cGMP levels fall due to hydrolysis by activated PDE. However, the cause of
the rod photoreceptor degeneration remains unknown.
1.5.5 - Peripherin//?D5
The peripherin/RDS gene encodes a photoreceptor specific glycoprotein found in the outer
membrane of rods and cones in the rim region of outer segment discs (Connell and Molday,
1990). The human gene was first identified by homology to the mouse rds (retinal
degeneration slow) gene, which, when homozygously mutated, causes abnormal
development and then a slow degeneration of the photoreceptors. The gene maps to human
chromosome 6pl2, consists of 3 exons, and encodes a 346 amino acid protein with over
90% homology to the predicted mouse protein (Travis et al, 1991). Comparisons of these
sequences with bovine and rat mRNAs have shown 85% identity overall, with the
conserved features of four putative membrane spanning regions, a potential glycosylation
site, and 12 cysteine residues (Travis et al, 1991). The native protein has a molecular
weight of 39 kD, and forms a disulphide-linked homodimer in the disc membrane, non-
covalently bonding with a disulphide-linked rom-1 dimer (Goldberg, Moritz and Molday,
1995). It has been suggested that this complex has a role in anchoring the discs to the
cytoskeleton of the photoreceptor cell, through homotropic or heterotropic protein
interactions (Moritz and Molday, 1996).
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Linkage to 6pl2 was reported for a large Irish kindred by Farrar et al (1991) who went on
to identify a three basepair deletion of a highly conserved cysteine residue in the
peripherin/RDS gene using SSCP. Affected members of this family showed late-onset
adRP, although cone and rod ERG responses were greatly reduced in young affected
members. These features are similar to the phenotype seen in heterozygous rds mice, where
outer segments are present but disorganised and shortened, and degeneration of
photoreceptors is much slower than in homozygotes (Hawkins, Jansen and Sanyal, 1985).
A further three mutations were identified by Kajiwara et al (1991) in another three adRP
families, after studying 139 unrelated adRP patients. Each mutation affected a highly
conserved residue, either removing or substituting a proline. However, in 1994 Kajiwara,
Berson and Dryja reported that one of these mutations affecting a leucine at position 185
(changing it to a proline) was also present in another two families, and in asymptomatic
carriers of RP. Each of these three families transmitted the disease to less than 50% of their
offspring. The probands were born to unaffected parents, and the mutation was present in
unaffected members. This led Kajiwara et al to the conclusion that an additional gene
defect at another locus could be responsible (as opposed to reduced penetrance of the
peripherin/RDS gene), and discovery of mutations in the ROM1 gene (discussed below) in
these families seemed to confirm this.
While most mutations in the peripherin/RDS gene have been seen to cause dominant RP,
other dominant retinal dystrophies have also been associated. These include RP with bull's
eye maculopathy (Kikawa et al, 1994), macular dystrophy (Wells et al, 1993), adult
vitelliform macular dystrophy (Wells et al, 1993), central areolar choroidal dystrophy (Reig
et al, 1995), pattern macular dystrophy (Nichols et al, 1993, Weleber et al, 1993), fundus
flavimaculatus (Weleber et al, 1993) and retinitis punctata albescens (Kajiwara et al, 1993).
Different phenotypes, including macular and peripheral dystrophies, have even been
reported in a single family with a three base-pair deletion (Weleber et al, 1993). This
suggests that other genetic and/or environmental factors could influence the clinical course
of the disease. One possibility is the involvement of proteins that interact with peripherin
in the rods and cones of the retina. This is exemplified by the proposed digenic inheritance
involving peripherin//?D5 and ROM-1, as it is has been shown that peripherin non-
covalently interacts with rom-1, a photoreceptor-specific protein (Bascom et al, 1992a,
Goldberg, Moritz and Molday, 1995). It further suggests that other genes implicated in RP
could also be responsible for macular disorders.
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1.5.6 - ROM-1
The ROM-1 gene was first identified by differential hybridisation to select human retina-
specific cDNAs (Bascom et al, 1992a). The isolated cDNA encoded a 351 amino-acid
polypeptide, which was found to be 35% identical to human peripherin (55% identity at
nucleotide level) with four regions of extended homology. Affinity-purified antibodies
originally localised the gene product to the outer segments of rod photoreceptors, and this
led to the designation "retinal outer segment membrane protein", rom-1 (Bascom et al,
1992a). Recently, bovine rom-1 (or a closely related homologue) was also identified in
cone outer segment disc membranes (Moritz and Molday, 1996). Because of the similarity
to peripherin, Bascom et al (1992a) also studied rom-1 and peripherin with a view to
identifying an association between the two proteins. Their results led them to suggest that
disulphide-linked dimers of both rom-1 and peripherin bind non-covalently to each other,
and that other proteins may associate with this complex. Further, they have hypothesised a
major role for this complex in the morphogenesis of the disc rim.
Bascom et al (1992b) then mapped the rom-1 gene to 11 q 13, a region to which four
retinopathies have been linked (Bascom et al, 1993) including Usher syndrome type IB
(Kimberling, Weston and Moller, 1994) and Best's disease (BMD), a juvenile vitelliform
macular degeneration (Stone et al, 1992). Because of the mutations already identified in
the peripherin gene (Farrar et al, 1991, Kajiwara et al, 1991), the similarities between the
two proteins, and the disorders linked to the region of the gene, Bascom et al (1993)
screened the gene for variants in 180 patients with inherited retinal degenerations. Six
polymorphisms and three rare variants were identified, but none were associated with the
disease.
Nichols et al (1994) also screened the rom-1 gene for mutations in 11 unrelated Best's
disease patients, but found no alterations in the coding sequence, and Graff et al (1994)
effectively excluded the gene in a multigeneration Swedish BMD family linked to 11 q 13,
because of a recombinational event between an intragenic ROM-1 polymorphism and the
disease phenotype.
ROM-1 mutations have however been identified in three families with RP in association
with peripherin mutations (Kajiwara, Berson and Dryja, 1994). This digenic inheritance
pattern required that both a mutation in ROM-1 and in the peripherin gene was present in
affecteds, with either mutation alone not causing RP. Two distinct one base pair insertions
were found in exon 1 of ROM-1, both resulting in a prematurely terminated protein ending
at codon 131. As the protein is severely truncated, it is likely that these mutant alleles do
not code for a functional gene product (i.e. are null alleles). Subsequently, Sakuma et al,
(1995) found one of these ROM-1 mutations in a simplex RP patient, but could not identify
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any mutation in peripherin/RDS. On examination, the mutation was also present in other
younger members of the family, only one of whom showed mild disease symptoms,
suggesting phenotypic heterogeneity. Possible explanations for this are that another
unidentified locus influences the phenotype, or that the mutation is not causing RP in this
case (Sakuma et al, 1995). More recently, Bascom et al (1995) identified four potentially
pathogenic ROM-] alleles among patients with adRP, without detectable peripherin defects,
but the affected families were too small to establish co-segregation of the disease with the
alleles.
1.5.7 - Myosin VIIA
Recessive mutations, predicted to code for non-functional proteins, have been identified in
the gene coding for myosin VIIA in patients with Usher syndrome type I (USHl)(Weil et
al, 1995). This is a disease which involves profound congenital deafness, vestibular
dysfunction and RP. Linkage to USH1 has been localised to four chromosomal regions;
14q32 (Kaplan et al, 1992), 11 pi5 (Smith et al, 1992), 11 q 13.5 (Kimberling et al, 1992)
and 10q21-q23 (Wayne et al, 1996). In humans, the region 11 q 13.5 (USH1B) is syntenic to
part of mouse chromosome 7, where the mutation responsible for the shaker-] (sh-1) mouse
is located. This mouse exhibits deafness and vestibular dysfunction, but no retinal
degeneration. Gibson et al (1995) identified three mutations (two missense and one splice
acceptor) in a gene encoding an unconventional myosin, type VII, in the shaker-] mouse.
This led Weil et al (1995) to consider the human homologue of this gene as a candidate for
USH1B, especially since some patients have microtubule defects in photoreceptor, nasal
ciliar, and sperm cells. They identified the human myosin type VIIA gene from a yeast
artificial chromosome covering the USH1B locus, and screened the gene for mutations in
nineteen families that showed linkage to this region. Five mutations were found: two
nonsense mutations, two missense mutations altering highly conserved residues, and one
deletion of two amino acids, one of which is highly conserved. It was suggested that all of
these mutations encode null alleles.
Myosin VIIA is an unconventional myosin, a family of proteins related to striated-muscle
myosin in head sequence, but divergent in tail sequence. All myosins move along actin
filaments by hydrolysing ATP, acting as motor molecules. Antibodies to the tail portion of
myosin VIIA have been produced to study its expression pattern (Hasson et al, 1995) and
have shown that it is expressed in the cochlear hair cells, RPE, testis, lung and kidney. The
presence of the protein in the RPE and cochlea confirms its role in Usher syndrome, and
abnormalities in sperm and bronchial function have been noted in some patients (Hasson et
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al, 1995). No kidney abnormalities have been reported, but this is possibly due to other
unconventional myosins having overlapping functions in kidney cells.
Unexpectedly, sh-1 mice with defects in the homologous gene do not have a retinal
degeneration. Possible explanations for this discrepancy included: the specific mouse
mutations observed, since each of the mutants still expressed myosin VIIA, the timescale of
the retinal degeneration, and that the corresponding human mutations could cause a
nonsyndromic deafness, as the gene for this condition (DNFB2) also maps to 1 lql3
(Guilford et al, 1994). However, a study of the expression of myosin VIIA in both mouse
and man revealed that the protein is expressed in the RPE only in mouse, but in the RPE
and photoreceptors of humans (El-Amraoui et al, 1996).
1.5.8 - RPGR
The most recently identified RP gene is responsible for the commonest form of X-linked
RP, previously designated RP3. RPGR (RP GTPase regulator) was identified by positional
cloning, using information from microdeletions in RP3 patients, and has been shown to be
mutated in seven affected individuals (Meindl et al, 1996). At present, the function of the
protein is unknown, but it appears to be ubiquitously expressed. The N-terminal half of the
predicted protein shows homology to RCC1 (regulator of chromatin condensation), which
regulates a GTPase, while the C-terminal half is highly charged and contains a putative
isoprenylation site for membrane anchorage. Meindl et al have suggested that the RPGR
protein may interact with a small GTPase, anchoring it to a membrane or vesicle, and hence
acting as a regulator of a specific type of membrane transport. This gene may also be
responsible for potentially allelic retinal dystrophies mapping to Xp21.
1.5.9 - Chromosomal regions linked to RP
In addition to the genes discussed above, mutations have recently been identified in the
microsomal triglyceride transfer protein gene in abetalipoproteinemia (Bassen-Kornzweig
syndrome), a rare recessively inherited disorder, characterised by fat malabsorption,
cerebellar ataxia and retinal degeneration (Narcisi et al, 1995). Mitochondrial mutations in
the gene coding for subunit 6 of ATPase have also been observed in NARP syndrome
(neuropathy, ataxia and retinitis pigmentosa) (Holt et al, 1990). Due to the high ATP-
dependence of the retina, pigmentary retinopathy is often a symptom of mitochondrial DNA
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mutations affecting the genes involved in oxidative phosphorylation (Brown, Lott and
Wallace, 1994).
Apart from the ten genes previously mentioned, where mutations have been identified,
many other chromosomal regions are linked to RP (see figure 1.6). However, this still
leaves many pedigrees that do not show linkage to any of these reported loci, such as the
postulated RP8 locus involved in a family of Irish origin (Kumar-Singh et al, 1993).
1.6 - CANDIDATE GENES FOR RETINITIS PIGMENTOSA
From the results of linkage studies it is apparent that many RP genes are still to be
identified. After localisation, the next stage is to search for candidate genes in the region of
interest. Many genes fall into this category, including all the genes coding for proteins
involved in the phototransduction cascade (see figure 1.5), all retina-specific proteins, other
unconventional myosins, genes implicated by vertebrate and invertebrate models (see
figure 1.7 for mouse models), and those involved in clinically related disorders. This
covers numerous possible loci, many of which have been mapped in the human genome.
1.6.1 - Genes Involved in Phototransduction
Rhodopsin is a protein consisting of opsin (coded for by the rhodopsin gene) covalently
bound to 11-c/s-retinal, which isomerizes to all-trans-retinal following photoactivation.
Retinol (vitamin A) and its derivatives are water-insoluble, and must be transported around
the body by carrier proteins. Seven of these specific binding proteins have been
characterised and mapped: serum retinol-binding protein (RBP4) to 10q23-q24, cellular
retinol-binding protein (RBP1) to 3q21-q22 (Rocchi et al, 1989), cellular retinoic acid-
binding protein (RBP5) to 15q22-qter (Guerts van Kessel et al, 1991), cellular retinoic acid-
binding protein II (CRABPIf) to 1 q21 (Elder et al, 1992), cellular retinal-binding protein
specific to visual tissue (CRALBP) to 15q26 (Sparkes et al, 1992), interphotoreceptor
retinol-binding protein (RBP3) to chromosome 1 Oq 11.2 (Liou et al, 1987, GDB), and
cellular retinol-binding protein type II (RBP2) to the short arm of chromosome 3, close to
RBP1 (Demmer et al, 1987). Deficiency of vitamin A is known to result in clinical
features similar to RP, as seen in abetalipoproteinemia, a defect in fat absorption, due to
mutations in the microsomal triglyceride transfer protein (MTP) (Narcisi et al, 1995).
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photoreceptors lost by 9 months.
Figure 1.7
Summary of Mouse Mutants with Retinal Degeneration (after Wright, 1994)
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with autosomal dominant, recessive, and simplex RP, and Ushers type I, using RFLPs at
each locus, and Southern blotting. No gene rearrangements or deletions were found, and no
linkage disequilibrium was observed within the sets of patients, or in the pedigrees studied,
suggesting these genes are not a major cause of RP.
Transducin, a guanine nucleotide-binding protein, is a heterotrimer composed of an a, [3
and y subunit. The a subunit exchanges GDP for GTP following interaction with activated
rhodopsin, and then dissociates from the (3 and y subunits to activate cGMP
phosphodiesterase. This step amplifies the visual signal, as one activated rhodopsin
molecule can in turn activate up to 500 transducin molecules. The a subunit varies between
rods and cones, with the rod specific gene (GNAT1) located on chromosome 3p21 (OMIM,
1996). Recently, Dryja et al (1996) identified a missense mutation in a highly conserved
residue (gly38asp) in the GNAT] gene, in affected individuals with the Nougaret form of
congenital stationary night blindness. It is possible that, as with rhodopsin and PDEB, this
gene could cause both RP and CSNB. The cone specific a subunit (GNAT2) has been
mapped to chromosomal region 1 p 13 (Morris and Fong, 1993), and is a candidate for RP18,
although Ringens et al (1990) could not identify any gene rearrangements, or suggestion of
linkage to this gene, in a set of 526 patients with autosomal dominant, recessive or simplex
RP. The a, (3 and y subunits are cell specific in the rods and cones (Peng et al, 1992), but
rod transducin is also found in vertebrate taste cells (Ruiz-Avila et al, 1995).
The y subunit of cGMP PDE is a candidate for RP as causative mutations have been
identified in the a and (3 subunits. The gene, located on chromosome 17q21.1, has been
studied by Hahn, Berson and Dryja (1994) in 704 patients with RP and related hereditary
retinal diseases. None of the sequence variants correlated with any phenotype, so it seems
unlikely that this gene is a common cause of RP, although it is still a candidate for the RP17
locus which maps to 17q22-q24 (Bardien et al, 1995). Studies of transgenic mice
homozygous for a null mutation in the PDEG gene have shown that they display
biochemical changes similar to those seen in mice homozygous for mutations in the PDEB
gene, suggesting that mutations in the PDEG gene could result in an RP phenotype in
humans (Tsang et al, 1996). Also, this work has shown that the gamma subunit is required
for normal function and stability of cGMP phosphodiesterase.
The cyclic nucleotide gated channel is composed of a (3 subunit, in addition to the a
subunit. The (3 subunit is coded for by a complex locus on chromosome 16q21, previously
thought to consist of two separate loci coding for a p subunit, and a glutamic-acid rich y
subunit, coded for by GAR] (Ardell et al, 1995). Recent studies have shown that the GAR1
locus in fact encodes the N-terminal portion of the P subunit. This portion, and the C-
terminal two-thirds of the protein can be transcribed separately, or as a polycistronic
message, separated from each other by six exons which are highly evolutionarily divergent
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(Ardell et al, 1996). Highly homologous channels are also found in kidney cells, and Ardell
et al (1995) have suggested that mutations in these genes could cause kidney defects as well
as retinopathy, making it an ideal candidate gene for the BBS2 locus.
1.6.2 - Genes Involved In Recovery Phase
All the genes involved in re-opening of the cGMP channels and dark adaptation following
phototransduction activation are potential retinopathy genes. The removal of cations from
the cell during phototransduction results in activation of recoverin (cancer-associated
retinopathy protein), which is thought to bind to rhodopsin kinase, and hence inhibit
rhodopsin phosphorylation (Chen et al, 1995). The three exons of the recoverin gene on
chromosome 17p 13 were screened by SSCP for mutations in 42 Spanish arRP families, but
none were detected (Bayes et al, 1995b). This gene also seemed to be a good candidate for
RP13, which maps to 17p 13, but analysis in the large South African family linked to this
locus failed to find any mutations (Greenberg et al, 1994). However, a particulate
(membrane) human photoreceptor guanylate cyclase (retGC), which catalyses the formation
of cGMP, has also been assigned to chromosome 17p 13 (Oliviera et al, 1994), so that this
gene (GUC2D) is worth investigating. Indeed, Perrault et al (1996) have recently identified
mutations in this gene in patients with Leber's congenital amaurosis, the earliest and most
severe form of inherited retinopathy. Guanylate cyclase activating proteins stimulate
synthesis of cGMP in photoreceptors by activating retGC. Two genes coding for GCAPs
(GCAP1 and GCAP2), are located on chromosome 6p21.1, within two centiMorgans of the
peripherin/RDS gene (Subbaraya et al, 1994). They have identical gene structures and
chromosomal localisations, and 50% sequence similarity, suggesting they arose relatively
recently from gene duplication (Surguchev et al, 1996). GCAP1 is specific to rod outer
segments (ROS), and GCAP2 is found in the retina, but not the ROS (Gorczyca et al, 1995)
- both are good candidates for RP. A gene for guanylate kinase (GUK1), the protein that
catalyses the conversion of GMP to GTP, has been localised to Iq32-q41, making it a
candidate for RP12, and Usher syndrome type II (Fitzgibbon et al, 1996).
Rhodopsin kinase (RK) helps inactivate rhodopsin by phosphorylation of the carboxy
terminal region of the protein. The RK gene has been assigned to chromosomal band 13q34
(Khani et al, 1996), the same region as Stargardt's dominant macular dystrophy has been
mapped to, suggesting RK as a possible candidate for this disease. Following this
phosphorylation, arrestin (S-antigen) can then bind to rhodopsin to block transducin
activation. Mutations in the arrestin gene on chromosomal region 2q37 have been
identified in patients with Oguchi disease, a rare form of CSNB, with very slow dark
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adaptation and fundus discolouration (Maw et al, 1995). Fuchs et al (1995) found a
homozygous one base-pair deletion in arrestin in five unrelated Japanese patients, which
was thought to result in a nonfunctional protein.
1.6.3 - Retina-specific Proteins
While many retina-specific proteins are known to exist, a large number have not yet been
characterised, or assigned a chromosomal location. A few that have been studied in more
detail, and seem to be good candidates for retinal degenerations, are mentioned here.
Phosducin is a protein present in the photoreceptors and the embryologically related pineal
gland. It is thought to have a role in phototransduction, by binding to the y and [3 subunits
of transducin following activation of the a subunit by rhodopsin. The human phosducin
gene has been mapped to chromosome Iq25-q32.1, and is highly homologous to the mouse
gene (Abe, Kikuchi and Shinohara, 1994). Two forms of RP have been linked to this
region, Usher type II and RP12, although the phosducin gene has recently been excluded in
RP12 (van Soest et al, 1996).
A 61 kiloDalton protein which is abundant and specific to the retinal pigment epithelium
has been identified, although its function is unknown (Nicoletti et al, 1995). It is conserved
in vertebrates, has been mapped to chromosome 1 p31 and appears to be developmentally
regulated. Therefore this gene (RPE65) is a candidate for disease involving the RPE.
1.6.3.1 - NRL
Using subtractive hybridisation, Swaroop et al (1991) isolated several retina-specific cDNA
clones. One of these has been shown to code for the neural retina leucine zipper gene
(NRL) (Swaroop et al, 1992), encoding an evolutionarily-conserved protein which is
expressed in all neural layers of the retina with strong expression in photoreceptor cells.
The gene has been localised to chromosomal region 14ql 1,1-ql 1.2 (Yang-Feng and
Swaroop, 1992) and consists of three exons, the first of which is untranslated (Farjo et al,
1993). It contains a basic motif and a leucine zipper domain, both of which show strong
homology to the \-maf oncogene product. This has led to Nrl being designated a member
of the bZIP family of proteins, which includes the fos and jun proto-oncogene transcription
factors. Members of this family can form hetero- or homo-dimers, and bind to AP-1 like
elements, which are thought to have a role in transcriptional regulation (Kerppola and
Curran, 1994a). The Nrl homo- and hetero-dimers can bind to the consensus sequence
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TGCN6-8GCA, and such a sequence is seen in the upstream promoter region of the
rhodopsin gene. Rehemtulla et al (1996) have shown that Nrl homodimers can mediate
transactivation of the rhodopsin promoter, and that a naturally occuring truncated form of
the protein can inhibit this transactivation in a "dominant negative" manner.
Studies of the expression of murine Nrl in the developing nervous system of mice have
shown that it is expressed exclusively in post-mitotic central nervous system neurons in
12.5 day embryos, and is down-regulated postnatally (Liu et al, 1996). High levels persist
in the photoreceptors and other retinal neurons. This suggests that Nrl plays a role in
maturation and/or establishment of the differentiated phenotype in neuronal cells, and may
maintain the differentiated state in the adult retina by regulating cell-specific gene
expression. It seems likely that Nrl has further target genes, in addition to rhodopsin, and is
a strong candidate for human retinopathies.
1.7 - METHODS OF MUTATION DETECTION
Once a candidate gene for a retinopathy has been identified, the next step is to try and find
mutations in that gene in patients. Methods of mutation detection in genes in which no
previous defects have been reported involve scanning hundreds of basepairs of DNA, whilst
trying to avoid the laborious process of sequencing the entire gene. This is particularity
important if the gene is large and contains many exons, or if there are many patients to be
screened. Nearly all commonly used techniques involve an initial polymerase chain
reaction (PCR) step to amplify exponentially a specific segment of the target DNA. This
step can also incorporate a label, such as biotin, fluorescein or radioactivity, into the DNA
product so that it can be tracked following polyacrylamide gel electrophoresis. Screening
methods can be broadly divided into three categories; those involving chemical
modification, electrophoretic mobility or enzymatic cleavage (Prosser, 1993), each of which
will be briefly discussed.
The most commonly used chemical modification method is chemical cleavage of mismatch
(CCM), also known as HOT. CCM (Cotton, Rodrigues and Campbell, 1988) involves
amplification of normal (wild-type) and test alleles, followed by annealing to form
heteroduplexes. Mismatched cytosine residues in the heteroduplex are then modified with
hydroxylamine, mismatched thymine residues with osmium tetroxide, and the resulting
product treated with piperidine which cleaves at the modified mismatched sites. The
products are then analysed on a denaturing polyacrylamide gel, and determination of their
length allows localisation of the mutation. This method can in theory detect 100% of
mismatches, provided both alleles are labelled, and can be used on fragments of over one
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kilobase (Roberts, Bobrow and Bentley, 1992), but the chemicals involved are toxic, high
quality reagents are necessary to avoid background contamination, and the procedure is
time-consuming. Another much less commonly used technique involves addition of
carbodiimide (CDI), a large molecule which binds to double-stranded DNA at sites of
mismatched G and T residues. This bound adduct can then be detected by antibodies to
CDI, or by blocking primer extension. This technique has been used to detect mutations in
large fragments of up to 7.2kb, but it is not widely used (Cotton, 1993).
Techniques based on electrophoretic mobility include single-stranded DNA conformation
polymorphism (SSCP), heteroduplex analysis (HA), and denaturing gradient gel
electrophoresis (DGGE). SSCP (Orita et al, 1989) is a simple and straightforward method,
involving PCR, denaturation to single-stranded products, followed by analysis on a non-
denaturing gel. Under non-denaturing conditions, single-stranded DNA folds in a manner
specific to its nucleotide sequence, which affects its mobility in a gel matrix. Fragments
with alterations in the nucleotide sequence frequently have different electrophoretic
mobilities when compared to normal fragments, which can be detected as a band shift in a
non-denaturing polyacrylamide gel. The smaller the fragments under test, the more
apparent is the change in mobility, and fragments of less than 200 basepairs are optimal
(Prosser, 1993). Also, gel conditions significantly affect the rate of detection, with
variations in gel and buffer constituents, and running temperature being important (Glavac
and Dean, 1993). Optimisation of these factors is necessary for efficient detection rates.
Heteroduplex analysis is very similar to SSCP, but uses double-stranded nucleic acids,
either formed during PCR or by post-PCR annealing of normal and test products. This
technique was first described (Keen et al, 1991) using a special type of polyacrylamide gel,
Hydrolink, manufactured by AT Biochem who have subsequently produced a more specific
product (MDE gel) for this method of mutation detection. Heteroduplex analysis also
works most effectively on fragments of a few hundred base pairs, but separation of
duplexes can be achieved on shorter gels, making non-isotopic detection methods an option
(Glavac and Dean, 1995).
Denaturing gradient gel electrophoresis (DGGE) (Myers et al, 1985) separates DNA
fragments in polyacrylamide gels containing an increasing gradient of denaturant, such as
formamide, urea or temperature. The fragment initially migrates according to its size, until
it reaches a point in the gel where it starts to denature, and is retarded in the gel. The
melting point of the fragment can be predicted, and optimised, using computer simulation
programmes (Fodde and Losekoot, 1994). Often GC-rich clamps of DNA are added to the
PCR primers, to increase the sensitivity of detection by preventing complete denaturation of
the fragment (Sheffield et al, 1989). This method works best on double stranded DNA of
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less than 500bp in length and, after optimisation of conditions, detects up to 100% of
mutations. Again, this method does not require the use of radioactivity.
The first version of enzymatic cleavage of mismatched hybrids involved the use of RNase A
(Myers, Larin and Maniatis, 1985). Heteroduplexes are formed using wild-type and test
RNA (or RNA and DNA), preferably both labelled, and subjected to RNase A digestion,
which should cleave at single base mismatches. The fragments are then run on denaturing
polyacrylamide gels, allowing for localisation of the site of mismatch. However, the
cleavage is often inefficient, especially at purine bases. This has led to the use of other
enzymes, such as T4 endonuclease VII (Babon, Youil and Cotton, 1995), which cleaves at
single base mismatches and insertions and deletions. As this technique allows for sensitive
detection and localisation of mutations in large fragments of DNA, other bacterial enzymes
are now being investigated as possible alternatives, the most popular being MutS, which is
discussed below.
1.7.1 - MutS
In E. coli, several pathways exist to correct mismatches introduced during replication. The
best characterised of these is the methyl-directed mismatch repair system (for review, see
Claverys and Lacks, 1986, and Modrich, 1987). This pathway uses the products of the
mutS, mutH, mutL and mutU genes, and is dependent on the methylation of adenine residues
in d(GATC) sequences (carried out by DNA adenine methyl transferase). The mutS gene
encodes a 97 kD protein which recognises and binds to double-stranded, hemimethylated
regions of DNA containing a mismatch. It is then joined by MutH protein, a d(GATC)
specific endonuclease, which cuts the unmethylated (newly synthesised) strand of DNA, 5'
to the d(GATC) sequence. Excision by MutH proceeds from the nick to the mismatch (1-2
kb), with the help of MutU (DNA helicase II), which is present to unwind the duplex DNA.
Other proteins, such as single strand DNA-binding protein, DNA polymerase III
holoenzyme and DNA ligase are known to be involved in the reaction (Au, Welsh and
Modrich, 1992). The role of MutL is yet to be revealed, but it is known to interact with the
MutS-mismatch complex, possibly forming an interface with MutH. All four mut genes are
essential for efficient mismatch repair, as mutations in any of these genes result in a mutator
phenotype (Au, Welsh and Modrich, 1992).
This methyl-dependent repair pathway recognises and repairs single base mismatches, and
insertions or deletions of up to four bases (Parker and Marinus, 1992). However, different
base mismatches are recognised with different affinities, and the sequence context is also
thought to affect repair efficiency (Au, Welsh and Modrich, 1992). In vivo, G-T and A-C
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mismatches are poorly recognised (Modrich, 1987), and base heterologies of over four
nucleotides, and C-C mismatches, are not corrected by this pathway (Smith and Modrich,
1996).
MutS is known to be involved in two other, less efficient, repair pathways, including the
very short patch (VSP) system, where MutL is also required (Modrich, 1987). Homologues
of the E. coli MutS protein have been identified in S. typhimurium (MutS), S. pneumoniae
(HexA), S. cerevisiae (MSH1, 2 and 3), S. pombe (Swi4) (Fleck, Michael and Heim, 1992),
mouse (Rep3) and man (hMSH2) (Reenan and Kolodner, 1992). In man the hMSH2 gene
is known to have a role in Lynch syndrome (hereditary non-polyposis colorectal cancer)
when mutated (Leach et al, 1993). The most highly conserved region of these proteins lies
at the C-terminus and contains a putative helix-turn-helix DNA binding motif, and a
nucleotide binding site, for which ATPase activity has been reported (Fleck, Michael and
Heim, 1992). The ability to hydrolyse ATP is characteristic of enzymes that travel along
DNA (Haber and Walker, 1991). The bacterial enzymes also share a region of N-terminal
homology (Habere;al, 1988).
MutS has obvious applications in mutation detection systems, because of its ability to
recognise and bind to single-base mismatches. Related proteins, such as MutT and MutY,
can only recognise a small number of mismatches, and hence are of limited use in scanning
for unknown mutations (Au et al, 1989; Lu and Hsu, 1992). Several groups have already
experimented with MutS as a mutation detection system. The first of these involved
identifying mismatches in denatured and re-annealed PCR-amplified sections of the CFTR
gene (Lishanski, Ostrander and Rine, 1994). PCR products of up to 500 bp were incubated
with MutS, and binding detected by a band shift assay. All heterozygote mutations tested
were detected, due to each mutant allele producing two different heteroduplex mismatches,
by reannealing with the normal allele. MutS has also been used in an exonuclease
protection assay, again detecting mutations in the CFTR gene (Ellis et al, 1994).
Following binding of MutS to heteroduplex DNA, the mixture is exposed to T7 polymerase
digestion, digesting homoduplexes to completion. The remaining MutS-bound
fluorescently labelled PCR fragments are then detected by electrophoresis on an automated
DNA sequencer. The position of the mutation can be estimated by sizing the fragments
detected.
Immobilisation of MutS has been shown to enhance its ability to detect mismatches, and
reduce background binding (Wagner, Debbie and Radman, 1995). The protein was bound
to nitrocellulose, and washed with buffer containing biotinylated 30-mers, with and without
mismatches. Eleven of the twelve possible mismatches were detected by
chemiluminescence, even in the presence of 1000-fold excess of normal DNA, the
exception being C-C mispairs. However, as noted by Lishanski, Ostrander and Rine (1994),
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each heterozygote will result in two mismatches, in this case C-C, and G-G, which is easily
detected. This mutation detection system could also be adapted for homozygote detection,
by adding wild-type DNA to test DNA before denaturation. Feng and Winkler (1995) have
since published a protocol for production and purification of His6-MutS, Hisg-MutH and
His6-MutL fusion proteins. The binding properties of the MutS fusion protein were
indistinguishable from the native protein, providing an excellent source of protein for
testing and use in routine mutation detection assays. It may also help in the development of
genomic mismatch scanning, an approach to cloning genes using MutS, by identifying
regions of idenity-by-descent among closely related, affected individuals (Nelson et al,
1993). As this system has only been tested in S. cerevisiae it remains to be seen if it can be
applied to the human genome, which is much larger, and richer in repetitive DNA
sequences.
1.8 - AIMS
The aims of this project were:
1) To produce a MutS fusion protein, with a view to using this in mutation screening
candidate genes for autosomal recessive forms of RP.
2) During the course of this project, linkage to four loci was identified for Bardet-Biedl
syndrome, a syndromic form of RP. Thus, another aim of this study was to identify linkage
to these loci in a set of 29 BBS pedigrees collected world-wide. In particular, we hoped to
confirm genetic heterogeneity for this disorder, and if possible, further refine the location of
any of the BBS loci and perhaps localise a further BBS gene.
3) To identify linkage within a set of eleven Sardinian autosomal recessive RP families.
As the Sardinian population is a genetic outlier within Europe, with comparative
homogeneity for other genetic diseases, it was predicted that there would be reduced non¬
allelic heterogeneity for arRP, hence increasing the likelihood of detecting linkage to





2.1 - CHEMICALS AND SOLUTIONS
Chemicals were purchased from BDH Chemicals Ltd. or from Sigma Chemical Co. Ltd.,
unless otherwise stated. Media components were purchased from Difco Labs. Sterilising
was carried out by autoclaving at 15 lb/sq. in. for 20 minutes, where appropriate.
2.2 - BACTERIAL CULTURE
2.2.1. - Media and additives
Unless otherwise stated, bacteria were grown on Luria-Broth (L-Broth) or Agar,
supplemented with appropriate antibiotics and chemicals.
L-Broth/Agar
1% w/v Bacto®-tryptone, 0.5% w/v Bacto-yeast extract, 0.5% w/v sodium chloride. 1.5%
w/v agar was added if required.
Kanamycin
Kanamycin was added to broth or agar at a final concentration of 50 p.g/ml to select for
bacteria carrying resistance to this antibiotic. A stock of kanamycin at 10 mg/ml in water
was filter sterilised and stored at -20°C.
X-gal (5-Bromo-4-chloro-3-Indolyl-(3-D-galactoside)
X-gal is a substrate for the enzyme (3-galactosidase, and was added to broth or agar at a
final concentration of 0.005% to select for recombinant plasmids using blue/white colour
selection. A stock solution of 10 mg/ml in DMSO was prepared in a polypropylene tube,
wrapped in aluminium foil, and kept at -20°C.
IPTG (Isopropylthio-(3-D-galactoside)
IPTG derepresses the Lac operon, and was added to broth or agar at a final concentration of
0.25mM to select for recombinant plasmids using blue/white colour selection. A stock
solution of 250mM in water was filter sterilised, and stored at -20°C.
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2.2.2. - Bacterial strains
E. coli NM522
(Gough and Murray, 1983)





endA 1 recA 1 gyrA96 thi hsdR 17 (rk~, mk+)
relA\ supEAA A(lac-proAB)




supEAA hsdR 17 recA 1 endA 1 gyrAA6 thi-1
re/Al lac F'[/;roAB+ lacf ZAM15 Tn70(tetr)]
E. coli pop 2136
(Kusters, Jager and
van der Zeijst, 1989)
supEAA hsdR 17 mcrA+ mcrB* rk~mk+
endAl thi-1 aroB mal-\
E. coli DH5ot™
(Gibco, BRL)
(<J)80d /acZAM15) recA\ endAl gyrA96 thi-l supEAA
hsdR\7 (rk\ mk+) re/Al deoR AdacZXA-argE) U169
Key: A{lac-proAB) deletion removes the lac operon and two genes required for proline
biosynthesis. These genes are usually carried on the F' episome.
hsd (r"m") restriction minus - transformed DNA is not cleaved by endogenous
restriction endonucleases; modification minus - DNA can be used to transform r+
strains.
hsd (r"m+) restriction minus (as above); modification positive - DNA is
unmethylated by hsd methylases.
endAl mutation increases plasmid yield, especially from mini-preps.
lacI'1 mutation causes overproduction of the lac repressor, and thus minimises
levels of lac expression in uninduced wild-type cells.
recAl strains are recombination deficient, which decreases their ability to rearrange
cloned sequences.
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/acZAM15 deletion removes the amino-terminal a-peptide of (3-galactosidase.
Vectors with lac selection carry a gene that encodes this peptide and rescues the
cells by a-complementation.
thi-1 strains cannot make thiamine, and hence won't grow on minimal media.
supE mutation suppresses amber (UAG) mutations.
gyrA96 mutation confers resistance to nalidixic acid.
relAl strains can synthesise RNA in the absence of protein synthesis.
TnlO - this transposon confers resisitance to tetracycline
mcrA/B mutations block restriction of methylated DNA at specific sites.
deoR strains can uptake large plasmids.
2.3 - PREPARATION OF DNA
2.3.1 - Preparation of high molecular weight bacterial DNA
200 mis of an overnight culture of NM522 was harvested at 4,700 x g for 7 mins in a
Beckman JA-14 rotor, and resuspended in 25 mis ice-cold buffer A (lOmM Tris-HCl, pH
8.0, ImM EDTA, pH 8.0, 0.1M NaCl). This process was repeated twice, and the cells
finally resuspended in 25 mis buffer A. 5 mis of 10 mg/ml lysozyme was added, and left
for 10 mins at 37°C. 30 mis of buffer A with 2% sarcosyl and 20 pg/ml DNase-free RNase
was added and incubated at 42°C for one hour. An equal volume of Tris-buffered phenol
was added, the mixture was vortexed and spun for 5 mins at 2,400 x g. The top aqueous
layer of volume V was retained and the phenol treatment repeated a further two times. 1/10
V 3M sodium acetate, pH 5.2, and 2.5 V ice-cold ethanol were added, and left for 30 mins
at -70°C. This was then spun at 6,500 x g for 15 mins, the ethanol removed from the DNA
pellet, and the DNA vacuum dessicated. The pellet was resuspended in 250 pi TE buffer
(lOmM Tris-HCl, pH 8.0, ImM EDTA, pH 8.0), transferred to a new tube and a further 250
pi TE buffer added. DNA concentration was estimated in a spectrophotometer using the
following equation :
A260 x 50 x dilution factor = Double-stranded DNA concentration (pg/ml)
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A.260 -*■ A280 gives an estimate of the protein or phenol contamination in the sample. A pure
preparation of DNA or RNA should have a ratio of 1.8 - 2.0. If the ratio was lower than
this, the sample was phenol/chloroform extracted again until this ratio was reached.
The DNA was diluted to 1 pg/pl in TE buffer, homogenised in a glass-glass homogeniser
for ten rounds, and run out on a 0.8% agarose gel to check shearing was sufficient for use in
PCR, aiming for < 100 kb fragments.
2.3.2 - Small scale preparation of plasmid DNA
This method was modified from the alkaline-lysis method of Sambrook, Fritsch and
Maniatis (1989). 1 ml overnight culture grown in selective broth was harvested at 13,400 x
g (Scotlab MicroCentaur) for 3 mins in an Eppendorf® tube, and the pellet resuspended in
180 pi of solution 1 (25mM Tris-HCl, pH 8.0, lOmM EDTA, pH 8.0, 50mM glucose) with
10 mg/ml lysozyme added. This was then incubated on ice for 2 mins, 400 pi freshly
prepared solution 2 (0.2M sodium hydroxide, 1% SDS) was added, and the mixture
vortexed. The tube was left on ice for 5 mins, 300 pi 3M sodium acetate, pH 5.2, was
added, vortexed, and incubated on ice for 10 mins. Following centrifugation at 13,400 x g
for 10 mins, the supernatant was decanted into a new tube, 500 pi isopropanol was added,
mixed and the sample respun for 5 mins at 13,400 x g. The pellet was resuspended in 200
pi TE, 100 pi Tris-buffered phenol added, and vortexed. 100 pi chloroform:iso-amyl
alcohol (24:1, v/v) was added and vortexed, and then spun for 5 mins at 13,400 x g. The
top aqueous layer of volume V was extracted to a new tube and 1/10 V 3M sodium acetate,
pH 5.2, and 2.5 V ice-cold ethanol added. The tube was incubated at -70°C for 30 mins,
centrifuged for 10 mins at 13,400 x g, drained and the pellet of DNA dried in a vacuum
dessicator. The DNA was finally resuspended in 20 pi TE.
2.3.3. - Medium scale preparation of plasmid DNA
The protocol used was essentially the same as 2.3.2, but on a larger scale. 50 mis overnight
culture was harvested at 5,000 x g for 10 mins in a Beckman JA-20 rotor, resuspended in 2
mis solution 1 with lysozyme, and left on ice for 10 mins. 4 mis freshly made solution 2
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was added, mixed and left on ice for 10 mins. 3 mis ice-cold 3M sodium acetate, pH 5.2,
was added, and the mixture left on ice for a further 10 mins. After centrifugation for 15
mins at 5,000 x g, the supernatant was decanted to a clean JA-20 tube. Half a volume of
Tris-buffered phenol was added, the solution vortexed, half a volume of chloroform: IAA
(24:1) added, vortexed, and respun for 10 mins at 5,000 x g. The top layer was removed to
another clean tube, two volumes of ice-cold ethanol and 1/10 volume 3M sodium acetate,
pH 5.2, added, and left at -20°C for 30 mins. After centrifugation for 10 mins at 5,000 x g,
the DNA pellet was resuspended in 200 pi TE buffer, 20 pi lmg/ml DNase-free RNase
added, and incubated at 37°C for 30 mins. 20pl 3M sodium acetate, pH 5.2, and 500 pi
cold ethanol were added, and incubated at room temperature for 10 mins. The DNA was
pelleted by spinning for 5 mins at 13,400 x g in a microfuge, vacuum dessicated, and finally
resuspended in 500 pi sterile TE.
DNA concentration was estimated using a spectrophotometer (2.3.1).
2.3.4 - Extraction of DNA from blood and cultured cells
Blood samples were frozen in sodium EDTA tubes until ready for DNA extraction, when
they were defrosted on ice. DNA was extracted using the Nucleon™ II kit for large
volumes (Scotlab), following the Nucleon II "protocol a" for DNA extraction as detailed in
the booklet. Cultured lymphoblastoid cells were harvested at 550g for 5 mins, and DNA
extracted using "protocol b" (for 1 x 107 to 3 x 107 cells) as detailed in the booklet. This kit
uses a silica matrix to bind contaminating proteins, and form a partially solid interphase
between the lower organic phase and upper nucleic acid phase, following chloroform
extraction. Once extracted, the DNA concentration was determined, stocks in TE buffer
were stored at -20°C, and working dilutions (in sterile water) kept at 4°C
2.3.5 - Extraction of PCR products from agarose gels
PCR products (100 bp - 1 kb) were extracted from < 2% low-melting point agarose
(Ultrapure™ LMP agarose, BRL) gels in 1 x TAE (40mM Tris-acetate, ImM EDTA, pH
8.0) containing 0.5 pg/ml ethidium bromide (from a 10 mg/ml stock). DNA bands were
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excised after brief UV transillumination and treated with a QIAquick™ gel extraction kit
(Qiagen), which adsorbs nucleic acids to a silica-gel membrane. The protocol was followed
as detailed in the QIAquick handbook.
2.3.6 - Preparation of cDNA
A solid-phase cDNA template was constructed using Dynabeads® 01igo(dT)25 (Dynal
A.S.) as detailed in the technical handbook (second edition). Briefly, lOmls of cultured
lymphoblastoid cells were harvested, washed in PBS (phosphate-buffered saline), re-
harvested, and frozen at -20°C. When required, the cells were thawed on ice, and
resuspended by pipetting in 1ml lysis/binding buffer in an Eppendorf tube. Poly A+ mRNA
was isolated from the cell lysate using 60 (tl of Dynabeads, thoroughly washed to remove
salts and detergent, and then solid-phase cDNA synthesised using Superscript™ II reverse
transcriptase (Gibco, BRL).
2.4 - POLYMERASE CHAIN REACTION (PCR)
2.4.1 - Preparation and extraction of PCR primers
Most primers were synthesised within the MRC Human Genetics Unit by A. Gallagher, on
an ABI PCRMate™ by phosphoramidite linkage. Fluorescein (FITC) labelling was carried
out during primer synthesis by addition of FluorPrime™ (Pharmacia AB). Following
deprotection, each primer in ammonium hydroxide solution was passed through a NAP®-
10 column (Pharmacia), and eluted in lOmM Na2HP04 buffer, pH 6.8. Some primers were
provided HPLC purified, making this step unnecessary. The absorbance of the primers at
260 nm was measured using a spectrophotometer and the concentration calculated using the
following formula:
Concentration (M) = A26o/ml -s- [(nA x 16,000) + (nG x 12,000) + (nC x 7,000) + (nT x
9,600)] , where n = number of bases (A, G, C, T ) in the oligonucleotide sequence.
Other primers were obtained from Oswel DNA Services, Edinburgh. They were supplied
HPLC purified and at pre-determined concentrations.
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The melting temperature of each oligonucleotide (in °C) was calculated using the equation
[4(G+C) + 2(A+T)] °C (Itakura, Rossi and Wallace, 1984). The initial test annealing
temperature for the PCR reaction was then taken as four degrees lower than the melting
temperature. Primer pairs were designed to have as similar melting temperatures as
possible, and some sequences were checked for self-annealing and dimer formation using
the Oligo program, designed by Rychlik and Rhoads (1989).
2.4.2 - PCR of E. coli mutS gene
This reaction was carried out in a 50 pi volume in a microcentrifuge tube, containing 1 x
GeneAmp® Perkin Elmer (Roche) PCR Buffer II (0.01M Tris-HCl, pH 8.3, 0.05M KC1),
ImM MgCE, 200pM dNTPs (Advanced Biotechnologies), 150 pmoles each primer, 1.5
units AmpliTaq® DNA polymerase (Perkin Elmer, Roche) and 50 ng sheared high
molecular weight E. coli DNA (see section 2.3.1). The reaction was overlaid with mineral
oil and placed in a thermal cycler using the following programme:-
(95°C, 3 mins) x 1; (95°C, 2 mins, 65°C, 2.5 mins, 72°C, 3 mins) x 25; (72°C, 5 mins) x 1.
The primers used had the following sequences, based on the putative sequence of the E. coli
mutS gene, as described by Schlensog and Bock (1991). They were also designed to
introduce an EcoRI site at the 5' end of the PCR product, and a BamHl site at the 3' end,
for forced ligation into the pAXl 1 vector (Zueco and Boyd, 1992) (see fig. 3.1).
Forward 5' TGG GAA TTC AGT GCA ATA GAA AAT TTC GAC 3'
Reverse 5' TCT GGA TCC TTA CAC CAG GCT CTT CAA GCG 3'
2.4.3 - PCR of microsatellite markers
PCR reactions were carried out in 25 pi reaction volumes (or lOpl volumes with scaled
down recipe) in 96-well microtitre plates (Thermowell™, Costar) containing 50 ng template
DNA, 10 pmoles each primer (one of which is FITC labelled), 1 x PCR Buffer II (Perkin
Elmer, Roche), ImM MgCB, 200pM dNTPs and 1.5 units AmpliTaq DNA polymerase
(Perkin Elmer, Roche). The reactions were overlaid with mineral oil, and placed in a
Hybaid Omnigene thermal cycler with the following program:-
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(94°C, 2 mins) x 1; (94°C, 1 min; 55°C, 2 mins; 72°C, 2.5 mins) x 24; (94°C, 1 min; 55°C,
2 mins; 72°C, 10 mins) x 1. The number of cycles was sometimes extended to 30 if too
little PCR product was produced. If reactions still failed, attempts were made to optimise
the magnesium concentration, annealing temperature and concentration of the primers.
2.4.4 - PCR amplification ofNRL gene from genomic DNA
All PCR reactions were carried out as described below. For SSCP and heteroduplex
analysis 1% (0.5 pi in 50 pi reaction volume) radioactively labelled [a-32P]dCTP (10
pCi/pl)(Amersham) was added to the reaction - radioactive PCR reactions were carried out
by K. Porter. If necessary PCR products were digested with appropriate restriction
enzymes to give fragments of a suitable size for analysis.
Exon 1
Primer sequences: (expected product size = 254 bp)
Forward 5'ACAGATGACCTCAGAGAGCTGG 3'
Reverse 5'GAAAACAGACAACAGAGAGCAGGTG 3'
Reactions were carried out in a 50 pi reaction volume in microcentrifuge tubes placed in a
Perkin Elmer Cetus DNA Thermal Cycler. The reaction contained 50-75 ng template DNA,
20 pmoles each primer, 1 x PCR Buffer II (Perkin Elmer, Roche), ImM MgCE, 200pM
dNTPs and 1.5 units AmpliTaq DNA polymerase (Perkin Elmer, Roche). The following
PCR program was used:
(94°C, 2 mins) x 1; (94°C, 1 min; 64°C, 2 mins; 72°C, 2.5 mins) x 40; (94°C, 1 min; 64°C,
2 mins; 72°C, 10 mins) x 1.
Exon 2A
Primer sequences: (expected product size = 271 bp)
Forward 5'GAAGAGGGACTTGGTGAAGAGG 3'
Reverse 5'CATGCCTGGTTCACTGAAGGTG 3'
The reaction was carried out as for Exon 1.
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Exon 2B
Primer sequences: (expected product size = 337 bp)
Forward 5'CTCACTGGGCTCCACACCTTAC 3'
Reverse 5'CTTCCTCTCTTGGGCAGTCCTC 3'
The reaction was carried out as for Exon 1, except an annealing temperature of 66°C for 2
mins was used (instead of 64°C).
This PCR product was digested with PvwII (at 37°C), to give fragment sizes of 204 bp and
133bp, for SSCP analysis.
Exon 3
Primer sequences: (expected product size = 573 bp)
Forward 5'ACCGAAACAGACTGCGTGGAAG 3'
Reverse 5'CTGGTAACGATGCAGAGAACCG 3'
The reaction was carried out as for Exon 2B, with the following alterations:
10% DMSO (final concentration) was added to the reaction mixture and the magnesium
concentration was increased to 1.5mM.
This PCR product was digested with Taq\ (at 65°C), to give fragment sizes of 186bp, 254bp
and 133bp, for SSCP analysis.
2.4.5 - PCR amplification of NRL cDNA
Primers were designed to amplify the exon boundaries of the NRL gene from a solid-phase
cDNA template (see fig. 6.4). The primer sequences and cycling conditions are detailed
below. For both reactions, nested primers were designed to eliminate multiple PCR
products seen after the first round of PCR.
Exon 1/exon 2
First round: Forward 5'GAAGCTGTGCCTGTCTGGCAC 3' (Primer 1)
Reverse 5'GTAGCCAGCCAGTACAGCTCC 3' (Primer 3)
The reaction contained 2.5 pi of cDNA Dynabeads (13 pig cDNA) in 1 x GeneAmp PCR
buffer II, 200pM dNTPs, 1.5mM MgCE, 25 pmoles each primer, 5% DMSO, 5% glycerol
and 1 unit of AmpliTaq, in a 25 pi reaction volume. The PCR cycling conditions were as
follows:
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(94°C, 2.5 mins; 64°C, 1 min; 72°C, 1.5 min) x 1; (94°C, 1 min; 64°C, 1 mins; 72°C, 1.5
mins) x 35; (64°C, 1 min; 72°C, 5 mins) x 1.
Second round: Forward 5'CTGTCTGGCTCTGGCACTGA 3' (Primer 5'0)
Reverse 5'ACTGAGCTGTAAGGTGTGGAG 3' (Primer 2)
This reaction was carried out as above, except that 0.5 pi of the first round of PCR was
used (in a 25 pi reaction volume), and the annealing temperature of the PCR reaction was
reduced to 60°C.
Exon2/exon3
First round: Forward 5'CTGGCCATGGAATATGTCAATG 3' (Primer 5)
Reverse 5'GCCTTGTAGAGATCGCGCTC 3' (Primer 6)
This PCR reaction was carried out as for the second round of exonl/exon2, but with 2.5 pi
cDNA Dynabeads used as the template in a 25 pi reaction.
Second round: Forward 5'TCACTGGGCTCCACACCTTAC 3' (Primer 4)
Reverse 5'GTTTAGCTCCCGCACAGACATC 3' (Primer 7)
This PCR reaction was carried out as for the second round of exonl/exon2, but using an
annealing temperature of 63°C.
2.5 - ELECTROPHORESIS
2.5.1 - Agarose gel electrophoresis
DNA fragments were visualised following electrophoresis on 0.8%-2.0% agarose gels in 1
x TAE (40mM Tris-acetate, ImM EDTA, pH 8.0), containing 0.5 pg/ml ethidium bromide
(from a 10 mg/ml stock). DNA was loaded in 1 x buffer (type II, Sambrook, Fritsch and
Maniatis, 1989) from a 6 x stock containing 0.25% bromophenol blue, 0.25% xylene cyanol
FF and 15% Ficoll® (Type 400, Pharmacia) in water. The gels were run in 1 x TAE buffer.
Following electrophoresis DNA was visualised by UV transillumination.
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2.5.2 - Polyacrylamide gel electrophoresis
Small SDS (sodium dodecyl sulphate) polyacrylamide gels were prepared using the
discontinuous buffer system, first described by Laemmli (1970), to analyse the protein
fractions collected following induction of transformed bacterial cells. 8% separating gels,
with 5% stacking gels, were made using the following recipe:
Separating gel Stacking gel
2.65 mis 1.2 mis acrylamide:N,N'-bis-acrylamide (30:8 v/v) solution
2.5 mis 2 mis gel buffer (stacking gel: 0.5M Tris-HCl, pH 6.8, 5mM
EDTA, 0.4% SDS; separating gel: 1.5mM Tris-HCl,
pH 8.8, 5mM EDTA, 0.4% SDS)
1.65 mis 1.3 mis 3% polyacrylamide
3.2 mis 3.4 mis deionised water
10 pis 10 pis TEMED
90 pis 125 pis 10% ammonium persulphate
Butan-2-ol was layered over the top of the separating gel to ensure a smooth interface
between the stacking and separating gels, and was thoroughly removed before the stacking
gel was added.
75 pi sample was mixed with 25 pi 4 x sample buffer (0.2M Tris-HCl, pH 6.8, 8% SDS,
0.4% bromophenol blue, 40% glycerol) and 5 pi 1M DTT, and heated for 3 mins at 100°C.
The gels were run in electrophoresis buffer (25mM Tris, 250mM glycine, 0.1% SDS, pH
8.3) at 20 mA for around 90 mins. Following electrophoresis, gels were fixed in 10% acetic
acid, 20% methanol for 30 minutes and then stained with Coomassie Brilliant Blue (50%
methanol, 7% acetic acid, 0.25% w/v Coomassie Brilliant Blue R®) for 5 mins (shaking).
Gels were destained overnight in 10% methanol, 7% acetic acid with pieces of sponge
added to absorb the dye as it leached from the gel. Alternatively, gels were not stained in
Coomassie Blue, but were used for electrophoretic transfer of proteins onto nitrocellulose.
2.5.3 - Preparation and running of ALF gels
Electrophoresis of fluorescein labelled microsatellite alleles was carried out using an
Automated Laser Fluorescence (ALF™) DNA sequencer (Pharmacia). Glass plates were
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washed thoroughly and wiped with isopropanol before use. Gels were prepared with 6%
Hydrolink® (Long Ranger™, AT Biochem Ltd.), a type of high resolution polyacrylamide,
in 0.6 x TBE (0.06M Tris base, 0.05M boric acid, 0.6mM EDTA) containing 7M urea
(Ultrapure, Gibco, BRL) and polymerised with 0.0875% TEMED and 0.035% ammonium
persulphate (APS). Gels were run in the same buffer at constant power (55W) and constant
temperature (50°C), with a 1.75 second sampling interval. Samples (usually 0.5 pi each
PCR product) were added to 3-6 pi loading buffer (95% formamide, 0.8% dextran blue and
25mM EDTA, pH 9.0), with appropriate size standards amplified from M13 vector DNA
using primers designed by Dr. D. Mansfield (MRC Human Genetics Unit, Edinburgh). This
mixture was then denatured at 95°C for 3 minutes, and cooled on ice prior to loading the
total mixture on the gel.
2.5.4 - Preparation and running of sequencing gels
Sequencing reaction products were run out on denaturing 6% polyacrylamide
(acrylamide:bisacrylamide 40:2, NBL Gene Sciences Ltd.) gels containing 7M urea in 1 x
TBE. Gel plates were cleaned thoroughly with detergent, wiped with ethanol before use
and sealed together on three sides with tape. The smaller gel plate was siliconised with
dimethyldichlorosilane solution to ensure that the gel would adhere to the larger plate. Gels
were polymerised using 0.15% TEMED and 0.035% APS, and run in 1 x TBE at 60 W
constant power for at least 30 mins prior to loading. After electrophoresis at 60 W for 90-
180 mins, gels were fixed in 5% acetic acid, 15% methanol for 20 mins before drying.
Once dried onto filter paper, gels were placed next to BioMax™ (Kodak) autoradiographic
film.
2.5.5 - Preparation and running of heteroduplex analysis gels
Heteroduplex analysis gels were prepared using Mutation Detection Enhancement (MDE™)
gel solution (AT Biochem) as detailed in the protocol. This gel is thought to improve the
resolution of conformationally altered DNA molecules, when compared to conventional
polyacrylamide. Gel plates were prepared as for sequencing gels. 70 mis of 1 x gel
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solution was polymerised with 0.04% TEMED and 0.04% APS, and run in 0.6 x TBE at a
constant voltage of 20 V/cm for an appropriate length of time. 5 pi of each PCR product
was heated at 95°C for 3 minutes, slowly cooled to 37°C, and added to 1 pi gel loading
buffer (AT Biochem) ready for loading. After electrophoresis, gels were dried onto filter
paper and placed next to X-Omat (Kodak) autoradiographic film.
2.5.6 - Preparation and running of SSCP gels
SSCP analysis gels were also prepared using non-denaturing MDE gel solution (AT
Biochem) as detailed in the protocol. 60 mis of 0.5 x gel solution (without urea) was
polymerised with 0.04% TEMED and 0.04% APS, and run in 0.6 x TBE at constant power
of 7 W for 14 hours at room temperature. 2 pi of each PCR was added to 10 pi stop
solution (95% formamide, lOmM NaOH, 0.25% bromophenol blue, 0.25% xylene cyanol),
heated to 94°C for 2 minutes, and then placed on ice prior to loading. After electrophoresis,
gels were dried onto filter paper and placed next to BioMax autoradiographic film.
2.6 - MANIPULATIONS OF DNA
2.6.1 - Restriction enzyme digestion
Restriction endonuclease enzymes were obtained from Boehringer Mannheim, and came
with an appropriate buffer supplied. Digestion reactions were carried out in 20 pi volumes
in the presence of 1 x buffer concentration at the optimum temperature for at least two
hours. One unit of restriction endonuclease activity is defined as the amount of enzyme
required to fully digest 1 pg substrate DNA in one hour at the appropriate temperature
under optimal conditions. Hence, a suitable amount of enzyme was added for the quantity
of DNA in the reaction. Following each digestion, DNA was cleaned up using the
GeneClean® kit (Biol01)(as detailed in protocol) to remove salts and small DNA
fragments. This method involves binding DNA to a silica matrix in the presence of sodium
iodide, washing the DNA, and eluting in TE or water.
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2.6.2 - Ligation reactions
Ligations of the vector and insert DNA were carried out using T4 DNA ligase (1
unit/pl)(Boehringer Mannheim) in a 25 pi reaction volume. The enzyme was supplied with
a 10 x buffer (20mM Tris-HCl, ImM EDTA, 5mM DTT, 60mM KCL, 50% glycerol, pH
7.5) which was used at 1 X concentration. Usually 1 pg plasmid was used with a 1-3 times
molar ratio of insert DNA, and ligation catalysed by 1 Weiss unit of ligase, which was
added last to the reaction mixture on ice. Reactions were carried out at 16°C overnight.
2.6.3 - DNA sequencing of plasmids
This protocol was carried out using the Sequenase® T7 DNA polymerase kit, Version 2.0,
from USB (Amersham), based on the Sanger chain-termination method (Sanger, Niklen and
Coulson, 1977). 5-10 pig plasmid DNA was first digested with RNase A (final conc.
0.1 mg/ml) at room temperature for 15 mins, and then ethanol precipitated.
This DNA was resupended in 8 pi of deionised water, and 1 pi sequencing primer (10
ng/pl) and 1 pi 1M NaOH added. This mixture was left at 68°C for 10 mins to denature the
template in presence of the primer. The annealing reaction was carried out with the
addition of 4 pi TDMN (0.3M TES, 0.05M DTT, 80mM MgCl2, 0.2M NaCl, 1%
chloroform, pH 1.6) at room temperature for 10 mins. The reaction mixture was then stored
on ice until ready to use. To the reaction mix, 4 pi labelling mix was added, containing 1 pi
0.1M DTT (from kit), 0.4 pi 5 x Sequenase labelling mix, 2.1 pi LoTE (3mM Tris, pH 7.5,
0.2mM EDTA) and 0.5 pi [a-35S]dATP (12.5 pCi/pl)(Amersham). Finally, 2 pi Sequenase
enzyme, diluted 1:5 with enzyme dilution buffer (from kit) was added, and the extension
reaction incubated for 5 mins at room temperature. 4 pi of this reaction was added to 2.5 pi
of each dideoxynucleotide termination mix (from kit, prewarmed at 37°C for 5 mins) and
incubated at 37°C for 10 mins before addition of 5 pi stop buffer (from kit).
Reactions were stored at -20°C, and before electrophoresis were heated at 95°C for two
mins, and then placed on ice. 5 pi of each termination reaction was loaded per well.
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2.6.4 - DNA sequencing ofNRL gene
This protocol was carried out using the Sequenase kit described in 2.6.3. PCR products of
the NRL gene were sequenced using the following method. 100 ng of PCR DNA in 6 pi
volume was added to 1 pi primer (0.5 pmoles), 2 pi reaction buffer (from kit) and 1 pi
DMSO, and the mixture kept on ice. This annealing reaction was left at room temperature
for 1 minute, placed at 100°C for three minutes, and then plunged into a bath of dry ice and
methanol. 3.5 pi sequencing mix, containing 1 pi DTT (from kit), 0.5 pi [a35S]dATP and 2
pi 1:9 labelling mix:deionised water, was added to the annealing reaction and pipetted up
and down to thaw. 1.5 pi Sequenase enzyme, diluted 1:5 in dilution buffer (stored on ice),
was then added, and the labelling reaction incubated at room temperature for 45 seconds. 3
pi of this mixture was then added to 2 pi of each dideoxynucleotide termination mix
(prewarmed at 42°C for 1 min), mixed, centrifuged, and incubated at 42°C for 5 mins.
After this termination reaction was completed, 4 pi stop buffer was added, and the reactions
were frozen at -20°C until ready to use. Samples were heated to 100°C for two minutes
before loading 2.5 pi to each well.
If problems were encountered with premature "stops" in the sequence (bands in all four
lanes), 1 pi formamide (or less, depending on the G/C content of the PCR product) (Zhang,
Hu and Deisseroth, 1991) was added to the annealing reaction, which was then denatured
for 10 mins at 100°C before being placed on dry ice.
Another sequencing protocol for difficult-to-sequence templates involved using the
IsoTherm™ DNA sequencing kit (Cambio) using a modified thermostable T7 DNA
polymerase, so that reaction steps can be carried out at 65°C. The reaction was carried out
as detailed in the protocol, except that the annealing mix was left at room temperature for 1
min, and then denatured for 3 mins (10 mins if using formamide) at 100°C. Briefly, the
template, buffer and primer were left at RT for 1 min, heated at 100°C, and then plunged
into a dry-ice/methanol bath. The IsoTherm DNA polymerase and [a35S]dATP were added,
and the mixture divided between each of the four ddNTP tubes and incubated at 65°C for 2
mins. Chase mix, containing 0.5mM dNTPs, was added to each tube, incubated for a
further 2 mins at 65°C, and the reaction stopped with formamide loading buffer. Samples
were heated to 70°C for 5 mins before loading 3pl, to avoid degredation of the sequencing
reaction products.
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2.6.5 - Preparation and sequencing of single-stranded DNA
This protocol was kindly provided by Dr. S. Kerr (MRC Human Genetics Unit, Edinburgh).
For single-stranded DNA sequencing, PCR reactions were carried out using a primer
labelled with biotin at the 5' end, at 0.1 pM final concentration, and an unlabelled primer
(final conc. 0.5pM) in a 50 pi reaction. The biotin-labelled strand of the product was then
captured using 20 pi Dynabeads M-280 Streptavidin (Dynal AS) prewashed in 100 pi
buffer A (250mM Tris, pH 8.0, 0.1% Tween® 20)). The beads were resuspended in 40 pi
deionised water, and the same volume of PCR and 6M lithium chloride added. This
mixture was shaken on a Vibrax mixer for 30 mins, and the beads were then pulled onto the
Dynal Magnetic Particle Concentrator (MPC®). The beads were washed in 100 pi buffer
A, washed again in 100 pi deionised water, and resuspended in 100 pi 0.1M NaOH (freshly
made) and left for 4 mins. They were then washed in 100 pi 0.1M NaOH, 100 pi buffer A,
100 pi TE (pH 7.5) and finally washed in 100 pi deionised water. The beads could be
stored in this way for up to a week until they were ready to be sequenced. They were then
resuspended in 7 pi deionised water, 1 pi sequencing primer (at least 0.8pM) added, 2 pi
Sequenase reaction buffer added, and the sequencing reaction carried out as detailed in the
Sequenase manual, or using the method described in 2.6.4.
2.7 - TRANSFORMATIONS
2.7.1 - Preparation of competent cells
Competent E. coli cells were prepared using the calcium chloride method, as described in
Sambrook, Fritsch and Maniatis (1989). Cells were harvested using a Beckman JA-20 rotor
at 2,000 x g for 5 mins, and 50 mis of cells were finally resuspended in 1 ml ice-cold CaCE
and left on ice for at least one hour, or up to a maximum of overnight.
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2.7.2 - Transformation of cells
For each ligation reaction, 150 |il of competent cells were used. The cells and the ligated
plasmid were left on ice for 60 mins, heat shocked at 42°C for two minutes, 1ml L-Broth
added and incubated at 37°C (shaking) for 60 mins. The cells were then diluted in L-Broth
and plated on L-agar containing Kanamycin, IPTG and X-gal, to select for colonies
containing recombinant plasmids.
2.8 - PROTEIN EXPRESSION
2.8.1 - Induction of fusion protein production
A culture of E. coli harbouring a recombinant plasmid under the control of the lac Z
promoter was grown in selective medium to an optical density of 0.6 - 0.8 at 600 nm.
Expression was induced by the addition of EPTG to a final concentration of 0.25mM, and
the culture was left growing at 37°C (unless stated) for a further four hours, with samples
extracted at various time-points.
2.8.2 - Fractionation of Bacterial Culture
Cells were harvested by centrifugation (7 mins at 3,800 x g in a Beckman JA-20 rotor), and
resuspended in 1/10 culture volume of lOmM HEPES, pH 7.2, with 1 mg/ml lysozyme.
The cells were left on ice for 20 mins, and then lysed by sonication with a micro-tip
sonicator (5 bursts of 5 seconds at full power, with 50 second cooling intervals on ice). The
lysate was clarified by centrifugation for 5 mins at 700 x g, to yield the pellet P3. The
resultant supernatant was respun for 20 mins at 31,300 x g, yielding the soluble S20
fraction and the insoluble P20 fraction. Both pellets were resuspended to the same volume
as the S20 fraction, in lOmM HEPES, pH 7.2. They were then analysed by electrophoresis
on an SDS polyacrylamide gel.
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2.8.3 - Western blotting
After SDS polyacrylamide gel electrophoresis, gels were placed next to a sheet of
nitrocellulose (Hybond™-ECL™, Amersham)(cut to size of gel) sandwiched between two
sets of four sheets of Whatman 3MM paper, and several porous pads. This whole assembly
was placed in a tank of transfer buffer (20mM NaHPC>4, 20% methanol, 0.02% SDS), and
run at 0.4 A overnight, or 1 A for 2 hours. The nitrocellulose was then rinsed in water to
remove excess SDS, and stained in Ponceau S (0.2 % w/v Ponceau S, 3% trichloroacetic
acid) for 5 mins to allow visualisation of transferred proteins, and destained in water and 1
x TBS (20mM Tris-HCl, pH 7.4, 0.15M NaCl). The filter was then washed in blocking
buffer (0.05% bovine serum albumin, 0.5% Tween 20, 1 x TBS, with 0.05% sodium azide
if blocking overnight) for 60 mins, or overnight. The blocking buffer was then replaced
with 15 mis of antibody solution (1.5 pi rabbit anti-bovine IgG conjugated to horseradish-
peroxidase (Sigma Immunochemicals), 0.05% BSA in 1 x TBS) and left shaking for 30
mins. It was then washed twice in 50 mis 1 x TBS, twice in 1 x TBS with 0.1% Tween 20,
and finally once in 1 x TBS.
2.8.4 - Detection of recombinant proteins
After Western blotting and adding anti-horseradish peroxidase labelled antibody, the filter
was treated with Enhanced Chemiluminescence (ECL, Amersham) reagents as detailed in
the manufacturer's instructions, wrapped in cling-film, and exposed to autoradiography
film, initially for 30 sees, and then for longer periods if necessary.
2.8.5 - Purification of recombinant proteins using IgG-Sepharose
IgG-Sepharose (Pharmacia) was stored as a 10% slurry in 1 x TBS at 4°C, and centrifuged
at 13,400 x g for 1 min. in a microcentrifuge prior to use, to remove the TBS. A soluble
fraction (S20, see 2.8.2) of volume v was prepared from a bacterial culture, and 1/9 v 10 x
TBS added, to give a final concentration of 1 x TBS, in a total volume of V. This was
incubated at 4°C overnight, on a rotating platform with 1/10 V packed IgG-Sepharose. This
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mixture was centrifuged at 13,400 x g for 1 min., and the supernatant retained - this fraction
should contain any proteins present in the soluble fraction of the culture that have not
bound to the IgG-Sepharose. The IgG-Sepharose was then washed twice, with V (1 x
TBS), and then twice in V (5mM ammonium acetate, pH 5.0). 0.5V ammonium acetate,
pH3.4 was added to the gel and incubated on a rotating table for 5 mins. This slurry was
then spun at 13,400 x g for 1 minute, and the supernatant retained. This fraction should
contain the eluted proteins. The IgG-Sepharose was then washed twice in V (1M Tris-HCl,
pH 8.0), and finally in V (1 x TBS), and resuspended in V (1 x TBS). The protein from
each fraction was precipitated by adding a final concentration of 10% Trichloroacetic Acid
(TCA), and centrifuging for 10 minutes at 13,400 x g in a microcentrifuge. The pellets
were then resuspended in 1 x loading buffer (25% 4 x loading buffer, see section 2.5.2,
2.5% 1M DTT, 1.25% 2M Tris (unbuffered)), and run on a polyacryalmide gel.
2.9 - LINKAGE ANALYSIS
2.9.1 - arRP families
Eleven nuclear arRP families from South-Central Sardinia, with ancestors of Sardinian
origin, were sampled by venepuncture after obtaining ethical approval and their informed
consent, and lymphoblastoid cell lines established at the European Collection of Animal
Cell Cultures at Porton Down, UK. Clinical examinations, including electrophysiological
and visual field testing, fundus examination and fluorescein angiography (see Fossarello et
al, 1993) were carried out at the University Eye Clinic of Cagliari. DNA was extracted as
detailed in 2.3.4, or extracted previously by M.Deans, as described by Wright et al (1987).
2.9.2 - BBS families
29 families with Bardet-Biedl syndrome, from the UK, Denmark, Norway, Switzerland,
Sweden, Egypt and Brazil were used in this study. The criteria for inclusion of families
were the presence of at least two affected members meeting the diagnostic criteria for three
out of five of the cardinal features (see 1.4.2), Sibs of affected individuals were required to
meet two instead of three of the cardinal signs. Subjects, including parents and unaffected
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siblings where available, were sampled by veno-puncture after obtaining ethical approval
and their informed consent. Lymphoblastoid cell lines for some of the patients were
established at the European Collection of Animal Cell Cultures at Porton Down, UK. DNA
was extracted as for arRP families (2.9.1) or sent by collaborating groups.
2.9.3 - Markers used in linkage analysis
All microsatellite marker sequences used in linkage analyses were obtained from Genethon
(Gyapay et al, 1994; Dib et al, 1996) or from the on-line Genome Database (GDB).
2.9.4 - ALP
Software for peak analysis and genotype filtering of ALF data was written in C and
developed on Sun Sparc and IBM PC compatible computers (Mansfield et al, 1994). These
programs have been unified to run under Microsoft Windows on IBM PC compatibles and
are freely available on request.
2.9.5 - Programs used in linkage analysis
Two-point linkage analyses were carried out using MLINK from the LINKAGE program
package, version 5.2 (Lathrop et al, 1984). Allele frequencies for microsatellite markers
were taken from the Genome Database (GDB) or from parents of the families if significant
differences were noted. Allele frequencies at the arRP disease locus were set at 0.992
(normal) and 0.008 (affected), and at 0.9999 (normal) and 0.0001 (affected) for BBS.
Multipoint lod scores were derived from markers using the LINKAGE program by means of
serial three-point analyses on adjacent loci, moving along one locus at a time. A linear
genetic map over equally spaced points derived from these lod scores was used for
heterogeneity analysis with a Fortran program applying the formulae for a group of families
with a proportion linked and a proportion unlinked (Terwilliger and Ott, 1994; Teague et al,
1994). In the case of BBS, the 3 chromosomes were combined as a single continuous map.
and a maximum likelihood Fortran search program applied an extension of Ott's formulae




PRODUCTION OF A MutS FUSION PROTEIN
3.1 - INTRODUCTION
Bacterial DNA repair enzymes are increasingly being recognised as potential tools for
mutation detection. In this project, the Escherichia coli enzyme MutS was chosen for
study. As described in section 1.7.1, this protein works together with MutH, MutL and
MutU (DNA Helicase II) to identify, and excise, short tracts of mismatched bases in newly
synthesised strands of DNA. As MutS is the component that recognises, and binds to, the
site of mismatch, it is a good candidate for detecting gene mutations and polymorphisms in
the human genome. Proposed uses of this protein have been to enrich a DNA mixture (from
two individuals) for regions of identity-by-descent, or to detect mutations in short stretches
of heteroduplex DNA (see section 1.7.1).
The production of a MutS fusion protein was undertaken as an approach to identify RP
genes. Staphylococcal protein A (SPA) was chosen as the affinity handle for the fusion
protein. This polypeptide can bind tightly to the Fc portion of immunoglobulin G (IgG), to
aid in purification by affinity chromatography. It is thought to have a minimal steric effect
on the protein, is stable in E. coli, and may inhibit proteolysis of the fusion product (Nilsson
and Abrahmsen, 1990). It can also act as an adjuvant for production of specific antibodies.
The aim of this study was to create an active fusion protein, bind it to an IgG-Sepharose
column, and use this to affinity purify fragments of DNA containing a region of
mismatched heteroduplex.
3.2 - PCR OF MutS GENE
Polymerase chain reaction primers were designed using the DNA sequence submitted by
Schlensog and Bock (1991), that putatively coded for the E. coli mutS gene. This sequence
was first reported for thefdv gene in E. coli, though the function of this gene was unknown.
However, its position in the E. coli chromosome, and 90% sequence similarity with the S.
typhimurium MutS protein, led Schlensog and Bock to suggest that this gene actually codes
for E. coli MutS. Reenan and Kolodner (1992) have also cited the fdv sequence as the
mutS E. coli gene in their report describing yeast MutS homologues. Hence, the sequence
(Genbank accession no. M8642) was used to design forward and reverse primers which
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added an EcoRI site to the 5' end of the gene and a BamHl site to the 3' end, for forced
cloning into pAXl 1 (Zueco and Boyd, 1992). The primers' sequences are shown below:
iscoRI
MS IF 5' TGG GlAA TTC AGT GCA ATA GAA AAT TTC GAC 3'
FIRST CODON
BamHl
MS 1R 5' TCT G^GA TCC TTA CAC CAG GCT CTT CAA GCG 3'
3' AAT GTG GTC CGA GAA GTT CGC 5'
STOP CODON
pAXll is a SPA fusion vector, constructed from a pK19 backbone, designed by Dr. A.
Boyd and Dr. J. Zueco in the Dept. of Biochemistry, University of Edinburgh, who kindly
donated some of the vector for use in this project. A plasmid map of pAXll is shown in
figure 3.1, with the multiple cloning site highlighted. This vector encodes fusion proteins
from the start codon (ATG), with the IgG-binding domains of protein A (spa, also
sometimes known as 'ZZ', Hammerberg et al, 1990) at the N-terminus. Expression is
controlled by the P|ac promoter. When the DNA fragment of choice is ligated in-frame into
the multiple cloning site (MCS) this inactivates the LacZa polypeptide, yielding white
recombinant colonies following transformation into an appropriate E. coli strain with the
LacZM15 deletion.
Figure 3.2 (lane 4) shows the results of PCR using the primers designed, which yielded a
single band from sheared E. coli genomic DNA. This product ("msl"), predicted to be
2,576 bp, lies between the 2.7 kb band and the 1.9 kb band of the DNA size marker, as
expected. As the distance migrated by a DNA fragment in an agarose gel is inversely
proportional to the log]0 of the number of base pairs in the fragment (Helling et al, 1974),
the size of the PCR product was calculated using a graphical method to be approximately
2,500 bp. msl was digested with restriction enzymes EcoRI and BamHl, as shown in lane
5. This digest also confirmed that msl did not contain any internal EcoRI or BamHl sites,
as expected. Simultaneously, pAXll (lane 2) was digested with the same restriction
enzymes, yielding a fully digested product (lane 3) of the expected size (3.13 kb).
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Smal Kpnl EcoRI Spel SphI BamHI Sail PstI
Figure 3.1 - Plasmid map of pAXll (from Zueco and Boyd, 1992).
Thin black lines and blackened arrows represent pK19 sequences. The open box represents
the spa gene. This plasmid confers resistance to kanamycin in transformed E. coli, and
yields blue or white colonies in strain NM522, in medium containing IPTG and X-Gal.
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Figure 3.2 - PCR of E. coli mutS gene
Photograph of ethidium bromide stained agarose gel containing the following:
Lane 1: DNA marker (band sizes as marked)
Lane 2: pAXl 1 plasmid
Lane 3: pAXl 1 plasmid following digestion with EcoBl and BamUl
Lane 4: PCR product msl
Lane 5: msl following digestion with fscoRI and BamHl
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3.3 - CONSTRUCTION OF pEBl
Digested msl and pAXl 1 were purified (to remove buffer, salts, DNA fragments) and used
in a ligation reaction, at an approximately 1:1 molar ration of vector:insert. This reaction
was used to transform freshly prepared competent NM522 E. coli cells, with a heat shock at
42°C for 2 minutes to increase transformation efficiency. The cells were then plated at
various dilutions onto L-agar plates containing kanamycin, to select for the presence of the
plasmid, and IPTG and X-gal to select for recombinants.
After overnight incubation, a variety of white and blue colonies were visible on the plates.
The negative control, of competent untransformed NM522 cells, had not grown, and the
positive control, of cells transformed with pAX12 (Zeuco and Boyd, 1992), yielded only
blue colonies. A selection of the white and white/blue colonies were picked for further
study, and inoculated into L-broth with kanamycin. Mini-preps of DNA were prepared
using these cultures, and digested with EcoBl and BamWl to check the size of the insert
fragment, as shown in figure 3.3. One of the plasmids containing an insert of the correct
size, and hence assumed to be msl, was then chosen for use in protein production, and
designated pEB 1.
3.4 -SEQUENCING OF pEBl INSERT
Before progressing further, it was important to check that the insert in the vector had the
correct DNA sequence expected for the putative MutS gene. This was carried out in two
ways. Dr. D. Porteous (MRC Human Genetics Unit) had kindly donated a sample of the
original MutS plasmid (pMS312) first reported by Su and Modrich in 1986. This was used
as a substrate for PCR using the primers (MSIF and MS1R) described in section 3.1, and
yielded a single band of the same size as msl. However, it is possible that this could have
been due to contamination of the plasmid prep with genomic E. coli DNA. pMS312 was
also digested using a set of restriction enzymes, to compare with the digest pattern found on
digestion of msl. It was hoped that this would further confirm that the E. colifdv gene was
the MutS gene, whilst avoiding sequencing the pMS312 plasmid. However, all attempts at
digestion of pMS312 yielded no visible bands on an agarose gel, perhaps due to low yield
of DNA from plasmid preps.
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Figure 3.3 - Restriction digestion of recombinant plasmids
Photograph of ethidium bromide stained agarose gel.
Lanes 1 and 9 contain PCR product msl
Lanes 2 and 10 contain linearised pAXl 1 (following digestion with EcoBl and BamWl)
Lanes 3-8 and 11-16 contain DNA from a variety of colonies, picked following
transformation of NM522 with msl ligated into pAXl 1. This DNA has been digested with
EcoR\ and BamHl, to yield the inserted fragment and the linearised plasmid.
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The second method involved direct sequencing of pEBl, which was carried out following
preparation of sufficient quantities of plasmid DNA. The Ml3 -40 and +40 primers, which
are supplied with the Sequenase DNA sequencing kit, were suitable for use with this
plasmid. Several different protocols for dideoxy termination DNA sequencing were used,
with varying results. Around 400 basepairs of DNA sequence was obtained from each end
of the plasmid insert, and confirmed that it had the expected mutS sequence.
3.5 -PROTEIN INDUCTION
Plasmid pEBl was transformed into competent E. coli cells. Cells containing the plasmid
were grown up in L-Broth with kanamycin, until they had reached an optical density at
600nm (ODeoo) of -0.6, corresponding to a cell concentration of around 5 x 108/ml. At this
point IPTG was added to the culture medium to induce production of the fusion protein for
up to four hours. Cells were extracted, harvested, and incubated with lysozyme, followed
by sonication to disrupt the cells. The resultant suspension was subjected to a low speed
clearing spin at 700 x g (3,000 rpm in a Beckman JA-20), the supernatant decanted, and
respun at 31,300 x g (20,000 rpm in a Beckman JA-20). This yielded three fractions: P3,
the pellet containing cell debris from the clearing spin; P20, the pellet from the second spin,
containing insoluble intracellular proteins; and S20, the supernatant from the second spin,
containing soluble proteins.
The P20 and S20 fractions were analysed simultaneously on two polyacrylamide gels. One
gel was stained with Coomassie blue dye, to reveal all proteins present. The other gel was
Western blotted onto nitrocellulose, which was then probed with an IgG antibody
conjugated to horseradish peroxidase (HRP), to detect proteins tagged with protein A. The
enzymatic activity of this antibody was then converted to light, using the enhanced
chemiluminescence (ECL) kit, and detected by brief exposure to autoradiographic film.
The results of these experiments are detailed below.
3.6 - INDUCTION OF NM522(pEBl)
The initial induction experiment involved inducing NM522 cells, transformed with pEBl,
at 37°C for four hours. The cells were harvested, processed as described above, and
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analysed on an SDS polyacrylamide gel and Western blot, both shown in fig. 3.4. The
Coomassie blue stained gel (a) does not reveal any obvious bands of the expected size of
113 kDa (97 kDa MutS and 16 kDa spa tag) in any of the fractions. However, the Western
blot (b) reveals the presence of a major protein A-tagged product, lying close to the 116
kDa marker, in the P3 and P20 fractions. No corresponding band was visible in the S20
fraction, even with prolonged exposure of the blot to autoradiographic film. The
experiment was repeated to confirm this result. This suggests that following four hours
induction at 37°C, all the fusion protein has formed into insoluble inclusion bodies,
discussed below.
3.7 - INCLUSION BODIES
Overproduction of a recombinant protein in E. coli often leads to the formation of
intracellular insoluble protein aggregates, known as inclusion bodies (IBs). IB formation
has been observed in the expression of fusion proteins, heterologous genes, and also high
level expression of endogenous genes, usually when under the control of a strong promoter
(Geisow, 1991). This phenomenon can be advantageous or disadvantageous depending
upon the protein and its proposed use. IBs can protect proteins from degradation by
proteolysis, probably due to their density preventing protease access (Enfors, 1992). This
density, and the purity of the protein in the IB, can also lead to straightforward purification
procedures. However, as the protein in the IB is biologically inactive and insoluble,
problems can be encountered in converting it to an active, soluble protein. The fusion
protein in this project was to be used in DNA-binding experiments, and hence had to be
non-denatured, and in its native conformation. Often the methods for denaturation and
refolding can be prohibitively time-consuming.
It is thought that formation of IBs is related to protein folding and assembly, with folding
intermediates being involved in aggregation (for review, see Hockney, 1994). Indeed,
mutations that alter elements of secondary structure have been shown to influence IB
formation (Chrunyk et al, 1993), and the introduction of a translational pause, promoting
correct intracellular protein folding, helps decrease aggregation (Hockney, 1994).
However, protein folding is also influenced by environmental factors, such as cellular
temperature, pH, and presence of other proteins, especially chaperones. These factors have
all been used as approaches to prevent IB formation (Hockney, 1994). In effect, most
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Fig 3.4 - Induction of NM522(pEBl) for 4 hours at 37°C
(a) Autoradiograph ofWestern blot of gel identical to (b)
(b) Coomassie blue stained 8% polyacrylamide gel. Lanes 1 and 5 contain high molecular
weight markers. Lanes 2, 3 and 4 contain fractions P3, P20 and S20 respectively.
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methods work by reducing the rate at which the protein is introduced into the cytoplasm, or
by altering the environment into which the protein is released.
3.8 - TIME-COURSE INDUCTION
The first approach to produce a soluble product was to carry out a time-course induction.
As inclusion body formation is associated with high levels of expression, the protein may
be produced in a soluble form soon after induction, when only low levels are present in the
cytoplasm. To investigate this possibility, induction was carried out as before, but samples
were extracted from the culture at 1, 2, 3 and 4 hour time-points. The gels run with the
samples P20 and S20 from this experiment are shown in figures 3.5 (a) and (b). The
Coomassie blue stained gel shown in (a) reveals faint bands of the correct size in the
supernatant fractions, with much greater amounts visible in the P20 fractions. The Western
blot (b) shows that this protein in the S20 appears to represent a protein A tagged protein,
with the largest soluble amounts present in the 2 and 3 hour time-point fractions.
Attempts were made to purify this protein from these two fractions using IgG-Sepharose.
However, the resultant material eluted from the IgG-Sepharose appeared to contain more
protein bands than the original S20, as shown in the Western blot in figure 3.6 (lane 1).
Some of the additional protein bands probably represent degradation products of the fusion
protein, or fragments of IgG that have become detached from the Sepharose gel matrix.
Lane 3 of fig. 3.6 also shows the unbound material from the IgG-Sepharose column,
showing that the 113 kDa band observed in figure 3.5 (b) did not run through the column
without being bound.
The time-course experiment was repeated to confirm that there was fusion protein present
in the soluble fraction following induction at 37°C for 1-4 hours. Only one gel was run,
with half the amount of each sample loaded, and then Western blotted as before, to detect
protein A tagged proteins. This Western blot is shown in figure 3.7, and shows that no
product of the expected size is visible in the soluble fractions. This suggests that the




Fig 3.5 - Time-course induction of NM522(pEBl) at 37°C
(a) Coomassie blue stained 8% polyacrylamide gel
Lanes 1 and 10 contain high molecular weight protein markers. Lanes 2, 4, 6, and 8 contain
the P20 fractions from NM522(pEBl) cells induced for 1, 2, 3 and 4 hours respectively.
Lanes 3, 5, 7, and 9 contain the S20 fraction from the same cells, induced for 1, 2, 3 and 4
hours respectively
(b) Autoradiograph ofWestern Blot of gel identical to (a)
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Fig. 3.6 - IgG-Sepharose affinity chromatography
Autoradiograph ofWestern blot of gel containing
lane 1 : S20 fractions from 2 and 3 hours induction, following purification with IgG-
Sepharose, and TCA precipitation
lane 2 : material from S20 fractions not bound by IgG-Sepharose column (TCA
precipitated)
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Fig. 3.7 - Time-course induction of NM522(pEBl)
Repeat ofWestern blot shown in fig. 3.5 (b), with half the amount of protein loaded
Lanes 1 and 10 contain high molecular weight protein markers. Lanes 2, 4, 6 and 8 contain
the P20 fractions from the NM522(pEB 1) cells induced for 1, 2, 3 and 4 hours respectively.
Lanes 3, 5, 7 and 9 contain the S20 fraction from the same cells induced for 1, 2, 3 and 4
hours respectively.
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3.9 - INDUCTION OF NM522(pEBl) AT 25°C
The next approach to produce the fusion protein in a soluble form involved inducing protein
production at a lower incubation temperature of 25°C. This approach has been successfully
used for several proteins, including interleukin-ip, where Chrunyk et al (1993) showed that
the percentage of recombinant protein produced in inclusion bodies decreased from 50-60%
at 42°C to around 20% at 32°C. Similar results have been found for production of human
interferons, where fermentation temperatures of 23-30°C resulted in 30-90% of the protein
being produced in a soluble form (Schein and Noteborn, 1988).
Induction of cells at a fermentation temperature of 25°C was carried out as described
previously, with culture samples extracted at 1 - 4 hour time points. The Coomassie blue
stained polyacrylamide gel (a) and corresponding Western blot (b) are shown in fig 3.8.
The gel (a) shows bands just below the 116 kDa marker in each of the insoluble fractions,
with most protein visible at the 3 and 4 hour time-points. This corresponds to the bands
seen in the Western blot (b) following probing with an IgG antibody. While this clearly
shows that the protein is not produced in a soluble form, it also shows that reduced
temperature greatly reduces degradation of the fusion protein, when compared to fig 3.5 (b),
showing the results of the induction at 37°C.
3.10 - USE OF DIFFERENT E. COLI STRAINS
Following the results of reduced temperature incubation, the next approach chosen was to
transform the pEBl plasmid into two different compatible E. coli strains. The strains
chosen, XL1-Blue and JM109, are both commonly used for production of recombinant
proteins. The use of alternative E. coli strains has been successfully employed in the
production of (3-lactamase, polio virus 3C protease, and HIV GAG-9, where it was shown
that protein solubility varied in WE. coli strains tested (Kenealy et al, 1987). It is not
known which genetic differences between strains cause this variation.
The induction experiments were carried out at 37°C, as for NM522 cells, except that
samples were extracted at 30 minutes, 1 hour, 2 hours and four hours. The Coomassie blue
stained gel and Western blot are shown in figures 3.9 (XLl-Blue) and 3.10 (JM-109). In
each gel, only the soluble fraction was loaded, to avoid contamination by overloading of the
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Fig. 3.8 - Time-course induction of NM522(pEBl) at 25°C
(a) Coomassie blue stained 8% polyacrylamide gel. Lane 6 contains a high molecluar
weight protein marker. Lanes 1, 3, 5, and 8 contain the P20 fraction from NM522 (pEBl)
cells induced for 1, 2, 3, and 4 hours respectively, at 25°C. Lanes 2, 4, 7, and 9 contain the
S20 fractions from the same cells, induced for 1, 2, 3, and 4 hours respectively, at 25°C
(b) Autoradiograph ofWestern blot of gel identical to (a)
67
Figure 3.9 - Time-course induction ofXLl-Blue(pEBl)
(a) Coomassie blue stained 8% polyacryalmide gel. Lanes 1, 2, 4 and 5 contain the 30 min.
and 1, 2 and 4 hour S20 samples respectively. Lane 3 contains a high molecular weight
protein marker.






Figure 3.10 - Time-course induction of JM109 (pEBl)
(a) Coomassie blue stained 8% polyacrylamide gel. Lanes 1, 2, 4 and 5 contain the 30 min.
and 1, 2 and 4 hour S20 samples respectively. Lane 3 contains a high molecular weight
protein marker.
(b) Autoradiograph ofWestern blot of gel identical to (a).
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insoluble fractions. Both Coomassie blue stained gels reveal no obvious protein of the
correct size. However, the Western blot for the transformed XL 1-Blue cells shows a faint
band near the 116 kDa marker, in the 4 hour time-point sample (fig. 3.9), and the
corresponding blot for the transformed JM-109 cells reveals a faint band at the same
position following thirty minutes induction (fig. 3.10). The induction experiment was
repeated in the XL 1-Blue cells for 3-6 hours, and in the JM-109 cells for 5-40 minutes, to
check for higher levels of soluble protein. However, in each case no increase was seen in
the levels of soluble fusion protein produced. The induction experiments were also
repeated at 25°C, but this resulted in a decrease in overall protein production, with only
degradation products visible following overnight exposure of the Western blot.
3.11 - SOLUBILISATION OF INCLUSION BODIES
When all efforts aimed at production of a soluble fusion protein fail, attempts can be made
to solubilise the protein from the IBs. Several protocols are available for extracting protein
in a denatured form from IBs, and subsequently renaturing it, to restore normal activity.
The most common approach is to use strong denaturants, such as 5-8M guanidine
hydrochloride or 6-8M urea. Other alternatives include SDS and acetonitrile/propanol, to
disrupt hydrophobic interactions, or pH > 9.0, to dismpt ionic interactions. A number of
variables can also influence solubilisation, in particular the incubation temperature,
concentration of protein and solubilising agent, and pH, with each protein requiring
different conditions.
Following solubilisation, the next step is to refold the protein by diluting or dialysing out
the solubilising agent. Again, factors such as the rate of dilution, and pH, and concentration
of components must be considered. In this study, attempts were made to solubilise the
protein from inclusion bodies using urea and guanidine hydrochloride, followed by
overnight dialysis. However, in both cases the protein precipitated out of solution, and
although further conditions could have been tried, it was decided that a less time-consuming
approach would be to subclone the pEB 1 mutS gene into a different type of fusion vector, in
an attempt to produce soluble fusion protein. This was not carried out however, due to time
constraints.
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3.12 - ALTERNATIVE APPROACHES
All previous attempts at MutS fusion protein induction had produced very low levels of
soluble protein. In some cases, fusion proteins remain insoluble with certain fusion tags,
but are more soluble when expressed from different constructs. A variety of commonly
used fusion systems are available for use, including the 10 amino-acid (aa) Streptavidin tag,
the 40 kDa Maltose Binding Protein, the 25 kDa glutathione-S-transferase, and the 6 aa
Histidine tag (for review see Nygren, Stahl and Uhlen, 1994). Each system has its own
specific method for affinity purification. The system planned for further use in this study
with MutS was the His tag, consisting of a string of six histidine residues, attached to the C
or N terminus of the protein. This polyhistidine tail has a high affinity for metal ions, and
is usually bound by a resin containing nickel ions. The strength of the affinity for this resin
means that a tagged protein can still be efficiently purified from solutions containing strong
denaturants such as 6M guanidine hydrochloride or 8M urea, allowing for purification from
inclusion bodies if necessary. Bearing in mind the experience of working with MutS fused
to SPA, this feature made the system particularly suitable. Once bound and washed, the
protein is then eluted from the column by competition with imidazole, or by reducing the
pH slightly (Hoffmann and Roeder, 1991).
At the end of 1995, a report was published detailing a purification protocol for producing a
His6-MutS fusion protein (Feng and Winkler, 1995). Unfortunately, time-constraints had
prevented work from progressing on the production of a MutS fusion protein prior to this
publication. Feng and Winkler found that most of the expressed fusion protein remained in
the soluble fraction, and discarded any inclusion bodies that were formed. This level of
solubility allowed purification under non-denaturing conditions, yielding purified protein
accounting for 15%-30% of the total soluble protein in cell extracts. The His6 tag was
subsequently removed by thrombin cleavage, without cleaving the MutS protein internally.
This protocol produced MutS with mismatch-binding activity, in a form suitable for use in
mutation and polymorphism detection experiments.
3.13 - DISCUSSION
This chapter describes attempts to produce an active MutS-protein A fusion protein in E.
coli. PCR primers have been designed that successfully amplify the E. coli MutS gene,
which could then be cloned into fusion vectors. In this project the pAXll fusion vector
71
was originally chosen. This vector tags the cloned fragment with 16 kDa IgG-binding
domains of Staphylococcal protein A, enabling straightforward detection and purification of
recombinant proteins. Attempts were made to produce such a fusion protein in an active,
soluble form, for use in DNA-binding. Early results indicated that the desired protein was
present in the insoluble fraction of the cell extract, suggesting it was being directed to
inclusion bodies upon synthesis within the cytoplasm. Despite efforts to prevent IB
formation, by altering the levels of expression, temperature of incubation, and host strain
used for synthesis, we were unable to produce suitable quantities of the fusion protein in a
soluble form. Attempts were made to solubilise the protein in the IBs with denaturing
agents, with the final aim of purification by affinity chromatography (with IgG-Sepharose),
but these too proved unsuccessful. FPLC was also employed to purify trace quantities in
the soluble cell extract, but this failed to yield perceptable amounts of protein.
The next stage of this work was to involve subcloning the MutS gene into a His6 fusion
vector, but no progress was made with protein expression before Feng and Winkler (1995)
published a protocol detailing purification of such a fusion protein. This will enable
production of active MutS for use in mutation detection, as described by Wagner, Debbie
and Radman (1995), who used MutS immobilised to nitrocellulose. The His6 fusion protein
could be used in a similar way, but immobilised to nickel Nitrilo-Tri-Acetic acid (NTA)
resin (Floffmann and Roeder, 1991).
In summary, a MutS fusion protein presents an ideal tool for mutation detection.
Preliminary results from groups working with MutS (see section 1.7.1) have shown that it
reliably detects and binds to most mismatches in vitro. The production of a MutS fusion
protein, for easy purification, and handling, widens the possible applications of this protein




LINKAGE MAPPING IN BARDET-BIEDL SYNDROME
4.1 -INTRODUCTION
Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder with four loci,
designated BBS1-4, situated on chromosomes 11ql3, 16q21, 3pl3-pl2 and 15q22.3-q23
respectively (Leppert et al, 1994, Kwitek-Black et al, 1993, Sheffield et al, 1994, Carmi et
al, 1995a) (see section 1.4.2). All of these loci have been localised solely by linkage
analysis, and no patients with BBS have been reported with cytogenetic abnormalities in
these regions. None of the corresponding BBS genes have been identified as yet.
The aim of this part of the study was to identify one or more BBS loci by genetic linkage
analysis in a set of BBS families collected world-wide. By the end of the project there was
a total of 29 families provided by collaborating physicians in U.K., Norway, Denmark,
Sweden, Switzerland, Brazil, Egypt and Italy. This represents one of the largest resources
of BBS patients currently available. At the start of the study no linkage had been reported
for BBS, and Dr. David Mansfield (formerly of MRC Human Genetics Unit) had analysed
ten polymorphic DNA markers on chromosome 18, nine markers on chromosome 2 and six
markers on chromosome 17. These specific chromosomes were analysed because of a
report of an attenuated form of BBS in a patient with a mosaic deletion of chromosome 18
(Dr. A. Wright, personal communication), and a 46, XX t(2p-;17p+) translocation in a
patient with BBS (Fannemel et al, 1993). However, no significant linkage was identified
within the set of families to any of these chromosomes.
The next stage of the project was to involve using microsatellite markers distributed at 20
cM intervals on every chromosome, in a genome-wide scan for a BBS gene. This was
interrupted at the end of 1993 when Kwitek-Black et al reported linkage between BBS and
markers on chromosome 16q21 in a large inbred Bedouin kindred from the Negev region of
Israel. Three microsatellite markers (D16S408, D16S400 and D16S421) were reported as
being linked to this locus, later designated BBS2, and so were analysed in all the available
families.
The next report of linkage came several months later, and led the search to chromosome
11 q 13, where Leppert et al (1994) had found significant linkage with two markers, in a
subset of 17 out of 31 North American families. These families were similar in size and
ethnic origin to the families used in the present study, and it was decided to analyse six
markers on chromosome 11 q 13. A further marker was later analysed, when results
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suggested that the locus could be several cM centromeric to the location originally
suggested by Leppert et al.
Later that year another report of linkage for BBS came from the same group who had
reported linkage for 16q, again using a large Bedouin family from the same region of Israel
(Sheffield et al, 1994). They found linkage between BBS and markers on the short arm of
chromosome 3. Again, our set of families was analysed using the three most closely linked
dinucleotide repeat markers, D3S1254, D3S1251 and D3S1271. However, these markers
were relatively uninformative in the families studied, but suggested no significant linkage.
The final report of a BBS locus came in 1995, again from the Sheffield group, using a third
inbred Bedouin kindred (Carmi et al, 1995a). They identified linkage on the long arm of
chromosome 15, using a DNA pooling method to find the common chromosomal region
inherited by the affected members of the family. The four most tightly linked microsatellite
markers in this region (D15S125, D15S131, D15S204 and D15S114) were analysed, and
suggested linkage in several of our families.
This chapter describes the results of these analyses using markers linked to three of the four
BBS loci, and attempts to assign, or exclude, specific BBS loci in each family.
4.1.1 - Families
Twenty-nine families diagnosed with Bardet-Biedl syndrome were used in this study. Most
are of European descent, and the ethnic origin of the family is indicated in the results. The
criteria for inclusion of families were the presence of at least two affected members of
whom at least one met the diagnostic criteria for three of the cardinal signs (retinal
dystrophy, Polydactyly, obesity, hypogenitalism and mental retardation). Sibs of affected
individuals were required to meet two instead of three of the cardinal signs. Many
associated features were also observed in the families, including brachydactyly, renal
anomalies, dental anomalies and liver disease. Brief clinical details for each family, where
available, are listed in the results (4.2.1 - 4.2.28). Parental consanguinity was present in six
of the pedigrees: BB7, BB13, BB18, BB20, BB25, BB31. The degree of consanguinity is
detailed in the pedigree figures or results section, where known. All available affected and
unaffected individuals were sampled by venepuncture after obtaining ethical approval and
informed consent.
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4.1.2 - Microsatellite Markers
Sequences for microsatellite markers were obtained from Genethon or the on-line Genome
Database (GDB). Markers were synthesised with one primer of each pair fluorescently
labelled for use in an automated laser fluorescence DNA sequencer (ALF, Pharmacia
Biotech). Figure 4.1 shows a typical pattern obtained with a dinucleotide repeat
microsatellite marker in a nuclear family. Each colour represents a separate lane in the gel,
loaded with the PCR reaction of one individual. "Stutter" or "shadow" peaks (as seen in
fig. 4.1) are usually observed when running dinucleotide repeat markers, possibly due to
polymerase slippage during the PCR reaction (Mansfield et al, 1994). These stutter peaks
are often used to aid in sizing the larger peaks, which correspond to the true alleles.
If accurate sizing of the peaks was required, the ALP program (Mansfield et al, 1994) was
used to size alleles, with internal size standards run in each lane, flanking the expected
product (see fig 4.1). One lane in each gel would also be devoted to a "gold standard"
sample, using DNA from CEPH individual 134702 as the template for the microsatellite
marker. Genethon markers are published with the allotype of this individual, which has
been accurately determined by sequence analysis. Following sizing, the ALP program
output was checked manually, and then converted to data in a form suitable for input into a
linkage program.
4.1.3 - Linkage Mapping
Linkage analysis was carried out by multipoint analysis using the LINKAGE program
package (Lathrop et al, 1984), by P. Teague (MRC Human Genetics Unit). LINKMAP was
used to obtain multipoint lod scores by a series of three-point analyses on adjacent loci
moving along the chromosome one locus at a time. A linear genetic map for each
chromosome studied was derived from these lod scores, and used for the analysis. Markers
and genetic distances were used as detailed below (section 4.2).
Heterogeneity analysis was carried out by P. Teague, using either the HOMOG program
package (Terwilliger and Ott, 1994), or a Fortran program which located the maximum lod
score using the formulae employed by HOMOG (Teague et al, 1994).
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Figure 4.1
Example of microsatellite alleles in a nuclear family, run with internal DNA size standards
on the ALF. Father = green lane (alleles 116 bp, 122 bp); mother = blue lane (122, 128);
child 1 = yellow lane (116, 122); child 2 = red lane (116, 128)
DNA size standard
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The results for each family for the loci on chromosomes 11,15 and 16 have been displayed
in the form of haplotypes in figures 4.5 - 4.32, These haplotypes have been deduced so as
to minimise the number of crossovers between markers. Seven markers on chromosome 11
were analysed, and these are shown in figure 4.2 with their relative distances apart in cM,
as calculated from Genethon data (Dib et al, 1996) and James et al (1994). Four markers
on chromosome 15 were analysed, and they are shown in figure 4.3. The three markers
studied on chromosome 16 are shown in figure 4.4, with genetic distances taken from
Genethon (Dib et al, 1996) and the radiation hybrid maps generated by the Whitehead
Institute at MIT (http://www-genome.wi.mit.edu/cgi-bin/contig/phys_map). Further
markers relevant to the subsequent mapping of these loci are also included in the figures.
Positive multipoint lod scores (> 0.10) are listed in the results for each family (4.2.1 -
4.2.28), with the maximum value and chromosomal location in cM. The conditional
probability of linkage to each locus is also included, with a probability <0.10 suggestive of
exclusion of that locus, and > 0.50 suggestive of linkage. The position of the markers
studied along each chromosome is listed below, as used in the multipoint linkage analyses:
Chromosome 11
D11S480 (61cM from 1 lpter) - D11S913 (69cM) - D11S987 (69.1cM) - D11S916 (80cM) -
D11S527 (85cM) - D11S906 (85.1cM) - D11S901 (92cM)
Chromosome 15
D15S125 (89cM from 15cen) - D15S204 (96cM) - D15S131 (96.1cM) - D15S114 (98.6cM)
Chromosome 16
D16S408 (74cM from 16pter) - D16S400 (81cM) - D16S421 (85cM)
The recombination distances between these markers differ in some cases from those
detailed in figures 4.2-4.4, as these figures use the most recent data, and the multipoint

















































Figure 4.2 - Location of linked genetic markers in chromosomal region llql3
Recombination distances are shown in centiMorgans. Markers used in this study are




























Figure 4.3 -Location of linked genetic markers in chromosomal region 15q22.31-q25.3
Recombination distances are shown in centiMorgans. Markers used in this study are





































Figure 4.4 - Location of linked genetic markers in chromosomal region 16ql2.1-q22
Recombination distances are shown in centiMorgans. Markers used in this study are
marked with an asterisk.
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4.2.1 - Family 1 - British (see fig. 4.5)
Clinical features: RP, obesity, Polydactyly, mental retardation (MR), very small kidneys
Chromosome 11 15 16
max. multipoint lod score 0.53 0.28




4.2.2 - Family 2 - British (see fig. 4.6)
Clinical features: RP, Polydactyly, diabetes mellitus, hypogonadism
Chromosome 11 15 16
max. multipoint lod score 0.28 0.28




4.2.3 - Family 4 - British (see fig. 4.7)
Clinical features: RP, borderline MR, hypogenitalism, Polydactyly, syn/brachydactyly,
obesity
Chromosome 11 15 16
max. multipoint lod score 0.04 0.40




4.2.4 - Family 5 - British (see fig. 4.8)
Clinical features: RP, Polydactyly of both hands, mild syn/brachydactyly, renal anomalies,
obesity, mild MR, genito-urinary abnormalities
Chromosome 11 15 16
max. multipoint lod score 0.73 0.71 0.62





Chromosome 11 Chromosome 15
□
IP
D11S480 5 ■ 5
D11S913 1 I 2
DI1S987 4 I 6
Dl1S916 (?) I (3)
D11S527 11 1 11
D11S906 4 1 4

















D11S480 5 ■ 2 5 | | 2 D15S125 6
D11S913 2 ! 2 2 1 2 D15S131 2
D11S987 6 ! 8 6 1 8 D15S204 ?
D11S916 3 i 3 (3) I3' D15S114 4D11S527 11 i 8 11
D11S906 4 4 4 1 4



















Haplotype analysis for family BB1, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results.
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Haplotype analysis for family BB2, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results.
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Chromosome 11 Chromosome 15
□
4P
D11S480 1 $ 6
D11S913 2 J 3
DI1S987 (2)| (2)
D11S916 9 | 5
DI1S527 3 | 10
D11S906 ?| ?

































D16S408 5 | 0 6
D16S400 5 | | 6




6 11 5 6 11:
Figure 4.7
Haplotype analysis for family BB4, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results.
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Chromosome 11 Chromosome 15
□
5P
D11S480 1 | ■ 3
D11S913 1 I 2
D11S987 6 a 3
D11S916 6 | 11
D11S527 3 I 11
D11S906 2 I 2


















7 3 | 7
2 2 I 2
3 3 | 3
6 (11) 1 («)
3 11 1 3
2 2
(5) 7 l 4
1□
5P
D15S125 7 1I| 8D15S131 (11)1 I (2)
D15S204 4I I 6
D15S114 4 111 4
4
D15S125 8 ■ 0 8
D15S131 11 I 1 12
D15S204 4 1 | 4













D16S408 4 H| 5
D16S400 1 g | 6
D16S421 5 Hi 5
D16S408 5 1 04
D16S400 6 |1 6
D16S421 5 ■ | 5
Figure 4.8
Haplotype analysis for family BB5, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results.
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4.2.5 - Family 6 - British (see fig. 4.9)
Clinical features: cone-rod dystrophy, moderate MR, obesity, Polydactyly, brachydactyly
Chromosome 11 15 16
max. multipoint lod score 1.80




4.2.6 - Family 7 - Asian - Consanguineous (Parents are first cousins) (see fig. 4.10)
Clinical features: Polydactyly of hands and feet, obesity, RP, mild MR
Chromosome 11 15 16
max. multipoint lod score 1.70 0.37




4.2.7 - Family 8 - Brazilian (see fig. 4.11)
Clinical features: RP, MR, Polydactyly, obesity
Chromosome 11 15 16
max. multipoint lod score 0.71




4.2.8 - Family 9 - British (see fig. 4.12)
Clinical features: RP, obesity, menstrual problems
Chromosome 11 15 16
max. multipoint lod score 0.42 0.10 0.72


























































Figure4.9 Haplotypeanalysisform lyBB6,fl ciS1,2ndB 4. Inferredallelesrinbr ck ts,qu stionmarkrepr sentnkn wnr sults.
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D11S480 '11 1


































D15S125 7 | B 3
D15S131 12 | I 13
D15S204 3 | I 4
D15S114 3d 15
D15S12S 3 ■ ■ 3
D15S131 13 IB 13


















5li56||55 I 0 5 5 |04
Figure 4.10
Haplotype analysis for family BB7, for loci BBS1, BBS2 and BBS4.





DUS480 1 IB4 s n n 4 5 n 4 5
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Haplotype analysis for family BB8, for loci BBS], BBS2 and BBS4.












D11S480 1 1 ^ 5 n 5
D11S913 3 1 3 2 11 2
D11S987 6 ■ 3 <6sl (5)D11S916 4 I 3 6
D11S527 11 1 ^ 6 n 6
DUS906 4 1 2 4 1 2


























Figure 4.12 Haplotype analysis for family BB9, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results.
90
4.2.9 - Family 10 - Swiss (see fig. 4.13)
Clinical features: RP, MR, obesity, Polydactyly
Chromosome 11 15 16
max. multipoint lod score 0.57 0.29 0.53




4.2.10 - Family 11 -Swiss (see fig. 4.14)
Chromosome 11 15 16
max. multipoint lod score 0.60 0.60 0.57




4.2.11 - Family 12 - Norwegian (see fig. 4.15)
Clinical features - RP, obesity, Polydactyly, brachydactyly, dental anomalies, liver disease,
hypogenitalism
Chromosome 11 15 16
max. multipoint lod score 0.60 0.58 0.30




4.2.12 - Family 13 -Norwegian - Consanguineous (parents are second cousins)(see fig.
4.16)
Clinical features - RP, Polydactyly, obesity
Chromosome 11 15 16
max. multipoint lod score 1.30 0.46 0.44





Chromosome 11 Chromosome 15
□
10P
D11S480 (1) 11 (5)D11S913 1 11 3
D11S987 6 11 8
D11S916 3 11 3
D11SS27 8 11 4
D11S906 4 II 2




D11S480 5 1 5 1 I H 5
D11S913 (?) (3) i n : 3
D11S987 6 10 6 pj ! 10
D11S916 (3) (6) 3 H ; 6
D11S527 (8) (10) 8 | ; io
D11S906 4 2 4 1 ! 2
D11S901 (6) (4) 6 | 4
D15S125 (7)!l (4) 4D15S131 21I 10 2
D15S204 41I 4 4
D15S114 4 @1 4 4
£ £
D15S125 7 0 Fj 4 4
D15S131 (2) A 1 4^ 10D15S204 4












Haplotype analysis for family BB10, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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D11S987 (8) | (6)
D11S916 7 | 7
D11S527 8 | 10
D11S906 5 m 2
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Haplotype analysis for family BB11, for loci BBS], BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
D
12P
D11S480 5 ■ 7
D11S913 1 I 2
D11S987 7 7
D11S916 11 7
D11S527 9 I 4
D11S906 (?) (3)
D11S901 6 I 6
■
12A
D11S480 7 ■ ■ 7
D11S913 2 I2
D11S987 7 I I6
D11S916 (7) 1(5)
D11S527 4II 1 11
D11S906 3 I I3
D11S901 6|1 15
■o
7 i 1 D15S125
2 B ! i D15S131
5 p i ii D15S204
5 §j : 6 D15S114














D15S125 7 | |j g 9
D15S131 2l ii 2
D15S204 3 1 H 6 (3)









D16S400 1 | I 1
D16S421 S | | S
-O
i
D16S408 50 0 2
D16S400 1 I 0 6
D16S421 5 0 05
Figure 4.15
Haplotype analysis for family BB12, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
13P (13M)
D11S480 1 | 6 (01 (1) D15S125D11S913 1 1 (1) 1 (1) D15S131
D11S987 8 2 (?) H (2) D15S204
D11S916 5 3 (?) H (3) D15S114
D11S527 2 2 2 I 8
D11S906 (?) (2) (?) 1 (2)
D11S901 7 1 7 (?) ® (5)
13A
D11S480 1 0 1 6D11S913 1 H1 1D11S987 8 07 2
D11S916 5 A 3 (3)
D11S527 2 I8 2
D11S906 (?) 0(2) 2







D15S125 9 00 7
DI5S131 2 0 H 2
D15S204 6 ■ 0 6









D16S421 3 0| 5
13A
D16S408 l|| 2
D16S400 (?) 01 (5)







Haplotype analysis for family BB13, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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4.2.13 - Family 14 - Norwegian (see fig. 4.17)
Clinical features - RP, obesity, Polydactyly, brachydactyly, dental anomalies,
hypogenitalism
Chromosome 11 15 16
max. multipoint lod score 0.71 0.72




4.2.14 - Family 15 - British (see fig. 4.18)
Chromosome 11 15 16
max. multipoint lod score 0.59 0.60




4.2.15 - Family 17 - British (see fig. 4.19)
Clinical features: RP, Polydactyly, obesity, mild MR, renal dysplasia, hypertension,
syndactyly
Chromosome 11 15 16
max. multipoint lod score 1.20




4.2.16 - Family 18 - Norwegian - Consanguineous (see fig. 4.20)
Clinical features - RP, obesity, Polydactyly, brachydactyly, hypogonadism, dental
anomalies, hypertension
Chromosome 11 15 16
max. multipoint lod score 1.50 2.61 0.30





Chromosome 11 Chromosome 15
D
14P
D11S480 1 | 5
D11S913 2 I 2
D11S987 (?) 1 (6)
D11S916 7 I 5
D11S527 8 I 8
D11S906 2 I 4















3 D15S131 2H| 15
7 D15S204 4 iy |4















D16S400 5 |1 6
D16S421 3 HB 8
Figure 4.17
Haplotype analysis for family BB14, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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D11S913 2 | I 2 2 12 D15S131
D11S987 8 H 1 4 8 1 4 D15S204
D11S916 8 0 i 8 8 1 8 D15S114
D11S527 8 0 I 12 8 B12
D11S906 1 1 ! 1 1 1'




D16S408 6 B | 5
D16S400 5 B | 1





D16S400 5 IB 6
D16S421 5 II 3
Figure 4.18
Haplotype analysis for family BB15, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
□
17P
D11S480 (?) | 110)
D11S913 1 I 2
D11S987 6 | 8
D11S916 5 1 I 5
D11S527 6 I 11
D11S906 4 1 4
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Haplotype analysis for family BB17, for loci BBS], BBS2 and BBS4.
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Figure4.20 HaplotypeanalysisformilBB18,l ciB S1,2ndB 4. Inferredallelesinbr ck ts,questionmarkepr entnkn wnr ult .
4.2.17 - Family 19 - British (see fig. 4.21)
Clinical features: RP, obesity, Polydactyly, hypogonadism, hypertension
Chromosome 11 15 16
max. multipoint lod score 0.69 0.69




4.2.18 - Family 20 - Egyptian - Consanguineous (see fig 4.22)
Clinical features - RP, Polydactyly (right hand), brachydactyly, syndactyly, mild obesity,
short stature
Chromosome 11 15 16
max. multipoint lod score 0.58




4.2.19 - Family 21 - British (see fig 4.23)
Clinical features: RP, Polydactyly, mild MR, renal anomalies
Chromosome 11 15 16
max. multipoint Iod score 0.60




4.2.20 - Family 22 - Swedish (see fig 4.24)
Clinical features - RP, obesity, Polydactyly, brachydactyly, hypogonadism, dental
anomalies
Chromosome 11 15 16
max. multipoint lod score 0.39
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i A i




















Haplotype analysis for family BB20, for loci BBS], BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
□
21P






D11S901 (?) ■ (5)
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21A
D11S480 1 | 1D11S913 2 I 2
D11S987 (7) 1 (8)
D11S916 6 I 7
D11S527 6 1 12
D11S906 (4) I (2)









1 D15S125 3 ||7
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D16S408 3| I 6
D16S400 6 II 5
D16S421 3Q| 3
D16S408 6 ■ H4
D16S400 (3)1 1?
D16S421 5 I 1 4
Figure 4.23
Haplotype analysis for family BB21, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
□
22?
D11S480 1 1 1
D11S913 3 I 1
DI1S987 4 I 6
D11S916 7 1 8
D11S527 8 1 2
D11S906 (2) 1 (?)
D11S901 8 1 5
I
D11S480 1 1 1
DUS913 1 1 1
D11S987 (6) (?)
D11S916 8 1 6
D11S527 2 5 8
D11S906 (?) \ (4)
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Haplotype analysis for family BB22, for loci BBS], BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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4.2.21 - Family 23 - Danish (see fig. 4.25)
Clinical features - RP, obesity, Polydactyly, clinodactyly, brachdactyly, hypogonadism,
mild MR, gout, hypodontia, liver and kidney disease, high blood pressure, diabetes mellitus
Chromosome 11 15 16
max. multipoint lod score 0.83 0.23




4.2.22 - Family 24 - Danish (see fig. 4.26)
Clinical features - RP, Polydactyly (fingers and toes), brachydactyly, mild MR, dental
anomalies, high blood pressure, obesity, irregular menstruation.
Chromosome 11 15 16
max. multipoint lod score 1.31 1.30




4.2.23 - Family 25 -Danish - Consanguineous (see fig. 4.27 and fsection 4.5)
Clinical features - RP, mild MR, Polydactyly, brachydactyly, clinodactyly, hypogonadism,
hypodontia, mild diabetes mellitus, obesity,
Chromosome 11 15 16
max. multipoint lod score 0.17 1.56t 0.29




4.2.24 - Family 27 - Danish (see fig. 4.28)
Clinical features - RP, obesity, Polydactyly, brachydactyly, MR, high blood pressure,
reduced hearing, hypogonadism, dental anomalies
Chromosome 11 15 16
max. multipoint lod score 0.61 0.43
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Haplotype analysis for family BB23, for loci BBS1, BBS2 and BBS4.































Haplotype analysis for family BB24, for loci BBS1, BBS2 and BBS4.
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D16S400 6 I g 6
D16S421 1 | Li 6 («j 11 (6) 6l|46 ■ H 6i ■ y 6
Figure 4.28
Haplotype analysis for family BB27, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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4.2.25 - Family 28 -Norwegian (see fig. 4.29)
Clinical features - RP, Polydactyly, obesity, mild MR, hypogenitalism
Chromosome 11 15 16
max. multipoint lod score 0.60




4.2.26 - Family 29- Italian (see fig. 4.30)
Chromosome 11 15 16
max. multipoint lod score 1.19




4.2.27 - Family 30 - Sweden (see fig. 4.31)
Clinical features - RP, obesity, hypogenitalism, Polydactyly, brachydactyly, renal cyst
Chromosome 11 15 16
max. multipoint lod score 0.72




4.2.28 - Family 31 - Norwegian - Consanguineous (see fig. 4.32)
Clinical features: RP, hypodontia, Polydactyly, brachydactyly, moderate obesity,
hypogonadism
Chromosome 11 15 16
max. multipoint lod score 1.82 3.00





Chromosome 11 Chromosome 15
□-
28P
D11S480 71I 6 1 1 5 D15S125
D11S913 1! I 3 3 | : 1 D15S131








8I I36 I 06
1













D16S400 1 || 6
D16S421 5 H| 7
28A
D16S408 4g|6
D16S400 1 ||| 6
D16S421 5II | 5
1
Figure 4.29
Haplotype analysis for family BB28, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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4
Figure 4.30
Haplotype analysis for family BB29, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Chromosome 11 Chromosome 15
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30P
D11S480 41| 1 5| 5 D15S125
D11S913 3il3 3 | 1 D15S131
D11S987 3 ! | 7 5 | 9 D15S204
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Haplotype analysis for family BB30, for loci BBS1, BBS2 and BBS4.
Inferred alleles are in brackets, question marks represent unknown results
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Figure4.32 Haplotypeanal sisforamileBB31,lociS ,BB 2a dS4. Inferredallelesibrack ts,questionmarksrepresentunknowesults.
4.3 - DISCUSSION
4.3.1 - Linkage To Chromosome 11
In the original report of linkage to chromosome 11 q, Leppert et al identified heterogeneity
within their set of 31 North American families. They achieved a lod score of 4.31 for all 31
families, with the gene for human muscle glycogen phosphorylase, PYGM, at a
recombination fraction (9) of 0.15, but on closer examination of the results they found that
this positive lod score was due to 17 of the families, with the remaining 14 having negative
lod scores. Heterogeneity analysis gave a significant result, (%2 = 5.62, 1 d.f., p = 0.0089),
and after removing the unlinked families from the analysis they obtained a lod score of
12.39 with PYGM (0 = 0.001), and a lod score of 6.03 with the microsatellite marker
D11S913 at 0 = 0.05. Although recombinants had been observed between these two
markers, they could not determine their relative order, and chose to estimate the BBS locus
relative to PYGM. Their analysis placed the locus in an interval 1 cM proximal and 2 cM
distal to PYGM, between the markers UT5150 and INT-2, the gene coding for fibroblast
growth factor type 3 (Dickson and Peters, 1987). As shown in fig. 4.2 it has since been
established that D11S913 lies approximately 2 cM distal to PYGM.
The original report of linkage to BBS] was based on a pooled set of small positive lod
scores, with individual family lod scores ranging from 0.12 - 1.79, the average score being
0.73. This result could have occurred by chance, but linkage to this region has since been
confirmed by Cornier et al (1995) who have identified a region of homozygosity on 1 lq in
two large inbred Puerto Rican families, both of which share a common haplotype,
suggestive of a founder effect for BBS in this population. This enabled them to place the
BBSI locus between the markers GATA8A08 and PYGM (see fig. 4.2), an interval of
around 10 cM.
In this study, statistically significant evidence of linkage has been obtained for a BBS locus
at 11 q 13, between D11S480 (which lies in the region of homozygosity identified by Cornier
et al) and D11S913. A maximum multipoint lod score of 6.26 was obtained at a position 5
cM distal to D11S480 and 3 cM proximal to D11S913 (see fig. 4.33), with a 90%
confidence interval (Z^ - 1) of 5 cM, and 95% confidence interval (Zmax - 2) of 8.5 cM
(Conneally et al, 1985). Considering the updated genetic positions of these markers (fig
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the PYGM locus. This result partially overlaps the interval reported by Cornier et al (1995),
but extends several cM distally.
Heterogeneity analysis also provided statistically significant evidence for genetic
heterogeneity, with a lod score of 6.26 assuming two loci (one linked and one unlinked) (%2
= 28.84, P = 0.0000), 28 times greater than the lod score of 4.82 obtained assuming a single
locus (%2 = 6.64, P = 0.005). When only the 1 lql3 locus is considered, 56% of families
appear linked, as opposed to 36% of families when all four loci (BBS1, BBS2, BBS4 and
unlinked) are considered simultaneously. When combining haplotype analysis and the
estimated conditional probabilities of linkage for each family, eight families show strong
evidence of linkage to BBS1 (BB1, BB5, BB6, BB12, BB15, BB21, BB23, BB24). BB13
and BB20, both of which are consanguineous (although the relationship between the
parents is not known for BB20), also appear linked to BBS1, but do not show homozygosity
for the markers studied in llql3. Homozygosity would be expected for BB13, where the
parents are closely related (second cousins) (see also results for chromosome 16, fig. 4.16),
although markers closer to the locus than those studied here may show identity-by-descent.
Based on results in other consanguineous families, where homozygosity has been observed
for markers flanking a BBS locus (see figs. 4.10 and 4.20), and the close proximity of
several of the markers studied to the region in which the BBS1 gene is located, this result
suggests that these families are not linked to this locus. Another three families (BB11,
BB14 and BB27) may also be linked to chromosome 11, but further work is required to
confirm this, and exclude them from linkage to other loci..
4.3.2 - Linkage To Chromosome 15
Carmi et al (1995a) used a form of DNA pooling to identify the BBS4 locus, using DNA
from a large inbred Bedouin kindred. All affected members were pooled, with unaffecteds
and parents of affecteds comprising another two pools of controls. These DNA pools were
used as templates for PCR reactions with microsatellite markers distributed throughout the
genome. One marker on chromosome 15q showed a shift towards a particular allele in the
affected sample, as compared to the multiple alleles for the control groups, and genotyping
of individual DNA samples was then undertaken for this and flanking markers. This
identified four linked markers as D15S125, D15S131, D15S204 and D15S114, at
chromosome 15q22.3-q23, as shown in fig. 4.3. Multiple recombinants with D15S125, and
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a single recombinant with D15S114, designated these as flanking markers. Maximum lod
scores of 4.09 with D15S131 and 4.66 with D15S204 were achieved at zero recombination
fraction, though the relative order of these two markers was undetermined. Genethon has
since established that D15S131 is 0.6 cM proximal to D15S204 (>1000:1 odds) (Dib et al,
1996), placing the BBS4 locus in a 8.5 cM interval. Most recently, the same group (Haider
et al, 1996) have redefined the limits of the BBS4 locus, using two inbred kindreds. They
now place the locus in a 4.3 cM interval, flanked by D15S131 (6.9 cM distal to D15S125)
and GATA89D04 (D15S823) (see fig. 4.3). This expands the previous limits of the gene
distally by 2.8 cM, disregarding the single unaffected recombinant which placed the gene
proximal to D15S114, as reported by Carmi et al (1995a) in the original family studied.
In this study, a maximum multipoint lod score of 6.10 was obtained at a location 5 cM
distal to D15S125, and 2 cM proximal to D15S131/D15S204 (see fig 4.34), The 90%
confidence interval spans 6 cM around the maximum lod score location, with the 95%
confidence limit extending to 7.5 cM (Conneally et al, 1985). Heterogeneity testing
showed statistically significant evidence for heterogeneity at odds of 180:1, with a lod score
of 6.10 under the hypothesis of two loci (%2 = 28.07, P = 0.0000), as compared to a score of
3.84 on the assumption of one locus (x2 = 10.39, P = 0.0006). When only the BBS4 locus is
considered, 35% of families appear linked, compared to 32% when all four loci are
considered. Seven families are consistent with linkage to BBS4 when haplotypes and
conditional probabilities are considered (BB7, BB14, BB18, BB19, BB29, BB30, BB31).
Haplotype analysis alone suggests a further three families (BB2, BB11, BB28) may be
linked to this locus.
Of these linked families, three are consanguineous (BB7, BB18 and BB31), and show
homozygosity for D15S125, D15S131 and D15S204, which is consistent with identity-by-
descent. Haplotype analysis in family BB18 (see fig. 4.20) confirms the observation of
Carmi et al (1995a) that D15S125 is a flanking marker, as a crossover in unaffected
member 18C places the locus distal to this marker. Haplotype analysis of pedigree BB31
(see fig. 4.32) also highlights two informative crossovers, one in affected male 31A, placing
the locus proximal to D15S114, and another in unaffected female 3IB, placing BBS4 distal
to D15S131, agreeing with the results of Haider et al (1996). This places the locus BBS4 in
the interval between D15S114 and D15S131, a genetic distance of 1.6cM (Dib et al, 1996),
narrowing the region reported by Haider et al by approximately 2 cM.
This size of interval (corresponding to a few megabases) would be suitable for a positional
cloning project to identify the BBS4 gene. Before this could be considered, the results in
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this family would have to be repeated, to confirm the data. In BB31, microsatellite marker
D15S114 is uninformative in the mother, requiring that the crossover in individual 3IB is
confirmed by typing a marker distal to D15S114 that is informative in both parents. The
diagnosis of Bardet-Biedl syndrome in this family would also have to be checked, to
confirm that 31B is unaffected, and that 31A and 31C are both affected with BBS. If all the
results indicate that the BBS locus must lie in this interval, the region could then be
narrowed further, if possible, using Genethon markers lying between D15S131 and
D15S114. Fourteen such new markers have been reported in this interval by Dib et al
(1996), but the genetic order has not been resolved with odds >1000:1 in this region.
Candidate genes localised to 15q22.3-q23 could be mapped using radiation hybrids, to
confirm their location within, or outside, the critical region, which could in turn allow for
mutation analysis of these genes in this family, and others families linked to the BBS4
locus.
4.3.3 - Linkage To Chromosome 16
Linkage was originally identified in another Bedouin kindred using five markers on the long
arm of chromosome 16 (Kwitek-Black et al, 1993). Three of the markers studied by
Kwitek-Black et al gave significant lod scores at zero recombination fraction - D16S408
(Zmax = 4.22), D16S265 (Zmax = 3.14) and D16S186 (Zimx = 3.50). Recombinational events
within the pedigrees placed the locus between D16S419 (9 cM centromeric to D16S408)
and D16S265 (see fig 4.4), defining them as flanking markers. The markers used in this
study included D16S408, and D16S400 and D16S421, two further Genethon microsatellite
markers distal to D16S408. Subsequent work by Kwitek-Black et al (1996) has narrowed
the region containing the BBS2 locus to 2.5 megabases, lying between U28692 and
D16S526 (see fig. 4.4). D16S408 lies within this interval.
This study achieved a maximum lod score of 1.09, under the hypothesis of genetic
heterogeneity (%2 = 5.02, P = 0.041), a result of borderline significance. This lod score is
achieved at a location 2 cM distal to D16S408, and 5 cM proximal to D16S400 (see fig.
4.35). When only the chromosome 16 locus is considered, 27% of families appear linked,
as compared to 24% when all loci are considered simultaneously. Conditional probabilities
and haplotype analysis indicate that three families are linked to BBS2 (BB4, BB9, BB10),
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which is taken as the criteria for linkage. Several other pedigrees may be linked to this
locus (BB1, BB2, BB5, BB11, BB12, BB21, BB22), but more markers in this region will
need to be studied to confirm any tentative linkage. However, BB13, a consanguineous
family, shows homozygosity for all three markers studied in the affected members. The
probability of this haplotype occuring by chance, assuming no linkage disequilibrium, is
0.004342 (1.884 x 10"5). This homozygosity suggests linkage (lod score of 0.46), despite
achieving a higher lod score of 1.30 for chromosome 11, where homozygosity is not
observed. This is probably due to the number, and informativeness, of markers studied on
each chromosome. BB25, another consanguineous pedigree, may be also be linked to
BBS2, though there is no evidence of identity-by-descent for the markers. Lod scores
suggested that BB25 was linked to chromosome 15, but this is clearly not possible when the
haplotypes are examined, and is due to inaccurate allele frequencies biasing the lod score.
4.3.4 - Families unlinked to BBS1, BBS2 and BBS4
Following linkage and haplotype analysis for BBS1, BBS2 and BBS4 in all 29 families, at
least three families (BB8, BB17 and BB28) show no signs of linkage to any of these loci
(figs. 4.11, 4.19 and 4.28). Initial linkage analysis with markers close to BBS3 was also
carried out during this study, but showed no sign of linkage for any of the families. While
more work with further, more informative, markers in this region is required for total
exclusion of this locus in these three families, this result also suggests the possibility that
there is a fifth BBS locus. This suggestion has also been raised by two other groups who
have identified genetic heterogeneity among BBS families. Sunden et al (1995) used 23
Canadian BBS families in linkage analysis studies, and found that none of the four
previously reported loci was a major disease-causing locus in their set of families. They
were also able to exclude linkage to any of the four loci in several families, suggesting the
presence of a fifth locus. A similar result has been reported by Bonneau et al (1996), who
have studied 16 families from France, North Africa and Portugal. Three showed linkage to
BBS3, two to BBS2 and one to BBS4, but linkage to all four loci could be excluded in seven
families, again suggesting a fifth locus that causes BBS.
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4.3.5 - Clinical Correlations
As BBS is known to be genetically and clinically heterogeneous, this raises the possibility
of identifiable clinical variation due to mutations in different loci. Carmi et al (1995b)
suggested specific correlations using clinical data from the three inbred Bedouin kindreds
whch have been used to identify the BBS2, BBS3 and BBS4 loci. They suggested that the
chromosome 3 locus is associated with Polydactyly of all limbs, the chromosome 15 locus
is associated with Polydactyly of the hands only, and with early-onset obesity, whereas the
chromosome 16 locus results in the "lean" form of BBS.
In an attempt to compare Carmi's data with the findings of this study, the main problem
encountered is trying to classify definitively the families studied as being linked to one
specific locus. The most reliable way to attempt this is to exclude a family if recombination
has occurred with markers that are thought to be flanking the locus, or in the case of
consanguineous families, to identify regions of homozygosity. On this basis, 8 families
appear to be linked to chromosome 11, and 7 to chromosome 15. There are no obvious
clinical differences between these families, or the other families in the study, suggesting
that the results of Carmi et al are probably more due to the inbred genetic backgrounds of
the families, further influenced by the comparatively small sample size studied. Another
possibility is allelic heterogeneity, where the specific mutations in the families studied by
Carmi et al result in slightly different phenotypes to those observed in the patients in this
study, who may have different mutations in the same genes.
This study emphasises the importance of recognising additional clinical features in the
diagnosis of BBS. Symptoms identified among the patients included renal anomalies,
dental anomalies, short stature, diabetes mellitus, deafness, hepatic fibrosis and
hypertension. Odea et al (1996) recently noted the importance of renal disease in the
prognosis of BBS. In a study of 21 families, 96% showed renal anomalies, and 75% of
deaths occuring during the study were due to renal failure. Other symptoms they identified
included diabetes mellitus in 25% of patients, and hypertension in 66%, probably due to the
renal disease. Another study, Riise (1996), found renal disease to be the cause of death in
50% of BBS patients. Hepatic fibrosis has previously been reported in several cases of
BBS, and has been diagnosed in two of the families in this study (Pagon et al, 1982;
Nakamura et al, 1990). Elbedour et al (1994) also noted the frequency of cardiac
abnormalities in BBS, suggesting that there is cardiac involvement in 50% of patients.
Hypogenitalism is thought to be more common among males, but Stoler, Herrin and Holmes
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(1995) have proposed that genital abnormalities among females are often missed in
childhood. This agrees with reports among patients of irregular menstruation (Green et al,
1989; R. Riise, personal communication), suggesting that such abnormalities should be
sought systematically. Overall, this study serves to emphasise the need for a
multidisciplinary approach to BBS to identify and treat the complications associated with
this disorder.
A report of obesity and increased height in carriers of BBS has suggested that the BBS gene
can influence growth in heterozygotes (Croft et al, 1995). This study was conducted in a
small sample size of 34 parents of BBS patients, and found four of the 15 fathers to be
severely overweight. This represents three times the expected number in a sample of this
size of American whites aged 35-74, and hence Croft et al have proposed that being a BBS
heterozygote carries a three-fold risk of being obese. Assuming a carrier rate of 1% for
BBS in the general population, Croft et al have suggested that 2.9% of all severely
overweight men are BBS carriers. They also found that BBS heterozygotes were taller than
comparable controls, and that BBS homozygotes were as tall, or taller, than comparably
aged women and men. This finding contradicts reports of short stature in BBS patients
from Schachat and Maumenee (1982), Green et al (1989) and this study (R. Riise, personal
communication). It appears that more research is required, with larger sample sizes, to
confirm or deny the findings of Croft et al . However, the study has emphasised the
importance of research into obesity in Western society, and hence the importance of
identifying the genes responsible for obesity syndromes such as BBS, Prader-Willi
syndrome and Alstrom syndrome. Preliminary research has suggested abnormal serum
leptin levels in BBS patients, but more work is required to find out if this is a general
obesity finding, or specific to BBS (R. Riise, personal communication).
4.4 - CANDIDATE GENES
The high level of non-allelic heterogeneity identified in BBS is unexpected for a rare
disorder with a comparatively specific diagnosis. Sheffield et al (1994) have suggested the
involvement of a ligand-receptor complex, protein sub-units, or proteins involved in a
common pathway, as there appear to be at least four separate genes causing a very similar
phenotype. The involvement of a wide range of organ systems suggests that the genes
involved may have widespread effects, a situation similar to that for Grieg
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cephalopolysyndactyly syndrome. This syndrome, the symptoms of which include
polysyndactyly, macrocephaly and facial anomalies, is caused by mutations in the GLI3
gene, which codes for a zinc finger protein (Vortkamp, Gessler and Grezschik, 1991).
Studies in mice have confirmed that this gene is expressed in the regions affected in Grieg
syndrome (Hui and Joyner, 1993).
Several candidate genes have been suggested for BBS, due to their genetic location,
expression pattern and phenotypic effects when mutated. One of these is the gene which
codes for the (3-subunit of the rod cGMP-gated cation channel (see section 1.6.1).
Mutations have been identified in the a-subunit of the CNCG protein in one form of arRP,
making the CNCG2 gene, coding for the (3 subunit of this protein, a candidate for the retinal
dystrophy seen in BBS (Ardell et al, 1996). Ardell et al (1995) have suggested that this
gene may also be involved in the renal disease seen in BBS, as highly homologous channels
have been found in the kidney. The CNCG2 gene maps to a complex locus on chromosome
16q21, in the same region as linkage has been reported for BBS, and Kwitek-Black et al
(1996) recently mapped it within the region (covering 2.5 megabases) in which the BBS2
gene must lie.
The gene coding for phospholipase C (3-3 (PLCB3) is found on chromosome 1 lql3, very
close to PYGM (Sinke and Geurts van Kessel, 1995), where the BBSI gene has been
mapped. This enzyme plays an important role in signal transduction, and is activated in
many cells as a result of stimulation by ligands such as growth factors, hormones and
guanine nucleotide binding proteins. Correspondingly, the gene is widely expressed in
tissues including the retina, brain and kidney, and comprises 31 exons, ranging from 36
basepairs to 571 basepairs in length (Mazurak et al, 1995). Another gene mapping to
chromosome 1 lql3 is the gene for the fibroblast growth factor 3 (FGF3, also known as the
oncogene INT-2){Peters et al, 1983). This was originally considered as a candidate for BBS
due to its expression pattern and genomic location. FGF3 is generally not expressed in
adult tissues, but is produced at precise stages of embryonic development, and fetal
development, where it is found in the retina, cerebellum, sensory regions of the inner ear,
and the teeth (Wilkinson, Bhatt and McMahon, 1989). A related protein of the fibroblast
growth factor family, FGF4, which lies close to FGF3 in 11 q 13 , is known to be involved in
limb development, and several genes coding for receptors for FGFs result in human skeletal
disorders when mutated (for review of FGF family and receptors, see Muenke and Schell,
1995). However, both these genes have been excluded as candidates for BBS by recent fine
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mapping which places them outside the region where the BBS gene lies (Cornier et al,
1995).
A further candidate gene on chromosome llq is the human homologue of the Drosophila
gene rdgB. The rdgB gene is thought to code for a phosphatidylinositol transfer protein,
which causes light and age dependent degeneration of the rhabdomeres and axons, by
affecting calcium ion mobilisation (Vihtelic, Hyde and Otousa, 1991). Two human
homologues of this gene have been identifed, one at 17p 13.3, the human
phosphatidylinositol transfer protein (Fitzgibbon et al, 1994) and another at llql3.5,
Drosophila-related expressed sequence 9 (DRES9) (Banfi et al, 1996). The DRES9 gene
was identified by searching an expressed sequence tag (EST) database for sequences with
homology to Drosophila genes, and was later linked to marker D11S913 by radiation
mapping. In Drosophila, this gene is expressed in the photoreceptors, antennae, and
sensory processing centres of the brain (Pak, 1995), making it a plausible BBS candidate in
man. Another gene coding for a protein involved in photoreceptor structure is the gene for
Rom-1 on 11 q 13, several cM proximal to PYGM. This is a candidate for the retinal
dystrophy observed in BBS, but it seems unlikely that this gene alone could also be causing
the many phenotypic manifestations of BBS, as Bascom et al (1989) have shown that this
gene is not expressed in the brain, kidney, liver, muscle, lymphoblasts or fibroblasts, and
appears to be photoreceptor specific.
Other genes involved in limb development, such as the homeobox (Hox) genes, are
candidates for BBS. For example, HoxD13 causes synpolydactyly in man when mutated
(Muragaki et al, 1996), and HoxD6 overexpression results in an extra digit in the chick
wing bud (Morgan et al, 1992). Also, the Hox4 gene family are involved in hand and foot
morphogenesis, and are co-ordinately expressed in the CNS and elsewhere in the body
mesenchyme (Tabin, 1992). These developmentally important genes are regulated in part
by retinoic acid (RA) and its derivatives (for review see Conlon, 1995), which are also
known to have a role in retinal function. Excess and deficiency of RA can cause a
syndrome with features such as craniofacial and limb abnormalities, heart and central
nervous system defects (Lammer et al, 1985). RA signal transduction is mediated in part
by cytoplasmic RA-binding proteins, CRABP-I and CRABP-II. Transgenic mice which are
homozygous null mutants for CRABP-II are viable and fertile, but have an extra postaxial
digit, as seen in BBS (Fawcett et al, 1995). CRABP-I is a closely related peptide, the gene
for which maps to chromosome 15q22, several cM distal to D15S114, in the region where
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the BBS4 locus could lie (Haider et al, 1996). All these genes could be considered as
candidates for BBS.
Obesity has recently been shown to be influenced by several genes, including the genes
coding for leptin and its receptor(s) (Lonnqvist et al, 1995, Chen et al, 1996). As obesity is
a symptom of BBS, it would be interesting to see if this syndrome is linked to any of these
genes. A study conducted by Reed et al (1995) suggested that genes that are commonly
involved in non-syndromic human obesity are not present in the regions where linkage to
BBS genes has been identified. As previously mentioned, work is ongoing to investigate
serum leptin levels, to find out if expression is altered in BBS patients.
Recently, the tub gene has been identified in the mouse mutant tubby. The human
homologue of this gene is a strong candidate for BBS because of the similarities between
the tubby phenotype and human BBS. This mouse mutant was a spontaneous autosomal
recessive mutation, first reported by Coleman and Eicher in 1990. It was initially
characterised by slow, progressive obesity, with mild hyperinsulinaemia and hypoglycaemia
in the absence of hyperphagia. Coleman and Eicher (1990) mapped the gene to mouse
chromosome 7, several cM from the Hbb (haemoglobin p chain complex) locus. This
region in the mouse is syntenic to chromosome lip 15 in humans, although some of the
genes in this region map to 1 lql3 (where BBS1 maps to), suggesting a break in the syntenic
relationship (Chung et al, 1996). The genetic map surrounding tub was recently refined by
Chung et al (1996) and allowed exclusion of several candidate genes in the region.
Heckenlively et al (1995) identified a new retinal degeneration mouse mutant rd5, which
showed early progressive hearing loss and progressive retinal degeneration, as seen in
Usher syndrome type I. When they mapped rd.5 to chromosome 7 they could find no
animals with the tubby phenotype without a retinal degeneration, although animals were
observed with retinal degeneration but no obesity. It seems likely that the rd5 and tubby
genes are either very closely linked, or that the phenotypes are pleiotropic effects of a single
gene.
Most recently Noben-Trauth et al (1996) identified two mutations in a candidate gene for
tubby. This gene is expressed predominatly in the brain, eye and testis, and the C-terminus
shows 62% identity at the amino-acid level to a putative mouse testis-specific
phosphodiesterase (p4-6), while the amino-terminal half is novel. Kleyn et al (1996) also
identified a mutation in the tubby candidate gene, and analysed the human homologue of
tub, which is 89% identical to the mouse gene. The encoded protein is predicted to be 94%
identical to the mouse protein, and Kleyn et al also found homology between these two
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proteins and a human retinal transcript of unknown function. Ohlemiller et al (1996) have
examined the cochlear and retinal degeneration in tubby mice, and concluded that while the
retinal phenotype is consistent with that seen in Usher type I, the progression and severity
of the hearing loss, without vestibular defects, suggests that clinically it is more similar to
Usher type II or HI. If tubby and rd.5 are caused by one gene, then BBS, and similar
syndromes such as Alstrom syndrome (which consists of retinal degeneration, sensorineural
deafness, obesity and diabetes) are suitable candidates, although hearing impairment is an
inconsistent feature of BBS.
4.5 - LINKAGE AND HOMOZYGOSITY MAPPING
The linkage analysis carried out in this study illustrates some of the difficulties encountered
when working with a genetically heterogeneous disease. This is further complicated by the
disorder being both rare and autosomal recessive, so that few large multi-generational
pedigrees are available. With this kind of condition, possibly the simplest way to attempt
gene mapping is to study large inbred families, using the technique of homozygosity
mapping, first suggested by Lander and Botstein (1987). Homozygosity mapping relies on
the parents of an affected individual both inheriting the disease gene from a common
ancestor. Thus, any markers closely linked to the disease gene will be identical in the
affected individual, as the same DNA flanking the gene has been passed down to each
parent, and then to the affected child.
This information is taken into account when calculating Iod scores, and greatly increases
the power of consanguineous families in linkage mapping. For example, families BB14 and
BB31 both appear linked to the BBS4 locus on chromosome 15, and both contain two
affected sibs, and one unaffected child. Family BB14, which is non-consanguineous,
achieves a lod score of 0.72 for this locus, whereas BB31 alone reaches a significant lod
score of 3.00, as the parents are second cousins once-removed. However, problems are
encountered in lod score calculations, as inbred pedigrees take longer, and more memory, to
compute, especially if several markers with multiple alleles are being studied, as in this
project. Furthermore, if the marker and disease gene frequencies are inaccurate, this can
lead to errors in the lod scores (see Terwilliger and Ott, 1994). This occurred with one of
the inbred pedigrees studied, BB25, for chromosome 15. This family has two branches
with affected children, one in which both parents are related, and the other with one
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unrelated parent. As all affected children have inherited one common haplotype with
comparatively rare alleles, this has increased the lod score, despite the two affected children
in one branch each inheriting different chromosomes from the unrelated parent (see
fig.4.27). Indeed, this family looks more likely to be linked to chromosome 16, despite a
lack of identity-by-descent. This result exemplifies the difficulty in selecting a suitable
population from which to estimate marker allele frequencies, especially when using
pedigrees from several different countries. In this study, allele frequencies were taken from
GDB (if published) or all assumed to be equal. Ideally, a group of unrelated individuals
from similar genetic populations would have been available for typing with the markers, to
gain an accurate allele frequency estimate.
Several human disease genes have been identified using homozygosity mapping, including
the genes for alkaptonuria (Pollak et al, 1993), spinal muscular atrophy (Gilliam et al,
1990) and Hirschsprung disease (Puffenberger et al, 1994). Usually the pedigrees are from
distinct populations, such as Japan where 1 in 25 marriages involve first cousins, compared
to 1 in 200 in the U.K. (Farrall, 1993). Other commonly studied communities include the
Mennonites, the Mormons of Salt Lake City, the Ashkenazi Jews and Bedouin tribes, such
as the three kindreds used in mapping BBS loci.
In the set of families studied in this project, six were consanguineous, although the degree
of relationship was not known for one of them (BB20). Nevertheless, this information still
meant that identity-by-descent was expected for markers flanking the locus, if the family
was linked to that particular locus. Because of homozygosity mapping, assignments to
specific loci were possible in four of the families. It also seems possible that several of the
other families studied are consanguineous, as the parents share a common haplotype for at
least one of the chromosomes studied (see figs 4.8 (BB5); 4.13 (BB10); 4.30 (BB29)). This
identity-by-state for chromosome markers suggests that each parent has inherited this piece
of DNA from a common ancestor, though they may be unaware of being distantly related.
This is to be expected with such a rare disorder.
4.6 - SUMMARY
This study has attempted to assign 29 families with Bardet-Biedl syndrome to specific,
previously reported, BBS loci. On the assumption of genetic heterogeneity, 36 % are linked
to BBS] (llql3), with a lod score of 6.26. From haplotype anlysis, eight families are
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consistent with this result. For the locus on chromosome 16q21, BBS2, a lod score of 1.09
was reached (assuming genetic heterogeneity), and only three families appear linked to this
region, though one consanguineous family shows homozygosity for all three markers
studied. For BBS4, on chromosome 15, at lod score of 6.10 was achieved, assuming genetic
heterogeneity, and seven families appear linked from haplotype ananlysis. Furthermore,
haplotype analysis in consanguineous pedigree BB31 highlighted two informative
crossovers, enabling us to narrow the BBS4 region from 4.3 cM (Haider et al , 1996) to
approximately 2.2 cM. Several families do not show linkage to any of the regions studied,
suggesting the possibility of a fifth BBS locus.
This work has highlighted problems encoutered in mapping a rare autosomal recessive
condition, especially when non-allelic genetic heterogeneity is present. The most reliable
gene assignments have been possible in consanguineous families, emphasising the power of
large inbred pedigrees in this type of gene mapping. However, care must be taken in
relying on linkage data alone, as small errors in gene frequency can dramatically alter the
final result obtained. Also, the number, and informativeness, of markers studied can alter
the lod score obtained for a specific locus. For reliability, this data should be considered in
parallel with haplotype analysis for each family, to confirm linkage results. Furthermore,
gene assignment is difficult in small families, where a lack of recombination does not
necessarily equate to linkage. This problem can be reduced where possible by using highly
informative markers, so that information can be obtained from all relevant meioses. This
study has also suggested the presence of a fifth BBS locus, and further linkage mapping or
candidate gene analysis could be carried out in the families that appear unlinked to any of
the previously reported loci.
Future work in attempting to identify causative genes for BBS could utilise the
consanguineous families that appear linked to one specific locus, by typing multiple closely
linked, highly informative, microsatellite markers in the regions of homozygosity. In this
way, the region of homozygosity may be narrowed, hopefully to several megabases, a
distance suitable for physical mapping efforts, or testing of candidate genes within the
region. In particular, the results of haplotype analysis in family BB31 have suggested that
further mapping work is required in this family to reduce the interval of homozygosity in
which the BBS4 locus may lie.
Finally, while genetic heterogeneity complicates the possibilty of prenatal diagnosis, this
study emphasises the need for a multidisciplinary examination of suspected BBS patients.
A thorough examination could allow early, and possibly preventative, treatment of
associated conditions to increase the quality of life, and prognosis, for patients.
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CHAPTER FIVE
LINKAGE MAPPING IN AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA
5.1 - INTRODUCTION
The major problem in mapping genes for autosomal recessive retinitis pigmentosa is the
expected nonallelic genetic heterogeneity. To date, four specific genes, rhodopsin, the
alpha- and beta-subunits of cGMP phosphodiesterase, and the alpha subunit of the cyclic
nucleotide gated channel, have been shown to cause arRP when mutated. These four genes
are thought to account for less than 10% of arRP cases (Dryja and Li, 1995). In addition to
these loci, linkage has also been reported to 6p21.3 (RP14) in a large kindred from the
Dominican Republic (Knowles et al, 1994), and to Iq31-q32.1 (RP12) in an extended
inbred Dutch pedigree, and more recently also in a large Pakistani pedigree (Leutelt et al,
1995), with preserved para-ateriolar retinal pigment epithelium (PPRPE), a clinically
distinguishable subtype of RP (van Soest et al, 1994). For the RP14 locus, the
peripherm/RAS gene has been excluded, but the guanylate cyclase activating protein genes
(GUCA1 and 2) which lie in the same region are currently being investigated as candidates
by Shugart et al (1995). Another gene coding for a protein which is abundantly and
exclusively expressed in the retina has also been mapped to the 400kb interval in which
RP14 must lie (Shugart et al, 1995), and is presently being screened in families with arRP
(A. Wright and M. North, personal communication). With at least six separate loci causing
arRP, and a high probability that many more genes will be involved, it is important to carry
out linkage studies for arRP loci in a genetically homogeneous population.
As with most autosomal recessive conditions, few extensive arRP pedigrees are available.
To reduce the complication of genetic heterogeneity without using extended families, a
genetically homogeneous and inbred population can be used for study. In this project the
south-central Sardinian population was selected, as it is known to be a genetic outlier, with
a comparatively high level of inbreeding. Furthermore, economic, religious and social
factors have encouraged establishment of large families in Sardinia. Finally, a high
proportion of the RP observed in Sardinia is thought to be recessively inherited, providing a
large selection of families to study.
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5.2 - RETINITIS PIGMENTOSA IN SARDINIA
Sardinia is the second largest island in the Mediterranean, lying 150 miles off the North¬
west coast of Italy, 10 miles south of Corsica. Much of the terrain is mountainous, with a
low population density, although there are several fertile alluvial plains in coastal areas.
Most of the population of around 1.5 million people is concentrated in the capital towns of
the four provinces - Cagliari, Sassari, Nuoro and Oristano (Bernardinelli et al, 1994). The
origin of the Sardinian population is thought to be multicentric, with evidence of
colonisation since the pre-Neolithic period (over 9000 years ago). Archealogical findings
indicate a "nuragic" culture, in common with other coastal and island areas of the
Mediterranean, around 6000 years later. Colonisation of the island introduced the
Phoenicians, Carthagians and Romans to Sardinia (Bernardinelli et al, 1994). The
inhabitants also suffered invasions by the Vandals, Byzantines, Saracens, and later
domination by the Pisans, Genoese, and Spanish, until finally becoming a region of Italy in
1861 (Cappello et al, 1996). However, the local inhabitants are thought to have taken
refuge in the central moutainous regions of the island, also avoiding outbreaks of malaria in
the lowlands (Workman et al, 1976).
Genetic analysis of polymorphisms, such as immunoglobulin allotypes, confirm this history
of the island's inhabitants, showing a strong association with Italian, North African and
Middle Eastern populations (Piazza et al, 1976; Menozzi et al, 1978). The comparative
isolation of the island from the rest of Europe, also seen through linguistic studies,
combined with a small initial population size, and genetic drift, has resulted in the modern
population being one of the most genetically deviant in Europe, second only to the Lapps
(see fig. 5.1) (Cavalli-Sforza and Piazza, 1993). Low migration has also meant that the
population has remained relatively stable, with low rates of immigration due to a poor
economy. Within the island, the geography has resulted in isolation of communities, with
increased levels of endogamy, resulting in genetic heterogeneity between small villages.
Consanguinity rates have remained quite high, particularly in the highlands, where 10% of
marriages were consanguineous in the middle of this century (Workman et al, 1976).
Many genetic disorders are prevalent in Sardinia due to this unique genetic background.
Particularly common are glucose-6-phosphate dehydrogenase deficiency and thalassaemia
(both of which are thought to confer increased resistance to malaria in the heterozygote),
multiple sclerosis, insulin-dependent diabetes and Wilson's disease (Bernardinelli et al,
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Figure 5.1 - Sardinia is a genetic outlier in Europe
Genetic tree of 26 European populations. FSt distances are based on an average of 88
genes. From Cavalli-Sforza, Menozzi and Piazza (1994).
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Sardinian population, probably due to a founder effect. This genetic homogeneity makes
the population ideal for the study of autosomal recessive diseases, as do the levels of
consanguinity, and the establishment of large families.
Eleven arRP families from south-central Sardinia (shown in fig. 5.2 and fig. 5.3),
comprising 28 affected and 44 unaffected members, were identified and sampled by Dr. M.
Fossarello (Dept. of Clinical Ophthalmology, University of Cagliari, Sardinia). Clinical
characterisation included complete ophthalmological examination with electrophysiological
and visual field testing, and fluorescein angiography (Fossarello et al, 1993). The
prevalence of arRP in south-central Sardinia has been reported to be 21.5% of all RP
families, but this is likely to be an underestimate, as many recessive cases will have only
one affected, and have been designated as simplex. However, when compared with 5% of
families having autosomal dominant RP, and 1.3% having X-linked recessive RP, arRP is
clearly the most common type of genetic RP within this population. Genetic analyses of
eight families with adRP from this region have shown that 50% have rhodopsin mutations
(Fossarello et al, 1993), a much higher proportion than in most populations, where
rhodopsin accounts for around a quarter of all adRP (Dryja, 1992). Indeed, three of the four
families in which rhodopsin defects were identifed shared exactly the same mutation. This
can be taken as further evidence of genetic homogeneity within this population.
5.3 - EXCLUSION OF CANDIDATE LOCI
Before this project began, previous work carried out by Dr. D. Mansfield involved
exclusion of candidate loci for arRP using markers in the regions surrounding candidate
genes. A dinucleotide microsatellite repeat in the first intron of the rhodopsin gene was
analysed, and allowed for the exclusion of 3 out of 9 of the Sardinian families. The (3-PDE
gene in chromosomal region 4pl6 could not be excluded due to a positive lod score with the
neighbouring marker HOX7, but a mononucleotide repeat in the 3' untranslated region of
the peripherin//?DS gene allowed the exclusion of this gene in 5 of the 9 families. A further
thirty markers were analysed on chromosomes 2,1, 11, 16, 18 and 21, all resulting in
negative lod scores, with the exception of one marker on chromosome 11. These results
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Figure 5.2 - Pedigrees of the eleven Sardinian families used in this study.
Individuals in brackets were not included in this study. For the two consanguineous
families the relationship between the parents is indicated.
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Figure 5.3 - Map of Sardinia, showing the relative geographic locations of the families
used in this study.
Each number represents the pedigree number, see fig. 5.2.
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5.4 - GENOME SCANNING FOR ARRP GENES
In an attempt to identify linkage among the set of 11 Sardinian families studied, 195
microsatellite markers were typed in collaboration with Dr. D. Mansfield. Most of the
highly informative markers used were taken from the Genethon catalogue, with an average
spacing of 20 cM. No significant lod scores (Z > 3) were obtained with the complete set of
families. However, considerable exclusions (as calculated by P. Teague) were possible
using Z < -2, excluding a total of 2,284 cM, representing 62 % of the genome (assuming a
sex-averaged length of 3,699 cM) (Dib et al, 1996), on the assumption of genetic
homogeneity. The genome exclusions are detailed in figure 5.4, showing the region
excluded from the results of each marker. Any lod scores > 0.50 have been highlighted in
bold. The approximate location of any candidate genes has been included, relative to the
markers studied. Regions excluded on the basis of genetic homogeneity included the genes
coding for (3-PDE, rhodopsin, CNCG1, a-PDE, y-PDE, phosducin, arrestin, peripherin//?DS
and the whole short arm of chromosome six, as linkage has been reported for arRP to 6p21
in a large inbred kindred from the Dominican Republic (Knowles et al, 1994). Figure 5.5
also shows these exclusions as a representation of each chromosome, highlighting the areas
not yet excluded. Although further analysis of regions not yet excluded could yield positive
lod scores, it seems highly likely that there is genetic heterogeneity among the families in
this study.
This suggestion of genetic heterogeneity led us to examine the individual family lod scores
for each marker, with particular attention paid to markers close to candidate loci. The loci
considered were phosducin (PDC), RP12 (van Soest et al, 1996), arrestin (SAg), rhodopsin
(RHO), the alpha, beta and gamma subunits of cGMP phosphodiesterase (PDEA, PDEB and
PDEG), the alpha and beta subunits of the cyclic nucleotide gated channel (CNCG1 and
CNCG2), RP14 (Shugart et al, 1995), peripherin (RDS), recoverin (RCV1), guanylate
cyclase (GUC2D), interphotoreceptor retinol-binding protein (RBP3), ROM-1 , rhodopsin
kinase (RFC) and the alpha and gamma subunits of rod transducin (GNAT1 and GNGT1).
Genetic locations for each locus were obtained from the Human Transcript Map
(http://www.ncbi.nlm.nih.gov/SCIENCE96/) or the Genetic Location Database (LDB)
(http://cedar.genetics.soton.ac.uk/). For all but one of the loci at least one of the families
showed signs of no recombination with the closest marker studied (see fig. 5.6). These









0.01 0.05 0.10 0.20 0.30 0.40
REGION OF
EXCLUSION
D1S243 1.00 -4.76 -1.08 0.08 0.60 0.44 0.14 0.00-3.05
D1S214 1.06 -10.13 -4.31 -2.18 -0.63 -0.15 -0.02 2.31-29.76
D1S228 1.11 -10.18 -4.35 -2.21 -0.63 -0.14 -0.01 16.95-44.39
D1S199 1.16 -11.70 -5.18 -2.75 -0.90 -0.26 -0.05 28.53-62.08
D1S255 1.23 -12.04 -5.45 -2.96 -1.00 -0.29 -0.05 49.02-82.57
D1S220 1.31 -9.48 -4.25 -2.28 -0.77 -0.23 -0.04 75.49-102.94
D1S305* 1.56 -10.63 -4.22 -1.93 -0.37 0.01 0.03 154.76-170.01
D1S196* 1.64 -11.06 -4.61 -2.27 -0.59 -0.10 0.00 172.08-199.53
D1S210* 1.66 -3.11 -0.70 0.02 0.31 0.21 0.06 190.13-193.18
D1S242* 1.67 -13.28 -6.41 -3.70 -1.46 -0.52 -0.12 174.76-214.41
D1S191* 1.70 -14.90 -6.51 -3.46 -1.22 -0.42 -0.09 186.59-220.14
D1S202* 1.70 PDC -8.66 -2.97 -1.02 0.17 0.28 0.10 198.79-207.94
D1S306 1.75 RP12 -7.20 -3.27 -1.80 -0.64 -0.21 -0.04 210.37-225.62
D1S237 1.81 -9.04 -3.33 -1.35 -0.09 0.12 0.05 227.94-243.19
D1S213 1.84 -11.67 -4.05 -1.42 0.21 0.38 0.15 236.72-251.97
D1S225 1.85 -13.23 -5.00 -2.15 -0.30 0.09 0.06 233.55-261.00
D1S251 1.85 -12.85 -4.64 -1.81 -0.02 0.25 0.10 239.65-254.90
D1S103 1.85 -8.56 -2.88 -0.94 0.23 0.33 0.12 242.70-251.85
D1S235 1.88 -6.83 -2.35 -0.80 -0.15 0.23 0.08 251.48-260.63
D1S304* 1.93 -7.58 -3.09 -1.49 -0.37 -0.06 0.00 263.06-275.26
D2S207* 2.05 -4.35 -1.23 -0.20 0.33 0.27 0.09 11.14-16.56
D2S168* 2.10 -2.43 -0.10 0.54 0.65 0.38 0.11 24.99-27.70
D2S171 2.18 -17.65 -7.59 -3.84 -1.04 -0.18 0.00 30.89-66.11
D2S119 2.25 -7.38 -2.43 -0.80 0.08 0.13 0.04 61.12-74.67
D2S134 2.32 -11.35 -4.83 -2.35 -0.50 0.01 0.05 75.09-99.48
D2S139 2.38 -9.30 -3.54 -1.50 -0.13 0.14 0.07 97.13-110.68
D2S160* 2.46 -8.47 -3.49 -1.60 -0.25 0.07 0.05 119.29-132.84
ill a (2) 2.46 -1.36 -0.62 -0.32 -0.09 -0.02 0.00 no exclusion
D2S114 2.53 -16.12 -6.49 -3.04 -0.66 -0.05 0.02 130.55-160.36
D2S141* 2.60 -14.66 -6.14 -2.98 -0.68 -0.04 0.03 149.94-179.75
D2S138 2.69 -16.82 -7.59 -4.09 -1.38 -0.43 -0.09 172.16-207.39
D2S155 2.76 -8.96 -4.28 -2.48 -1.04 -0.42 -0.10 194.26-224.07
D2S126 2.83 -16.96 -8.26 -4.84 -1.95 -0.71 -0.16 208.23-248.88
D2S206* 2.90 SAg -0.70 0.41 0.65 0.57 0.31 0.09 no exclusion
D2S140* 2.98 -18.27 -8.70 -4.96 -1.88 -0.64 -0.14 249.78-274.17
D3S1270* 3.00 -4.75 -1.63 -0.58 0.03 0.10 0.04 0.00-2.37
D3S1293* 3.16 -2.02 -0.23 0.28 0.43 0.26 0.08 34.91-37.28
D3S1260* 3.25 -3.91 -1.19 -0.23 0.30 0.25 0.08 53.51-60.62
D3S11 3.26 GNAT1 -14.77 -6.86 -3.84 -1.39 -0.44 -0.08 41.62-77.12
Figure 5.4
Table of lod scores and exclusion regions using microsatellite markers in the set of 11









0.01 0.05 0.10 0.20 0.30 0.40
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EXCLUSION
D3S1312 3.35 -2.28 -0.46 0.09 0.31 0.20 0.06 79.18-81.55
D3S1276* 3.48 -9.16 -3.96 -2.05 -0.63 -0.17 -0.03 99.99-121.32
D3S1278 3.57 -25.43 -12.12 -6.95 -2.66 -0.91 -0.19 109.11-154.14
RHO (3) 3.63 RHO -3.43 -0.89 -0.04 0.41 0.33 0.11 142.01-153.86
D3S1273 3.64 -7.77 -2.12 -0.23 0.79 0.67 0.24 162.72-170.13
D3S196 3.71 -10.32 -4.46 -2.31 -0.69 -0.16 -0.02 142.05-149.16
D3S1306 3.72 -6.70 -1.60 0.10 0.94 0.73 0.25 174.55-195.88
D3S1282 3.80 -6.90 -3.42 -1.99 -0.76 -0.26 -0.05 181.46-212.27
GLUT2 (3) 3.85 -11.53 -5.45 -3.06 -1.10 -0.35 -0.07 190.78-221.59
D3S1262* 3.89 -10.92 -5.00 -2.77 -1.00 -0.33 -0.07 151.21-177.28
D3S1265 3.98 -10.72 -3.89 -1.52 -0.03 0.19 0.08 221.23-230.71
D4S179 4.01 PDEB -6.36 -3.02 -1.72 -0.65 -0.22 -0.05 0.00-7.00
D4S431 * 4.05 -9.34 -4.12 -2.17 -0.70 -0.20 -0.03 3.29-22.81
HOX7 (4) 4.06 1.13 1.04 0.90 0.59 0.30 0.08 no exclusion
D4S403* 4.12 -4.60 -2.01 -1.06 -0.34 -0.10 -0.02 18.14-30.34
D4S391 4.20 -6.59 -2.16 -0.66 0.23 0.27 0.10 35.12-47.32
D4S230 4.21 -8.59 -4.45 -2.73 -1.18 -0.46 -0.11 27.48-59.20
D4S174 4.27 -9.43 -3.95 -1.86 -0.34 0.05 0.05 47.53-64.61
D4S405* All -9.74 -3.95 -1.87 -0.42 -0.04 0.01 47.53-64.61
D4S428* 4.30 CNCG1 -5.35 -2.15 -1.02 -0.24 -0.03 0.00 56.34-68.54
D4S190 4.30 -6.72 -2.86 -1.47 -0.45 -0.11 -0.02 56.34-68.54
GRB1 (4) 4.32 -7.44 -2.93 -1.31 -0.19 0.07 0.04 60.58-72.79
D4S392 4.37 -12.95 -5.74 -3.04 -0.97 -0.26 -0.04 61.43-93.15
D4S189 4.43 -3.42 -0.82 0.08 0.54 0.44 0.16 86.37-93.69
ALB (4) 4.45 -4.00 -1.97 -1.16 -0.46 -0.17 -0.04 88.17-100.37
D4S407* 4.55 -8.44 -3.32 -1.51 -0.28 0.01 0.02 109.39-121.59
D4S191 4.62 -9.98 -4.19 -2.10 -0.60 -0.14 -0.02 119.36-141.32
D4S424* 4.68 -10.04 -4.23 -2.11 -0.58 -0.12 -0.01 132.10-154.06
D4S622* 4.84 -8.20 -3.65 -1.96 -0.67 -0.21 -0.04 168.49-185.57
D4S408 4.94 -9.01 -3.83 -1.94 -0.55 -0.13 -0.02 189.71-206.79
D4S171 4.97 -8.96 -4.29 -2.46 -0.95 -0.33 -0.07 203.39-212.20
D4S426* 4.99 -8.11 -3.55 -1.86 -0.58 -0.16 -0.03 200.32-212.20
D5S432 5.10 -0.49 0.56 0.73 0.56 0.29 0.08 no exclusion
D5S419* 5.19 -9.85 -4.04 -1.95 -0.47 -0.06 0.01 28.58-44.26
D5S407* 5.31 -12.98 -5.79 -3.10 -1.03 -0.30 -0.06 43.34-76.94
D5S424* 5.39 -15.45 -6.92 -3.71 -1.23 -0.35 -0.06 56.90-94.98
D5S401* 5.46 -7.10 -2.68 -1.16 -0.16 0.05 0.03 84.18-95.38
D5S421* 5.57 -2.94 -0.01 0.79 0.92 0.55 0.16 108.15-114.87
D5S399* 5.67 PDEA -10.15 -4.31 -2.17 -0.60 -0.12 -0.01 118.95-143.59
D5S400* 5.82 -18.72 -8.79 -4.97 -1.87 -0.64 -0.14 139.63-182.19
Figure 5.4 (cont.)
Table of lod scores and exclusion regions using microsatellite markers in the set of 11
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D5S408* 5.92 -16.42 -7.79 -4.46 -1.72 -0.61 -0.13 161.63-184.03
D6S344* 6.01 -4.22 -1.14 -0.16 0.32 0.26 0.08 2.01-4.08
F13 (6) 6.06 -10.05 -4.65 -2.56 -0.90 -0.29 -0.06 5.86-26.56
D6S277 6.06 -15.28 -7.29 -4.18 -1.61 -0.55 -0.12 0.00-30.70
D6S202 6.11 -9.21 -3.43 -1.43 -0.18 0.06 0.03 13.84-28.33
D6S259 6.13 -11.88 -5.30 -2.82 -0.92 -0.26 -0.05 9.58-40.63
D6S289* 6.14 -7.09 -2.63 -1.06 -0.04 0.13 0.06 21.94-32.29
D6S109 6.16 -11.46 -4.89 -2.44 -0.62 -0.07 -0.02 17.69-44.60
D6S105 6.21 -11.37 -4.72 -2.23 -0.42 0.05 0.06 27.74-54.65
TNF (6) 6.22 -7.34 -2.18 -0.39 0.63 0.58 0.21 38.03-48.38
D6S291* 6.24 RP14 -7.23 -2.77 -1.20 -0.17 0.05 0.03 42.05-52.40
FTHP1 (6) 6.26 -5.38 -2.17 -1.01 -0.21 -0.01 0.01 46.08-56.43
RDS (6) 6.30 RDS -10.06 -4.70 -2.60 -0.89 -0.25 -0.04 43.77-74.82
D6S294* 6.38 -14.43 -7.06 -4.16 -1.69 -0.62 -0.14 55.72-95.05
D6S275* 6.50 -10.79 -4.87 -2.63 -0.88 -0.25 -0.04 83.99-115.04
D6S268* 6.56 -4.31 -1.75 -0.84 -0.20 -0.03 0.00 106.41-116.76
ARG (6) 6.63 -2.34 -1.02 -0.53 -0.16 -0.04 -0.01 122.55-128.76
D6S292* 6.68 -5.22 -1.51 -0.32 0.30 0.26 0.09 130.54-140.89
D6S290* 6.76 -3.85 -1.35 -0.50 0.00 0.07 0.03 148.70-154.91
D6S264* 6.89 -4.56 -0.95 0.13 0.55 0.36 0.11 174.84-181.05
D6S281 6.99 -3.13 -0.73 -0.01 0.29 0.20 0.06 194.95-201.10
D7S531* 7.03 -14.80 -6.88 -3.85 -1.42 -0.48 -0.10 5.52-23.32
D7S513* 7.09 -11.34 -5.33 -3.01 -1.11 -0.37 -0.08 2.32-32.58
D7S493* 7.19 -10.77 -4.35 -2.06 -0.47 -0.05 0.01 22.50-45.64
D7S484* 7.30 -5.40 -1.69 -0.49 0.16 0.17 0.06 49.86-58.76
D7S506* 7.41 -18.17 -8.81 -5.15 -2.06 -0.75 -0.17 52.30-96.80
D7S502* 7.43 -6.43 -2.05 -0.58 0.25 0.27 0.09 73.78-82.68
W30 (7) 7.60 -6.54 -3.17 -1.83 -0.71 -0.24 -0.05 101.50-117.52
D7S479* 7.60 GNGT1 -5.14 -1.96 -0.84 -0.11 0.04 0.02 105.06-113.96
D7S480* 7.69 -4.35 -1.27 -0.27 0.23 0.20 0.06 121.62-130.52
D7S500 7.78 -16.52 -7.87 -4.52 -1.74 -0.61 -0.13 122.16-163.00
D7S505 7.89 -8.00 -3.46 -1.80 -0.56 0.01 0.01 154.86-170.88
D7S550* 7.98 -5.16 -1.98 -0.88 -0.15 0.01 0.01 174.98-182.10
D8S262* 8.03 -9.96 -4.66 -2.63 -0.99 -0.34 -0.07 0.00-18.75
D8S265 8.13 -11.33 -4.86 -2.49 -0.76 -0.20 -0.03 6.15-35.39
D8S282 8.21 -6.77 -2.88 -1.46 -0.42 -0.10 -0.01 28.06-40.10
D8S260 8.43 -9.26 -4.05 -2.12 -0.67 -0.19 -0.03 59.51-81.87
D8S273 8.56 -10.71 -4.30 -2.01 -0.41 0.01 0.04 81.14-103.50
D8S257 8.62 -9.13 -3.42 -1.44 -0.15 0.09 0.05 96.29-108.33
D8S266 8.77 -9.20 -3.96 -2.02 -0.59 -0.14 -0.02 116.09-138.45
Figure 5.4 (cont.)
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D8S274 8.88 -4.62 -0.97 0.16 0.64 0.45 0.15 141.27-148.15
D9S54 9.03 -14.44 -6.78 -3.85 -1.49 -0.54 -0.12 0.00-22.52
D9S171* 9.25 -14.62 -6.70 -3.67 -1.27 -0.38 -0.07 22.64-59.15
D9S170* 9.75 -8.15 -3.04 -1.25 -0.07 0.14 0.06 117.58-130.72
D9S158 9.98 -12.04 -5.48 -3.01 -1.07 -0.35 -0.07 145.65-164.63
D10S213 10.31 -1.24 -0.09 0.21 0.26 0.14 0.04 no exclusion
D10S196 10.40 RBP3 -6.99 -2.57 -1.05 -0.10 0.07 0.03 65.44-78.11
D10S219* 10.58 -7.75 -3.24 -1.61 -0.45 -0.10 -0.01 98.15-110.82
D10S185 10.68 -8.72 -3.56 -1.71 -0.40 -0.04 0.01 114.51-130.80
D10S186* 10.91 -13.08 -5.88 -3.18 -1.09 -0.33 -0.06 147.25-181.64
D10S212* 10.99 -4.36 -1.80 -0.88 -0.24 -0.05 0.00 174.45-181.70
D11S922* 11.02 -7.39 -2.33 -0.60 0.42 0.43 0.16 1.62-7.62
TH (11) 11.02 -12.26 -5.61 -3.06 -1.04 -0.30 -0.05 0.12-18.12
D11S916* 11.51 ROM-1 -3.10 -0.69 0.04 0.34 0.23 0.07 76.61-81.11
D11S906* 11.54 -2.13 -0.36 0.15 0.31 0.19 0.06 82.79-84.29
D11S527 11.55 -10.31 -3.88 -1.59 -0.06 0.22 0.10 78.36-91.86
D11S901* 11.58 -5.66 -1.91 -0.67 0.06 0.13 0.05 84.54-95.04
D11S931* 11.62 0.58 0.51 0.42 0.26 0.13 0.03 no exclusion
D11S873 11.62 -8.75 -3.46 -1.51 -0.15 0.13 0.07 89.28-102.78
D11S919 11.65 -9.75 -3.99 -1.95 -0.52 -0.11 -0.01 92.47-108.97
D11S900 11.66 -14.66 -5.74 -2.60 -0.48 0.04 0.05 88.03-116.53
D11S927 11.70 -16.40 -6.70 -3.18 -0.67 -0.01 0.05 92.77-124.27
D11S939 11.76 -1.62 0.64 1.19 1.11 0.64 0.19 no exclusion
D11S912 11.88 -1.24 0.45 0.85 0.79 0.44 0.13 no exclusion
D11S968* 11.98 -8.74 -3.60 -1.75 -0.45 -0.08 0.00 145.48-154.48
D11S490 11.99 -6.48 -1.54 0.05 0.81 0.63 0.21 148.54-156.04
D12S81* 12.56 -5.62 -1.88 -0.63 0.08 0.14 0.05 88.30-99.50
D12S78 12.67 -9.80 -3.48 -1.31 0.02 0.20 0.08 105.30-119.70
D12S76* 12.81 -8.47 -3.87 -2.14 -0.78 -0.26 -0.05 124.17-148.17
PLA2 (12) 12.81 -14.07 -6.77 -3.94 -1.59 -0.59 -0.13 116.17-156.17
D12S97* 12.95 -6.29 -2.44 -1.06 -0.13 0.06 0.04 154.25-162.25
D13S175 13.06 -12.06 -5.48 -3.00 -1.05 -0.33 -0.07 5.75-22.65
D13S219* 13.26 -4.02 -1.51 -0.66 -0.12 0.00 0.01 25.35-34.45
D13S155* 13.40 -3.89 -0.83 0.12 0.52 0.36 0.11 43.10-49.60
D13S16 13.62 -11.72 -5.17 -2.72 -0.86 -0.24 -0.04 57.25-87.15
D14S50* 14.04 -5.46 -1.70 -0.46 0.25 0.27 0.10 2.70-8.80
D14S64* 14.13 NRL -11.47 -5.43 -3.04 -1.05 -0.30 -0.05 2.08-32.58
D14S80* 14.16 -9.57 -2.69 -0.43 0.75 0.63 0.21 14.48-25.46
D14S75* 14.28 -18.41 -8.45 -4.64 -1.61 -0.50 -0.09 15.27-55.53
D14S66 14.39 -9.78 -4.42 -2.37 -0.78 -0.23 -0.04 35.51-63.57
Figure 5.4 (cont.)
Table of lod scores and exclusion regions using microsatellite markers in the set of 11
Sardinian arRP families. * markers analysed by the author.
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MARKER CHROMO¬ LOD SCORES REGION OF
NAME SOMAL AT RECOMBINATION FRACTIONS EXCLUSION
POSITION 0.01 0.05 0.10 0.20 0.30 0.40
D14S68 14.67 -15.15 -7.18 -4.10 -1.57 -0.54 -0.12 66.64-104.46
D14S65 14.84 -8.16 -3.07 -1.28 -0.12 0.10 0.05 100.70-114.12
D14S78 14.88 -8.97 -3.78 -1.87 0.48 -0.07 0.00 104.63-114.39
D15S122 15.06 -13.47 -6.21 -3.45 -1.24 -0.41 -0.08 5.07-23.55
D15S132* 15.41 -4.76 -0.97 0.26 0.79 0.55 0.17 40.56-48.26
D15S127 15.77 -15.86 -7.79 -4.60 -1.88 -0.70 -0.16 63.29-104.87
D15S120 15.99 -17.59 -8.28 -4.65 -1.66 -0.50 -0.09 89.08-110.20
D16S407 16.13 -11.22 -4.85 -2.44 -0.64 -0.10 0.00 15.43-29.56
D16S403* 16.33 -12.23 -5.09 -2.48 -0.60 -0.06 0.02 29.03-55.72
D16S408* 16.56 CNCG2 -7.60 -3.11 -1.51 -0.39 -0.07 0.00 65.40-79.53
D16S261 16.72 -5.00 -1.87 -0.82 -0.15 0.00 0.01 87.90-98.89
D17S849 17.00 -12.43 -5.73 -3.13 -1.05 -0.29 -0.05 0.00-14.56
D17S796 17.11 RCV1 -16.55 -7.43 -3.87 -1.19 -0.28 -0.03 22.48-57.84
GUC2D
D17S799 17.25 -11.31 -4.80 -2.39 -0.61 -0.09 0.01 17.62-44.66
D17S798 17.42 -9.47 -3.60 -1.48 -0.07 0.18 0.08 45.73-60.29
D17S791* 17.51 PDEG -7.80 -2.17 -0.30 0.68 0.57 0.19 59.40-69.80
D17S807 17.68 -7.62 -1.99 -0.13 0.86 0.72 0.26 80.66-91.68
D17S785* 17.81 -2.72 -0.32 0.39 0.62 0.41 0.13 100.09-106.33
D17S784* 17.91 -6.62 -2.25 -0.79 0.06 0.15 0.05 110.88-119.20
D18S59* 18.00 -4.62 -1.51 -0.48 0.09 0.13 0.04 0.00-4.29
D18S62* 18.14 -7.17 -2.17 -0.50 0.43 0.41 0.15 11.61-21.62
D18S35 18.40 -7.73 -3.19 -1.52 -0.33 -0.01 0.02 42.37-55.24
D18S34 18.60 -8.90 -3.72 -1.83 -0.45 -0.05 0.01 65.70-81.13
D18S60 18.72 -7.15 -2.65 -1.05 0.01 0.18 0.07 81.99-94.86
D18S70* 18.99 -7.72 -3.20 -1.57 -0.40 -0.07 0.00 115.41-123.99
INSR (19) 19.13 -5.41 -2.59 -1.44 -0.49 -0.14 -0.02 6.89-20.21
D19S221* 19.32 -8.22 -3.05 -1.20 0.00 0.19 0.08 27.77-41.09
D19S210* 19.95 -8.66 -4.04 -2.27 -0.85 -0.29 -0.06 91.08-107.37
D20S95* 20.17 -6.30 -1.94 -0.51 0.27 0.27 0.09 10.30-21.29
D20S27 20.33 -5.51 -1.74 -0.47 0.28 0.29 0.10 26.96-35.51
D20S101 * 20.50 -6.96 -2.52 -1.00 -0.03 0.12 0.05 42.15-53.13
D21S120 21.11 -8.60 -3.22 -1.27 0.01 0.22 0.09 4.27-12.26
D21S210 21.40 -8.89 -3.72 -1.83 -0.46 -0.05 0.01 15.86-30.68
D21S259* 21.68 -7.51 -3.04 -1.45 -0.36 -0.06 0.00 33.68-46.23
D21S168 21.76 -11.98 -5.45 -3.01 -1.12 -0.39 -0.09 28.19-61.26
D22S284* 22.69 -7.59 -2.57 -0.88 0.12 0.21 0.07 34.42-44.95
Figure 5.4 (cont.)
Table of lod scores and exclusion regions using microsatellite markers in the set of 11
















































































































Figure 5.5 - Exclusion map
Pictorial representation of chromosomal regions excluded by the 195 microsatellite markers
used in this study, based on the assumption of genetic homogeneity among the eleven







Phosducin Iq25-q32.1 D1S202** 2 (0.60), 3 (1.20),4 (0.38), 8 (0.40)
RP12 Iq31-q32.1 D1S306* 2 (0.60)




Rhodopsin 3q21.3-q24 RHO*** 7 (0.85)
Phosphodiesterase-
beta subunit
4pl6.3 D4S179** 1 (0.60)
Cyclic nucleotide gated
channel - alpha subunit
4pl2-cen D4S428** 1 (0.30)6(0.30), 8(0.41)
Phosphodiesterase-
alpha subunit
5q31.2-q34 D5S399* 3 (0.30), 8 (0.43)
RP14 6p21.3-p21.2 D6S291*** 2(0.31), 6(0.30), 8(0.31)
Peripherin 6p21.2-cen RDS*** 2 (0.30)
Transducin -
gamma subunit
7q21.3 D7S479** 1 (0.58), 5 (0.76)
Interphotoreceptor
retinol binding protein
10qll.2 D10S196** 1 (0.30), 2 (0.60), 4 (0.37), 5 (0.45),
6 (0.30)
ROM-1 11 q 13 D11S916* 4 (0.40), 5 (0.57), 6 (0.30), 8 (0.50)
Rhodopsin kinase 13q34 No markers
nearby
Cyclic nucleotide gated
channel - gamma subunit
16q 13 D16S408** 1 (0.30), 3 (0.30), 4 (0.46), 13 (0.31)
Recoverin 17p 13-p 12 D17S796* 1 (0.73)
Guanylate cyclase 17pl3.1 D17S796**
Phosphodiesterase-
gamma subunit
17q21.1 D17S791** 2(0.30), 3(1.20), 5(1.01)
Figure 5.6
Table showing individual families with positive lod scores > 0.30 (in brackets) for markers
close to specific candidate loci. *** within 1 cM of the candidate gene; ** within 5 cM;
*within 10 cM.
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gene in question, to establish if the linkage is real, or has occurred by chance with the initial
marker studied. If the results still suggest linkage in any families, SSCP analysis could be
used to scan the exons of the candidate gene in the obligate carriers and affected members
of the family.
Recently, work has begun examining the phosphodiesterase gamma subunit gene on
chromosome 17q21.1. Individual lod scores in families (see fig. 5.6) highlighted this as a
possible region of interest, with two families achieving lod scores > 1.0 for the closest
marker studied, D17S791. Unfortunately this gene has not been precisely mapped, so an
approximate genetic location was taken from the Genetic Location Database (LDB), and
placed the gene within 5 cM of D17S791. Multipoint lod scores were calculated by P.
Teague, using the three closest markers studied, D17S798, D17S791 and D17S807. The
lod scores are shown in figure 5.7, with the maximum likelihood location given as a
distance from the PDEG gene. Dr. F. Manson (MRC Human Genetics Unit) is examining
this gene, which codes for 87 amino-acids, in families 2, 3, 5, 7, 11 and 12. As the exact
gene location is not known and only three markers have been used in the linkage analysis,
any families showing signs of linkage within 42 cM of the approximate gene location are
being studied. This gene is a strong candidate for arRP (see section 1.6.1) but previous
SSCP analysis in 142 arRP patients failed to reveal any mutations (Hahn, Berson and Dryja,
1994).
5.5 - CHROMOSOME 14qll
Close examination of the results of the 195 markers studied revealed two chromosomal
regions where further investigation was required. The first of these was a region of
chromosome llq, where exclusions were not possible due to low positive lod scores for
several microsatellite markers, including D11S902, D11S914 and D11S903. Several retinal
disorders, including Usher syndrome type I, Bardet-Biedl syndrome and Best's vitelliform
macular dystrophy, have been linked to this region, and linkage was investigated using
further microsatellite markers, by Dr. D. Mansfield (results not shown). However, no
significant results were obtained when further markers were studied in each of the families.
The other interesting result was obtained with microsatellite marker D14S80, in
chromosomal region 14ql l.l-qll.2. When the lod scores for each individual family were
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PEDIGREE NUMBER MAXIMUM LOD SCORE APPROXIMATE DISTANCE
FROM PDEG
1 0.72 56 cM proximal
2* 0.60 18 cM proximal
3* 1.17 OcM
4 0.23 110 cM proximal
5* 1.21 18 cM proximal
6 0.00
7* 2.05 42 cM distal
8 0.40 96 cM distal
11* 0.85 42 cM distal
12* 0.59 42 cM distal
13 0.35 68 cM distal
Figure 5.7
Table showing maximum multipoint lod scores, and their location, for each family, using
markers flanking the PDEG locus. Direct DNA sequencing of this gene is being carried out
in families marked with an asterisk.
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studied, it was clear that a subset of five of the eleven families were linked to this marker,
with no recombinants, while the remainder appeared unlinked. The summed lod score of
these five families gave a significant result, Z = 4.17, at 0 = 0.00. Heterogeneity analysis,
using the HOMOG program (Ott, version 3.3) confirmed that a subset of families (a= 0.65)
were linked to this locus (%2= 7.156, p= 0.03).
Further Genethon microsatellite markers in the flanking region (D14S264, D14S64,
D14S275, D14S262 and D14S252) (see fig 5.8), spanning a total of 6 cM, were studied in
the set of eleven families, and the results analysed in the form of haplotypes, and multipoint
lod scores (as calculated by P. Teague). Linkage to this region was excluded in six of the
families, with support for linkage heterogeneity (a= 0.24) at borderline significance
(p=0.065). Haplotype analysis revealed a region of homozygosity in family ARRP1,
suggesting identity-by-descent (IBD), despite no report of consanguinity in this pedigree.
None of the affected individuals from other pedigrees that appeared linked to this region
showed homozygosity for these markers. However, further investigation of this family by
Dr. Fossarello was able to confirm the presence of consanguinity, as the parents are second
cousins (co-efficient of inbreeding, F=0.0156). This suggested that the two affected sibs
studied (BB and BD) had inherited an IBD region from a common ancestor. This region of
homozygosity, shown in figure 5.8, spans four of the markers (D14S64 - 4 cM -
D14S80/D14S275 - 2 cM - D14S262, Gyapay et al, 1994), covering a total of 6 cM. In
affected children of a consanguineous mating, several cM surrounding the disease gene are
usually identical-by-descent. Other regions in the genome will also be homozygous by
chance, but will vary between affected and unaffected children.
In family ARRP1, the coefficient of inbreeding is 0.0156, meaning that at 1.56% of
autosomal loci the offspring will be predicted to have inherited two identical copies of a
gene from each parent, both inherited from a common ancestor (Bittles et al, 1991). As the
region of homozygosity around D14S80 spans 6 cM, representing 0.16% of the genome,
this accounts for approximately 10% of the loci where IBD is expected in the offspring of
this family. This region of homozygosity could have occurred by chance, as the
homozygous alleles present are commonly found within the Caucasian population.
However, based on the allele frequencies from the six Sardinian families tested with these
markers, the expected proportion of individuals homozygous for all four alleles is less than
0.01%, assuming no linkage disequilibrium.
Interest in this region of the genome increased when it was discovered that a candidate gene




























BA BB (BC) BD
D14S264 4 8 6 I5 6 5
D14S64 5 4 4 I4 4 4
D14S80 6 5 5 I5 5 5
D14S275 4 1 4 I4 4 4
D14S262 4 1 1 1 I1 1 1
D14S252 1 1 3 3 1
Figure 5.8
Pedigree of family ARRP1, showing haplotypes for markers on chromosome 14q.
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1.5.6), had been mapped to the same cosmid as the microsatellite marker D14S64, in
chromosomal bands 14ql 1.1-ql 1.2 (A. Swaroop, personal communication). The highly
conserved, retina-expressed NRL gene, which may have a role in the regulation of
rhodopsin expression (Rehemtulla et al, 1996), comprises three exons, the first of which is
untranslated, covering a total coding region of around 700 base pairs. The comparatively
small size of this gene made it ideal for screening for mutations in this affected family.
This gene, and the results of candidate gene screening using SSCP and heteroduplex
analysis, and direct DNA sequencing, are detailed in Chapter Six.
5.6 - HOMOZYGOSITY MAPPING
At the start of this study no DNA was available from the third affected sib of family
ARRP1, individual BC. When interest increased in this family we were able to obtain DNA
for individual BC. Initial analysis with the microsatellite markers shown in fig. 5.8
revealed that homozygosity was also present in this individual for markers D14S64,
D14S80 and D14S262 (see fig. 5.9a). D14S275 proved difficult to PCR amplify in this
individual, and two different results were originally obtained. However, following
resynthesis of the primers for this marker, the PCR reaction was successful, and appeared to
show that BC was not homozygous for D14S275. This result was repeated and confirmed,
and suggested three possible explanations; (i) that the marker order was incorrect, and that
D14S275 lay outwith the region of homozygosity; (ii) that a double crossover had occurred,
which was highly unlikely in the small interval involved; or (iii) that the homozygosity seen
in the other two individuals was not due to identity-by-descent. The maximum multipoint
lod score for family ARRP1 (including BC) for the markers studied was 2.4, at a locus
defined by the microsatellite markers D14S262 and D14S252 (see fig. 5.10). This result
still suggested linkage, although the region of interest had shifted to D14S262 and
D14S252, distal to D14S64 and the NRL candidate gene (assuming the published order of
markers is correct).
To investigate this region in more detail further Genethon markers were studied, following
the publication of their sequences in 1996 by Dib et al. The markers chosen were
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A - Initial haplotype analysis for family ARRP1, including individual BC
B - Haplotype analysis of family ARRP1 with further markers on chromosome 14q,
showing lack of homozygosity in individual BC
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Chromosome14 ConsanguineousF milyARRP1 CentiMorgans
Figure5.10-MultipointanalysisfoamilyARRP1withmarkerssindic ted. Markerpositions,representedbyvert callin s,cor e pondthd st ncftmarkerfrom centromereofchrom some14.
confirmed the order and distances between the markers (all at odds >1000:1) as shown
below, with the exception of D14S252, which was not included in the 1996 map:
D14S972 - 1.2 cM - D14S264/D14S64 - 0.6 cM - D14S1032 - 0.1 cM - D14S1041 - 3.6 cM
- D14S80/D14S275 - 1.3 cM - D14S1042 - 0.1 cM - D14S262
The results of these markers indicated that the apparent homozygosity in BC was due to
uninformative alleles from D14S64 and D14S80 in the mother, although the family remains
linked to markers below D14S275. Indeed, BC has inherited a different maternal haplotype
from BB and BD proximal to D14S1042, but this only became clear after analysis of fully
informative microsatellite markers in this region. However, this family still shows no
recombination with markers distal to D14S275 in all three affecteds, suggesting that another
gene on chromosome 14q could be causing the arRP in this family.
5.7 - DISCUSSION
This project has attempted to map genes causing arRP within a genetically isolated
population. The eleven families chosen for study were from south-central Sardinia, a
genetic outlier with a high proportion of arRP, and comparative and atypical distribution of
homogeneity for other genetic diseases. For example, over 95% of all Sardinian (3-
thalassaemia chromosomes are accounted for by one mutation ((339) (Rosatelli et al, 1992),
and only five common haplotypes (one of which accounts for over half of all Sardinian
mutations) have been identified for Wilson's disease (Figus et al, 1995). The Sardinian
population is also thought to be comparatively homogeneous with respect to glucose-6-
phosphate dehydrogenase (G6PD) mutations, and has the lowest frequency of Rhesus
negative genes in the Mediterranean (Bernardinelli et al, 1994). Diseases associated with
the unique distribution of HLA-types in this population are also particularly prevalent,
including insulin-dependent diabetes mellitus associated with HLA-B18-DR3, and multiple
sclerosis, associated with DR4 and DQw3 (Bernardinelli et al, 1994). Based on this data,
the assumption was that fewer arRP mutations would be present within this population,
hence increasing the likelihood of detecting linkage to specific loci.
The unique genetic composition of Sardinia is probably largely due to random genetic drift.
A small founder population, estimated at 700-1800 at saturation in the late Paleolithic
period around 9,000 years ago expanded to 150,000 by 1,500 B.C., and was augmented with
colonisation by Phoenicians and Carthagians from North Africa about 2,000 years ago
(Bernardinelli et al, 1994). The geographic isolation of the island, with little migration or
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immigration in the last two millenia, has not diluted the effects of drift, which has altered
the gene frequencies within this population - some alleles in the founder population have
been enriched, while rarer mutations have been lost. A combination of drift and selection
(due to heterozygote advantage) have influenced the prevalence of disorders such as (3-
thalassaemia and G6PD.
A similar genetic situation is seen in Finland. Archaeological evidence shows that the
country has been inhabited for up to 10,000 years, but the present population of 5 million
are thought to be largely descended from a small number of founders (including Germanic
and Baltic immigrants), approximately 2,000 years ago (de la Chapelle, 1993). Subsequent
immigration has had little effect on this isolated population. In Finland there is a high
incidence of over thirty (mostly autosomal recessive) genetic diseases which are rare
elsewhere, including Usher syndrome type III, aspartylglucosaminuria and diastrophic
dysplasia (de la Chapelle, 1993). Where the defect has been identified, most of these
conditions have been shown to be highly homogeneous. Again, this is probably due to
genetic drift, enriching the population for specific genetic mutations. This is further
confirmed by the low prevalence of other diseases that are comparatively common
elsewhere, such as cystic fibrosis and phenylketonuria, where the mutations have been lost
in this population through drift.
Within the Finnish population, linkage disequilibrium - the non-random association of
alleles at linked loci - has allowed for finer localisation of causative genes than the expected
1-2 cM in conventional linkage mapping. Linkage disequilibrium is influenced by the
number of generations the mutation has passed through in the population, and the
recombination frequency of the region the gene lies in. When this information is known,
calculations can be made regarding the position of the gene relative to flanking markers
(Jorde, 1995). Indeed, linkage disequlibrium is a powerful tool for fine-mapping disease
loci, and is most likely to be successful in isolated and well-defined populations, such as
Sardinia and Finland. Other isolate populations, including the Old Order Amish, French
Canadians, Ashkenazi and Yemenite Jews, and Louisiana Acadians have been used for such
studies (Zlotogora, 1994).
Genetic mapping with eleven Sardinian arRP families, using 195 genome-wide
microsatellite markers, was unable to identify any consistent linkage. Large exclusions
(62% of the genome) were possible on the assumption of genetic homogeneity. Although
some positive lod scores were obtained, none were statistically significant (Z > 3.0) with all
eleven families, suggesting nonallelic heterogeneity within this population. This may be
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due to the genetic heterogeneity observed between communities within Sardinia, especially
between highland and lowland villages (Workman et al, 1976). High consanguinity rates,
especially among the upper classes, and in highland communities (Workman et al, 1976), in
combination with a founder effect and genetic drift will have contributed to this local
differentiation. Thus, the population could be thought of as a being composed of many
smaller, previously isolated communities.
One region of interest, in chromosomal region 14q 11, was noted from the results with
microsatellite marker D14S80. This marker appeared linked in a subset of five families,
and was investigated using further flanking markers. The results initially revealed a region
of homozygosity covering 6 cM in two affected members of a consanguineous family. As
this region is thought to include the NRL gene, a candidate for retinal dystrophies, it was
decided to investigate NRL within this family, using mutation analysis. This gene, and the
results of the analysis, are described and discussed in Chapter Six. However, when DNA
became available for analysis from the third affected individual in this pedigree, the region
of homozygosity was decreased, and analysis with further flanking markers confirmed that
the original homozygosity was due to uninformative parental markers. Nevertheless, this
family still show no recombination with markers distal to D14S275 (see fig. 5.9b and 5.10),
suggesting that another gene in this region could be causing the arRP in this family. One
possible candidate is the ChxlO gene at 14q24.3 (Burmeister et al, 1996), which is briefly
discussed in Chapter Six.
Following the lack of linkage with genome-wide microsatellite markers, a closer
examination of the individual family lod scores was undertaken for each marker. As many
candidate genes for retinal dystrophies have been mapped, careful consideration was given
to microsatellite markers within 10 cM of such loci. Initial indications suggest that several
families merit further investigation for each locus and work has already begun examining
the PDEG gene in several of the Sardinian families. More closely linked markers are now
available for many of the loci, and these could be studied in families where exclusion is not
possible, to confirm or refute any tentative linkage. This positional candidate approach
could also be used for other candidate genes, such as rhodopsin kinase, recently mapped to
13q34, a region where no microsatellite markers have previously been studied in the
Sardinian families. This method does not rely on genetic homogeneity, but considers each
family individually. However, as most of the families available for study are small, and not
consanguineous, the lod scores obtained will be low.
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For further analysis of data with the set of families used in this study, it may be useful to
consider the power of the study - that is, to estimate the probability of detecting linkage
with a given set of families and markers. Several computer simulation programs are
available for this purpose, including SLINK and SIMLINK (discussed by Terwilliger and
Ott, 1994). This information could be particularily useful when looking at a subset of
families, as the lod scores may not be significant (Z > 3.0), but are still unlikely to have
occurred by chance alone. The subject of significance of linkage results has recently been
debated by Lander and Kruglyak (1995, 1996) with reference to multifactorial traits, but
several of the points can also be applied to Mendelian traits (Curtis, 1996). In particular,
they point out the importance of accurately reporting, and following-up, results even if they
are not highly significant, as there is no way of distinguishing real results from false
positives until they have been further investigated. Furthermore, the possibility of
oligogenic inheritance for RP highlights the importance of careful interpretation of results
from linkage studies.
The increase in density of marker maps, such as the Genethon human genetic linkage map,
with over 5,000 microsatellites and an average interval size of 1.6 cM (Dib et al, 1996),
facilitates gene localisation. The location of the gene can subsequently be narrowed using
information from linkage disequilibrium studies, homozygosity mapping, animal models,
and transcript maps. However, this method can still be time-consuming. Candidate gene
screening is another way to identify causative genes, but care must be taken in choosing the
type of screening technique employed, especially when dealing with a limited number of
samples. In a population such as the Sardinian families used in this study, it is very
possible that there is a limited number of mutations, which may be rare in other
populations. This can also be seen as a disadvantage of working with a founder population,
as common mutations in outbred populations, which are of more use in genetic testing and
diagnosis, may be under-represented in the founder population.
This project has highlighted the problem of genetic heterogeneity in arRP, even within a
genetically isolated population, and emphasises the increased power of consanguineous
pedigrees in linkage mapping. Since the start of this work, DNA from a further five
Sardinian families with arRP has become available. These include a family where the
parents are second cousins, and a large, extended, multi-generational family. The latter
could be used for DNA pooling, a method employed to identify linkage in Bardet-Biedl
syndrome by Carmi et al (1995a). This approach involves combining DNA samples from
affected members of the pedigree, and comparing the alleles observed in this group (for a
specific marker) with the alleles observed in a pooled group of unaffected members. If the
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alleles in the affected group show a shift towards homozygosity, this suggests linkage
disequilibrium with the disease phenotype, and hence linkage to the disease.
This kind of approach could also be used in more homogeneous populations, such as the
island of Tristan de Cunha, where most of the inhabitants are direct descendants of 15
original settlers (Roberts, 1980). The estimated carrier frequency of arRP in this population
is as high as 1 in 6, making it ideal for linkage mapping of arRP. However, even in a single
large arRP kindred, genetic heterogeneity can be present, as identified by van Soest et al
(1994) and Leutelt et al (1995). Both groups studied extended pedigrees, and found genetic
and clinical heterogeneity between separate branches of each family. They found that the
PPRPE phenotype correlated with linkage to chromosome lq, and that the branches with
normal RP were not linked to this region, suggesting that two different arRP genes are
segregating within these families. These studies emphasise the need for precise clinical




MUTATION DETECTION IN NRL
6.1 - INTRODUCTION
Chapter five detailed the results from genome-wide linkage mapping, using eleven arRP
families from south-central Sardinia. No significantly positive lod scores (Z > 3.0) were
obtained, but closer examination of the results indicated a positive result on chromosome
14q, for marker D14S80, in a subset of families. Further microsatellite markers in the
surrounding region revealed the possibility of a region of homozygosity-by-descent, in one
consanguineous family, ARRP1. A candidate gene for retinal degenerations, the neural
retina leucine zipper gene (NRL), lies close to D14S80, and was considered a good
candidate for arRP in this inbred family. This chapter describes work carried out to identify
NRL mutations in this family, using three methods of mutation detection. The NRL gene is
also discussed, with reference to its possible role in the retina, and regulatory mechanisms.
6.2 - NRL
In higher eukaryotes, gene expression is partially controlled through regulation of
transcription, involving cA-acting regulatory sequences recognised by trarcs-acting DNA-
binding proteins. At least ten classes of such nuclear transcription factor proteins are
known, including the paired-box (PAX), homeobox (HOX), and basic domain-leucine
zipper (bZIP) families (for review see Mitchell and Tijan, 1989). Mutations in the genes
encoding some of these factors are known to result in specific human diseases. For
example, mutations in PAX-3 and PAX-6 cause Waardenburg's Syndrome (Tassabehji et al,
1992) and aniridia respectively (Ton et al, 1991), and synpolydactyly is associated with
mutations at the HOXDJ3 locus (Muragaki et al, 1996).
Using a subtractive hybridisation technique, Swaroop et al (1992) identified a new member
of the bZIP family of transcription factors. A human cDNA (AS321) was isolated from an
enriched adult retinal library, and was found to be exclusively and highly expressed in all
cells of the adult neural retina, particularly in the photoreceptor cells. This cDNA was used
to isolate additional clones from a retinal library, most of which had 1.3 kb transcripts,
although one clone of 2 kb was found, due to an extended 3' untranslated region. Another
cDNA isolated, designated DD10, contained an in-frame deletion of 105 amino-acids from
the full-length open-reading frame (ORF) of 237 residues, and has since been shown to be
present in the human retina (Rehemtulla et al, 1996). The deduced polypeptide sequence
from the normal ORF contained several conserved phosphorylation sites, and a periodic
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repeat of leucine residues preceded by a putative basic DNA-binding region. The C-
terminal region showed strong sequence similarity to the jun/fos proto-oncogenes of the
bZEP family, with 75% similarity in one exon to v-maf, suggesting functional similarity in
this region.
The gene was also shown to be evolutionarily conserved, with homologous transcripts
detected in the retina of several species from baboons to frogs, and low-stringency Southern
blotting identified homologues in Saccharomyces cerevisiae and Drosophila melanogaster.
Swaroop et al proposed the name NRL (Neural Retina Leucine zipper) for this gene, which
was later mapped to 14qll.l - ql 1.2 by in situ hybridisation to chromosome spreads (Yang-
Feng and Swaroop, 1992). Analysis of the murine homologue, nrl, showed around 90%
homology to the human gene in the coding region, with significant homology in the 5' and
3' untranslated regions (Farjo et al, 1993). The basic motifs and leucine zipper are
identical, with strong conservation of the Proline/Serine/Threonine-rich putative
transactivation domain (see fig 6.1), which is also seen in the jun family of proteins. In
mouse, the 3' untranslated region contains a polymorphic AGG repeat, which shows
variation between different strains. A reduced form of this repeat is also seen in the human
gene (Swaroop et al, 1992).
The NRL gene is composed of three exons covering around 6 kb, the first of which is
untranslated. The 5' upstream region contains a consensus CAP sequence, a CCAAT box,
binding sites for AP-2, AP-1 and two helix-loop-helix binding proteins, suggesting complex
regulation of this gene (Farjo et al, 1993).
6.3 - bZIP PROTEINS
In bZIP proteins, the leucine zipper region allows homo- or hetero-dimerisation, via
hydrophobic interaction between the two parallel a-helices. The adjacent basic region is
thought to extend the a-helices and make sequence-specific contact with the phosphodiester
backbone of DNA (Ellenberger et al, 1992). This dimerisation allows increased specificity
and combined control of transcriptional responses.
Proteins in the bZIP family include Fos, Jun and related proteins, which, when dimerised,
can bind to cAMP response element (CRE)-like sites, and activator protein-1 (AP-1) sites
(Kerppola and Curran, 1994a). Nrl and c-maf (the cellular equivalent of the viral maf
transforming proto-oncogene) are designated as members of a new sub-family of bZIP
proteins, along with MafK, MafF, and kr (the kreisler gene, involved in segmentation)











(408 bp) start codon ->dd10
tcccagcccagctccagaatggccctgccccccagccccctggccatggaatatgtcaatgactttgacttgatgaagtttgagIgtaaa
























Figure 6.1 - NRL coding sequence and exon/intron boundaries. PCR primer sequences are
underlined with continuous lines, specific domains and codons are in bold. The region of
extended homology with v-maf is underlined with a dotted line. The polyadenylation addition
signal (not shown) is located 289 bp 3' to the E3D primer. Numbers below bold single
nucleotides refer to nucleotide numbers in the Genbank Human NRL gene product mRNA
sequence, accession number M81840.
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Nrl proteins (containing the leucine zipper and basic regions) can homodimerise and bind to
a range of AP-1 and CRE sites. These peptides have also been shown to associate with
each other in vitro, and with jun and fos, but not with more distantly related members of the
bZIP family. The resultant dimers can then bind to AP-1 sites with varying affinities. The
consensus sequence that Nrl homo- and hetero-dimers bind to, designated the NRE - Nrl
response element - is shown below, where the central section is similar to an AP-1 site or
CRE-site (Kerppola and Curran, 1994a):
TGC(TGA(G)CTCA)GCA
Rehemtulla et al (1996) identified an NRE-like sequence, among other DNA-binding sites,
in the promoter region of the rhodopsin gene. This NRE is highly conserved in human,
bovine and mouse rhodopsin. This suggested that Nrl could have a role in the
transcriptional regulation of this photoreceptor-specific protein. Electrophoretic mobility
shift assays showed that retinal nuclear extract contains proteins that interact with the
rhodopsin NRE, and addition of Nrl-specific antiserum revealed that Nrl (or an
antigenically similar protein) was one of the proteins binding to this site (Rehemtulla et al,
1996).
Co-transfection of rhodopsin and Nrl in CV-1 cells, which do not naturally express these
proteins, has shown that Nrl can transactivate the rhodopsin promoter (Rehemtulla et al,
1996). However, co-transfection with the naturally occurring truncated form of Nrl (DD10)
did not cause expression. The presence of this alternatively spliced NRL mRNA in the
human retina has been shown using reverse-transcription and sequence analysis
(Rehemtulla et al, 1996). When DD10 was transfected with normal Nrl, the DD10 protein
actively inhibited Nrl-mediated transactivation of the rhodopsin promoter, probably by
competing with Nrl homodimers for binding to the NRE (Rehemtulla et al, 1996).
The presence of an alternatively spliced isoform is a common strategy for regulation of
transcription factor activity (reviewed by Lopez, 1995). A similar situation is seen with
another member of the bZDP family, the cAMP response element modulator (CREM), of
which three isoforms are known to exist. As with the truncated form of Nrl, two of these
isoforms lack the transactivator domain, and inhibit binding of the normal protein, by
binding to the CRE as homodimers or heterodimers (Foulkes and Sassone-Corsi, 1992). It
seems likely that the truncated isoform of Nrl acts as a negative regulator of wild-type Nrl.
Liu et al (1996) have analysed the expression of murine Nrl (nrl) by in situ hybridisation of
an antisense nrl probe to embryonic, neonatal and adult mouse sections, and reverse
transcription PCR (RT-PCR). Expression was first detected in 12.5 day embryos in the
brainstem, spinal cord and cephalic mesenchyme. This expression expanded throughout the
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nervous system during neurogenesis, but was always restricted to specific differentiated
neurons that had migrated to their final positions. Postnatally, nrl was down-regulated in
the brain and spinal cord, and three months after birth only a weak signal was detected in
the forebrain by RT-PCR analysis. However, high levels were detected in all nuclear layers
of the adult retina and the photoreceptor inner segments. These results suggest that nrl has
a role in the maturation and/or establishment of the differentiated neuronal phenotype, and
that in the retina it may maintain the differentiated state of cells by regulating the
expression of specific genes.
6.4 - PCR OF NRL EXONS
The NRL gene is composed of three exons, the first of which is not translated. The start
codon is situated near the beginning of the second exon, which is 408 bp in length,
encoding 127 amino-acid residues. This exon also contains the proline/serine/threonine-
rich putative transactivation domain, and the proline-rich activation domain, both of which
are deleted in the naturally occurring truncated form of Nrl mRNA (DD10). The third
exon, comprising 333 bp from the splice site to the stop codon, coding for 110 residues,
contains three specific regions. The first of these is the region of extended homology with
v-maf, the next is the basic motif, thought to be involved in DNA binding, and the final
region is the leucine zipper, containing five highly conserved leucine residues (see fig. 6.1).
The PCR primers designed to amplify each exon, for mutation analysis and DNA
sequencing, are shown in fig 6.1. They produce fragments of 254 bp and 573 bp
respectively, for exons 1 and 3. Exon 2 was amplified in two overlapping fragments, 2a
(271 bp) and 2b (337 bp). For mutation analysis by SSCP, the 2b fragment was amplified
and analysed electrophoretically by PAGE, both without digestion and following digestion
with Pvull, producing fragments of 133 bp and 204 bp. The exon 3 fragment was analysed
both without digestion and following digestion with Taql, giving fragments of 186 bp, 254
bp and 133 bp.
Initially, problems were encountered with PCR amplification of exon 3. This was probably
due to the very high GC-content of this region (74%), as stretches of DNA with a high GC-
content are often difficult to amplify, due to the formation of complex secondary and
tertiary structures which inhibit the primer binding to the template. The PCR primers were
redesigned, and different magnesium concentrations, annealing temperatures and primer
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concentrations used, but the best results were achieved when 10% dimethylsulphoxide
(DMSO) was included in the reaction. DMSO is thought to improve PCR by eliminating
non-specific amplification, altering the thermal activity profile of the DNA polymerase, or
destabilising secondary structures (Sidhu, Liao and Rashidbaigi, 1996), and its use with Taq
polymerase was first reported by Shen and Hohn (1992).
6.5 - SSCP MUTATION DETECTION
The single-stranded conformation polymorphism technique (SSCP, introduced in section
1.7) developed by Orita et al (1989) has proved effective at detecting polymorphisms and
mutations in many genes, including the cyclic nucleotide gated channel (CNCG1, Dryja et
al, 1995), peripherin/RDS (Farrar et al, 1991) and the alpha subunit of phosphodiesterase
(.PDEA, Huang et al, 1995) in arRP. SSCP detects alterations in single-stranded DNA
(from denatured PCR products) as a result of their differing mobilities in a gel matrix. The
mobility is altered by the nucleotide sequence of the fragment, which in turn alters the
intramolecular interactions that produce the three-dimensional folded structure. This
alteration in mobility is very difficult to predict, even for a known mutation, as it seems to
depend upon the surrounding base sequence, and not the overall proportion of each
nucleotide within the fragment (Glavac and Dean, 1993). As the changes in mobility may
be very small, the ability to detect them depends upon the size of the DNA fragment, and
the gel matrix in which the fragments are electrophoretically separated.
SSCP has a reported detection rate of between 35% and close to 100% (Glavac and Dean,
1993). However, various experimental conditions can be altered, such as the length and
temperature of electrophoresis, the type of gel matrix and running buffer, and additions to
the gel such as glycerol. Whilst optimisation of these parameters is ideal for each fragment,
this is not always possible or practicable when using SSCP as a scanning method to search
for unknown mutations, and detracts from the simplicity and speed of this method which
makes it so useful. In this project, only one set of SSCP conditions was used, as
heteroduplex analysis (HA) and direct DNA sequencing were being used together with
SSCP. Together, HA and SSCP are thought to have a detection rate close to 100% (White
et al, 1992). We chose to analyse the NRL gene using a specialised type of gel matrix, the
Mutation Detection Enhancement (MDE) gel, closely related to Hydrolink (manufactured
by AT Biochem), which is also suitable for use in HA. The gels were ran at 7W at room
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temperature for 14 hours. Glavac and Dean (1993) have reported that gels run at room
temperature at 10W gave similar separation to gels run at 4°C.
6.6- HETERODUPLEX MUTATION DETECTION
Unlike SSCP, heteroduplex analysis (HA) does not rely on the formation of secondary
structures within single-stranded DNA, but rather involves direct detection of
heteroduplexes between wild-type and mutant sequences, due to their slower migration in
an acrylamide (or similar vinyl polymer) gel. These heteroduplexes can be formed during a
PCR reaction (as in this project), or post-PCR, by mixing the PCR products from "normal"
and "mutant" DNA, allowing them to denature and re-anneal slowly, forming hetero- and
homo-duplexes. For recessive disorders, the heteroduplexes form during PCR of DNA
from carriers, such as the parents of affecteds, as they have one normal allele and one
mutant allele. If the affected members have inherited the same mutation from each parent,
their DNA should form mutant homoduplexes, which may also migrate differently from
"wild-type" homoduplexes. For the consanguineous family studied in this project, we
would expect this to be the case.
It has been estimated that HA detects approximately 80% of mutations, but that HA and
SSCP together may detect nearly all mutations (Cotton, 1993). This method was first
reported by Keen et al, (1991) using a specific form of acrylamide designed for detecting
mutations, Hydrolink (AT Biochem). Subsequently, normal polyacrylamide gels have also
been used, both denaturing and non-denaturing, although White et al (1992) have suggested
that 15% urea is optimal for HA analysis, as it increases separation between homoduplexes
and heteroduplexes, eliminates doublets that can form in some homoduplex samples, and
helps sharpen bands without denaturing the double-stranded DNA. Since 1992, numerous
genes have been screened for mutations using HA, including the rhodopsin and
peripherin/RDS genes (Inglehearn et al, 1992; Meins et al, 1993). We chose to use the
MDE matrix (also used for SSCP analysis), with 15% urea added. The gels were run at
room temperature, at 600 V constant voltage (20V/cm), for 15 - 20 hours, depending on the
size of fragments to be resolved. As HA with MDE gel is suitable for PCR products of
between 200 and 600 basepairs (MDE Heteroduplex Kit Protocol, AT Biochem), the larger
exon fragments (2b and 3) were not digested.
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6.7 - RESULTS OF MUTATION DETECTION
Primers were chosen which flank each of the NRL exons (see fig. 6.1), and used to amplify
each exon (fragments 1, 2a, 2b, and 3) in all available individuals from family ARRP1 (BP,
BM, BA, BB, BC, BD), and a normal control (CEPH DNA). Each primer lies at least 67
basepairs from the closest splice site, so that every product contained at least 67 bases of
intronic sequence. The PCR fragments for exons 2b (337bp) and 3 (573bp) were digested
with restriction enzymes to produce fragments of less than 300 bp for SSCP analysis.
Radioactive PCR reactions and enzyme digestion were carried out by K. Porter. Both
heteroduplex analysis and SSCP techniques were used to screen each exon in all the
individuals. No evidence of any sequence alteration was observed in any of the family
members or unaffected controls (see figs. 6.2 and 6.3 - fragment 2b is not shown for HA).
This analysis covered the whole coding region, all splice junctions, and included 527
basepairs of intronic sequence.
6.8 - DNA SEQUENCING
In mutation detection, DNA sequencing is often regarded as a final step, following the use
of scanning methods to localise putative mutations. In a gene with a large coding region,
and many exons, the use of direct DNA sequencing is impractical for the whole gene, and
scanning methods such as SSCP and heteroduplex analysis can be used to narrow down the
region of search. However, these alternative, quicker methods are not always 100%
effective, and may miss mutations that can be detected using DNA sequencing. Sequencing
also has the advantage that it precisely defines the nature and position of the defect in the
gene. The most commonly used form of DNA sequencing involves the chain-termination
method first described by Sanger et al (1977). This can be used to sequence both PCR
products and DNA cloned into appropriate vectors.
Problems can often be encountered when attempting to sequence double-stranded GC-rich
regions of DNA. Typical artifacts encoutered include ambiguous signals, premature stops
and high background, possibly due to the formation of secondary structures, and the higher
melting temperature of GC-rich DNA. The NRL gene is very GC-rich, especially in exon
three, which is also thought to code for the functionally important leucine zipper and basic
domains. Overall, the coding region covering exons two and three is 68.5% guanine and
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SSCP analysis of samples from all members of family ARRP1, for exon fragments 1, 2a, 2b and 3.
Fragment sizes are indicated for the appropriate band.
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Heteroduplex analysis for all members of family ARRP1, for exonic fragments 1, 2a and 3.
Fragment sizes are indicted for the appropriate band.
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cytosine residues, with exon two having a G-C content of 63.8%, and exon three a G-C
content of 73.9%. This led to problems in sequencing these regions, especially due to high
background and "stops" - bands in all four reaction lanes.
Several methods have been proposed to reduce or eliminate these problems. Woodford,
Weitzmann and Usdin (1995) have suggested the use of buffers free from monovalent
cations, especially potassium ions, to eliminate premature chain termination in guanine-rich
stretches of DNA. The reason for the success of this method may be that these ions usually
aid the stability of DNA secondary structures that can form in G-rich regions. A suitable
buffer, containing only Tris-HCl and magnesium chloride, is supplied with the IsoTherm
DNA sequencing kit (Cambio). This kit also contains 7-deaza-GTP instead of dGTP, to
reduce band compressions during electrophoresis, and a thermostable form of DNA
polymerase, cloned from the thermophilic bacterium Bacillus stearothermophilus. This
enzyme has an optimal reaction temperature of 65°C, thus reducing the problems of
secondary structure encountered at the 37°C reaction temperature used with the Sequenase
sequencing kit (USB). Templates were also boiled for at least three minutes and snap-
frozen to ensure complete denaturation. The use of DMSO (used in the PCR of GC-rich
exon 3), which was incorporated into the annealing reaction at 10% concentration (see
section 2.6.4), has been suggested to eliminate background and increase signal intensity
(Winship, 1989). For very GC-rich regions, the best results were achieved when
formamide, which weakens hydrogen bonding between nucleotides, was added to the
annealing reaction. The amount of formamide was determined by the percentage of GC
nucleotides in the PCR product (% formamide = 0.7 [GC% - 50]) (Zhang, Hu and
Deisseroth, 1991). This succeeded in eliminating most of the stops in the sequence, and
increased band intensity, enabling us to read far more of the sequence.
6.9 - RESULTS OF DNA SEQUENCING
DNA sequencing was carried out in each exon of the NRL gene, using DNA from affected
individuals BB and BD, and their father BP. All the coding region and at least 50 basepairs
upstream from both 5' and 3' splice sites was sequenced in at least one affected individual.
DNA sequencing also included reverse transcribed cDNA PCR products from individual
BB (and a normal control) that covered each exon/exon boundary in order to exclude
mutations affecting RNA splicing (see fig. 6.4). This approach also allowed us to check for
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Figure 6.4 - Intragenic mutation analysis ofNrl
Diagram illustrating the strategy used to amplify nested PCR fragments from a solid-phase cDNA
library. Also pictured are the final PCR products containing exon/exon junctions from affected




















Figure 6.5 - DNA sequencing of exon/exon junctions
Template DNA from a nested PCR reaction (see Fig. 6.4) including the exon2/exon3 junction was
amplified from a solid phase cDNA template from individual BB, and a normal control.
Nucleotide positions correspond to the numbering used in the Genbank Human NRL gene product
mRNA sequence, accession number M81840
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were not available, lymphoblastoid cell lines derived from blood samples were used to
create a solid-phase cDNA template. Nested PCR products were detectable from this
template due to illegitimate transcription - the transcription of tissue specific genes at very
low levels in inappropriate cell types (Kaplan, Kahn and Chelly, 1992). The promoter
region was not analysed because this is a less common site of mutation. We found that no
mutations were present in the coding sequence of the NRL gene, or intron/exon boundaries
of this gene, in the affected individuals when compared to the sequence obtained from a
normal control (CEPH DNA) (see fig. 6.5), and the sequence of the NRL gene as
determined by Dr. A. Swaroop's group in Michigan (personal communication). This result
was also confirmed by Dr. A. Swaroop and co-workers, who were sent the PCR primers and
DNA from BB and BD. We also detected only bands of the expected size, and no
alternatively transcribed products, following nested PCR from the solid-phase cDNA
template (see fig. 6.4).
6.10 - DISCUSSION
The possible presence of mutations in the NRL gene in individuals with autosomal recessive
RP has been investigated in an inbred family from Sardinia, ARRP1. This family showed
homozygosity of three adjacent markers in three affected members suggesting a
homozygosity-by-descent region in which the NRL gene has been mapped. This gene was
analysed for mutations in family ARRP1. Individual NRL exons, including flanking
intronic sequence, were PCR amplified and subjected to mutation analysis by SSCP,
heteroduplex analysis and direct DNA sequencing. No variations from the genomic
sequence determined by Swaroop et al were identified in any of the samples investigated
(including normal controls). Furthermore, this result was confirmed by Swaroop et al, who
also failed to find any sequence alterations in two of the affected individuals from family
ARRP1.
The DNA sequencing included at least 50 basepairs of intronic sequence upstream from the
splice sites. As well as enabling us to exclude splice site mutations, this region is predicted
to contain the branch splice site, the point where base pairing occurs between the small
nuclear ribonucleoprotein particle (snRNP) U2, one of the snRNPs involved in the
formation of an active splicing complex (Norton, 1994). Mutations in this site have been
shown to cause partial androgen insensitivity in the androgen receptor gene (Reifenstein
Syndrome) (Ris-Stalpers et al, 1994) and familial hypercholesterolemia in the LDL
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receptor gene (Webb et al, 1996), but can probably be discounted in this family for the NRL
gene. We were also able to exclude cryptic splice site mutations, as no alternatively spliced
products were detected following nested PCR. However, other intronic regions, some of
which may be important in maintaining mRNA stability have not been analysed. Distal and
proximal promoter or enhancer mutations cannot be excluded either, although 67 basepairs
of sequence proximal to the first exon, and 85 basepairs distal to the stop codon were
included in the SSCP and heteroduplex analysis and no variant bands were detected. In this
consanguineous arRP family we would expect affected children to have inherited two
copies of the same mutation. As no visible difference was seen between the size of exonic
PCR products for affected and unaffected individuals, this suggests that large intragenic
deletions can be excluded as a cause of mutation. In summary, most common types of
mutation have been excluded in the NRL gene in this family with autosomal recessive RP.
The highly conserved NRL gene is thought to be a good candidate for involvement in retinal
diseases. It is highly expressed in the adult retina, where it may have a role in the
transcriptional regulation of rhodopsin, and is very likely to have many other target retinal
protein genes (Rehemtulla et al, 1996). The NRL mouse homologue has also been shown to
be widely expressed throughout neurogenesis, in differentiated cells of the central and
peripheral nervous system. It is downregulated in the brain after birth, with very low levels
detected in the neocortex and brainstem in the adult. High expression levels are detected in
the adult retina, especially in the three nuclear layers and the inner segments of the
photoreceptors (Liu et al, 1996).
This expression pattern is similar to that of a member of the POU family of transcription
factors, Pit-1. The Pit-1 protein is exclusively expressed in the adult pituitary, but is also
expressed throughout embryogenesis in the developing neural tube. Pit-1 has been shown
to be mutated in combined pituitary hormone deficiency (Radovick et al, 1992), where the
mutant protein can still bind to its DNA-binding site, preventing the normal protein from
binding, but cannot activate transcription. This causes the disease to be dominantly
inherited, as one mutant copy of the gene is sufficient to inhibit gene activation. A similar
biphasic expression pattern is also seen with CHX10, encoded by a member of the
homeobox gene family also located on chromosome 14 (14q24.3) (Ploder et al, 1995). This
gene is expressed in the developing brain, spinal cord, and neuroblasts in the eye, but is
restricted to the inner nuclear layer of the mature retina (Liu et al, 1994). Finally, another
member of the bZIP family, c-fos, is also expressed in the nervous system during mouse
development, and may form a transcriptional regulatory complex with Nrl in neural cells
(Caubet, 1989).
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As transcription factors are critical in gene expression, and one transcription factor can
interact with many genes, inactivation of a gene coding for such a protein may be lethal.
Nrl is expressed throughout development of the nervous system, suggesting that lack of this
protein could cause significant and potentially severe disruption of neuronal differentiation.
However, Pit-1 is also expressed in the developing neural tube, but mutations in this gene
are compatible with survival. A possible reason for this may be an overlap in expression
patterns between transcription factors, so that other proteins are able to replace the function
of Pit-1 in the developing neural tube, but in the adult, the high tissue-specific levels of
expression of the mutant protein result in a discernible lack of function for target genes.
Likewise, mutation of the NRL gene could result in a retinal disorder due to high expression
levels in the adult retina. The predicted pattern of inheritance of such a disorder depends
upon how many functional copies of NRL are required for sufficient transcriptional
activation. Many transcription factor diseases result from mutation of one allele, causing
either a dominant negative mutation, as seen with Pit-1 or a dominant loss-of-function
mutation (haplo-insufficiency) as with Pax-6, although this type of mutation can also be
recessively inherited if one copy of the gene can produce enough protein to induce
transcription (Latchman, 1996). The ability of Nrl to form dimers suggests that mutations
in this gene could cause a dominant negative effect, as the mutant protein encoded by one
copy of the gene may interfere with wild-type Nrl, and other proteins that Nrl can dimerise
with.
What other genes, in addition to rhodopsin, are targets for Nrl? The tissue specificity of
expression in the adult suggests that most targets will be found in the three nuclear layers of
the retina and the inner segments of photoreceptors. As the Nrl recognition element (NRE)
sequence is conserved in the promoter of all mammalian opsins, other retinal opsin genes
may be targets for Nrl, such as the blue-, green- and red- pigment opsins present in cone
cells. Fos, another member of the bZIP family, is induced in ganglion cells by light. As
this protein cannot homodimerise, it is possible that it may dimerise with Nrl, hence
responding to light by increasing the expression of opsin (Kerppola and Curran, 1994b).
Further putative target genes include glutathione-S-transferase, and NAD(P)H:quinone
reductase, due to the presence of a suitable recognition site for dimers formed by Nrl, Maf,
Fos and Jun (Kerppola and Curran, 1994b). A database search for genes with similar
recognition sequence motifs could reveal other potential targets for these proteins.
In conclusion, no mutations have been identified in the NRL gene in a consanguineous
family with autosomal recessive RP. This finding correlates with the results of further
linkage analysis in this family, which showed the suggested identity-by-descent in affected
173
members to be due to uninformative markers (see Chapter Five). The expression pattern
of the NRL gene, and targets of the transcribed protein, could reveal diseases in which this
gene may be involved. Mutated NRL is a possible candidate for developmental defects of
the nervous system due to expression during neurogenesis, but high levels of expression in
the adult retina suggest that it has many target genes in this tissue, including rhodopsin.
Thus, Nrl remains a good candidate gene for retinal disorders, and could be considered in
mutation analysis for patients with RP and related disorders. The family studied, ARRP1,
may still be linked to chromosome 14q, despite a lack of homozygosity, as a maximum
multipoint lod score of 2.4 was obtained at a location defined by markers D14S252 and
D14S262, distal to the NRL gene. Thus, other retinally expressed genes that lie in this
region may be causing the arRP seen in this family. One candidate is the previously
mentioned homeobox gene coding for CHX10, as a premature stop codon in this gene can
cause microphthalmia, a thin hypocellular retina and optic nerve aplasia in the mouse
(Burmeister et al, 1996). This gene has previously been examined using SSCP analysis in a
set of patients, 17 with microphthalmia, 11 with anophthalmia, 64 with Leber's congenital
amaurosis, and 12 with arRP, but no mutations were identified (Ploder et al, 1995).
However, this gene is still a candidate for retinal disease, and may merit further




Retinitis pigmentosa is a common genetic cause of blindness, affecting around 1 in 4000
individuals worldwide. The autosomal recessive form is one of the most severe and
prevalent types of RP, whose true frequency may often be underestimated. No proven cure
or preventative treatment is currently available, although high doses of vitamin A (18,000
i.u. daily, close to a potentially toxic dose) have been reported to slow the loss of a cone
electroretinogram response (Berson et al, 1993). Identification of genes responsible for RP
increases our understanding of the mechanisms of cellular dysfunction, allows for accurate
diagnosis, and may eventually lead to successful treatments.
Seven genes have been identified that cause simplex RP when mutated. Of these, four have
been shown to cause arRP - rhodopsin (Rosenfeld et al, 1992), the alpha and beta subunits
of cGMP phosphodiesterase (Huang et al, 1995; McLaughlin et al, 1995), and the alpha
subunit of the cyclic nucleotide gated channel (Dryja et al, 1995). All of the proteins coded
for by these genes are involved in the phototransduction cascade that takes place within the
rod outer segment. However, together these four loci are thought to account for less than
10% of all arRP cases (Dryja and Li, 1995). Linkage for arRP has also been reported to
6p21.3 (RP14) in a large pedigree from the Dominican Republic (Knowles et al, 1994), and
to Iq31-q32.1 (RP12) for a relatively uncommon specific type of RP, PPRPE, in extended
kindreds from the Netherlands and Pakistan (van Soest et al, 1994; Leutelt et al, 1995).
Overall, this suggests that there are still a large number of genes causing arRP that await
identification.
One aim of this project was to localise arRP genes in a set of eleven families from south-
central Sardinia, using linkage mapping. As arRP is known to be nonallelically
heterogeneous, the Sardinian population was chosen for its reported genetic homogeneity
for adRP (Fossarello et al, 1993) and other genetic diseases. Also, this population has a
very high proportion of arRP cases (21.5% arRP compared to 5% adRP and 1.3% xlRP),
possibly due to increased levels of inbreeding, and religious and economic factors have
encouraged the establishment of large families.
Using an automated laser fluorescence DNA sequencer (ALF, Pharmacia) 195
microsatellite markers were typed in cooperation with Dr. D. Mansfield in all eleven
families, but failed to detect any significant linkage. While it is possible that a major
causative gene lies outwith the regions covered by the markers used in this study, this result
also suggests that there is genetic heterogeneity within this group of families. A possible
reason for heterogeneity may be that highland and lowland communities were highly
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isolated until this century, so that the whole Sardinian population can be considered as
being composed of many small isolates, each having experienced its own founder effect,
and undergoing genetic drift. This suggestion correlates with geographical, historical,
linguistic and archaeological evidence, and studies on polymorphisms amongst Sardinian
villages support this prediction, by demonstrating significant heterogeneities, especially
between lowland and highland settlements (Workman et al, 1976).
Previous work by Dr. Mansfield had excluded some of the families for linkage to genes
such as rhodopsin and peripherin using closely linked markers. It is still possible that the
families not yet excluded may have mutations in these, and other strong candidate genes.
However, the PDEB gene has been examined by Dr. D. Farber and colleagues (University
of California) in the eleven Sardinian families used in this study. They have not detected
any mutations, although they did detect several variants that did not segregate with the
disease. Work is also currently underway by Dr. F. Manson (MRC Human Genetics Unit)
to investigate the gene coding for the gamma subunit of PDE, with which some of our
families showed no recombination. No mutations have previously been reported in this
gene, even though it is a strong candidate for retinal degenerations, as mutations have been
identified in the two other subunits that comprise the active cGMP phosphodiesterase
enzyme. Work by Tsang et al (1996) has also shown that targeted disruption of the gamma
PDE gene in mice results in a rapid retinal degeneration, and that this subunit is necessary
for activity and stability of PDE in vivo.
Close examination of individual lod scores has suggested other regions worth investigation
in particular families. The main problem with further linkage work in the individual
families is that most are small two generation pedigrees, so that high lod scores providing
definite linkage to, or exclusion from, specific loci is not possible unless many densely-
spaced markers are used. However, any families not showing recombination with markers
closely linked to a candidate gene may merit further investigation, perhaps by screening the
candidate gene for mutations in an affected individual and an obligate carrier. The
suggestion of genetic heterogeneity has led us to consider the candidate gene approach, as
successfully used by Dryja et al to identify mutations in PDEB, PDEA and CNCGJ. A
large number of candidates for arRP - with a structural or biochemical role in rod
photoreceptors - have been cloned, and their genomic structure elucidated. In addition,
many have been localised to specific chromosomal regions. In the original set of eleven
two-generational Sardinian arRP pedigrees only two were consanguineous, but we have
since obtained another consanguineous pedigree and two large extended kindreds. These
will be more powerful for use in linkage mapping, initially to candidate regions, and if
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required, in a full genome scan. Any promising candidate genes could then be tested in the
smaller pedigrees for mutation.
A combination of positional cloning and candidate gene analysis, the positional candidate
approach, using initial linkage mapping followed by candidate gene screening in the region
of interest, was adopted with one consanguineous family, ARRP1. An interesting result
was noted with marker D14S80 in 14qll, with a subset of five of the families showing no
recombination. Flanking markers were typed in these families, and appeared to reveal a
region of homozygosity in four markers (D14S64, D14S80, D14S275 and D14S262)
covering 6 cM in two affected individuals from this one family, ARRP1, suggesting
identity-by-descent for this region. A good candidate gene for RP, coding for the neural
retina leucine zipper protein (Nrl) was mapped to the same region (14ql 1.1-ql 1.2) by
Yang-Feng and Swaroop (1992), and was found to be on the same cosmid clone as one of
the homozygous markers (D14S64). This gene codes for a conserved member of the bZIP
family of transcription factors, which is highly expressed in the adult retina, with transient
expression in the developing nervous system (Liu et al, 1996). Furthermore, the promoter
region of the rhodopsin gene has been shown to contain a conserved binding site for the Nrl
protein, suggesting a role for Nrl in regulation of this and other retina-specific proteins
(Rehemtulla et al, 1996). It was decided to screen this gene in the ARRP1 family using
heteroduplex analysis and SSCP. No band shifts were identified, and DNA sequencing of
the whole coding region, and adjacent splice sites, also failed to reveal any base changes in
this family. Thus, this gene has been excluded for the common causes of mutation in this
pedigree. Further linkage mapping with another affected member of ARRP1 has since
confirmed this result, by showing that the suspected homozygosity in this individual was
due to uninformative parental alleles. While Nrl is still a good candidate for retinal
degenerations, its expression pattern during embryogenesis suggests that mutations in this
gene could have more widespread effects than a retinal degeneration alone. The family still
shows no recombination with three markers in this region, distal to D14S275, so that
another gene on chromosome 14 may be responsible for the disease. However, it is also
likely that this is a chance association between the markers and the disease, as only one of
the markers studied is homozygous in this consanguineous family.
The results of linkage analysis with this one inbred family did however prove the power of
working with consanguineous families. Homozygosity mapping, a form of linkage
mapping, relies on the principal that each affected member of a consanguineous union will
have inherited two copies of the mutated gene from a common ancestor, and hence will
have inherited identical alleles at loci closely flanking this gene. This greatly increases the
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power of mapping, by considering all the meioses in past generations in which
recombination could have occurred between the gene and flanking markers. This approach
has been used to map several genes for rare autosomal recessive traits, as fewer families are
required to achieve a significant lod score. For example, Hirschsprung disease was mapped
using a large Mennonite kindred (Puffenberger et al, 1994) and three genes causing Bardet-
Biedl syndrome have been mapped using large Bedouin kindreds (Kwitek-Black et al,
1993; Sheffield et al, 1994; Carmi et al, 1995a).
Another form of genetic mapping which could be used in an isolated genetic population
such as Sardinia is linkage disequilibrium mapping. This relies on a similar principle to
homozygosity mapping, but considers the spread of an ancestral haplotype (carrying a
mutation) throughout a whole enclosed community, thus greatly increasing the available
sampling population. This approach has been successfully used in several populations,
including the Finnish, the Ashkenazim and the Old Order Amish, to map genes responsible
for rare autosomal recessive disorders. This method is also able to narrow the region in
which the causative gene must lie, by at least an order of magnitude compared to the results
of normal linkage mapping (de la Chapelle, 1993).
In summary, in specific inbred or isolated groups, specialised types of genetic mapping can
provide a powerful means of localising the region in which a gene for an autosomal
recessive disorder may lie. However, in the small non-consanguineous Sardinian pedigrees
we have studied there is no clear sign of high levels of homogeneity, leading us to consider
candidate gene analysis. A potential limitation of the candidate gene approach is the
reliability of the method of mutation detection employed. SSCP, the most commonly used
technique, has been reported to detect as few as 35% of mutations, although this detection
rate can be increased by employing a variety of electrophoresis conditions (Glavac and
Dean, 1993). Heteroduplex analysis (HA), another widely used technique, has the
advantage that it can easily be used without the need for radioactive detection, as protocols
are available for silver-staining and ethidium bromide staining. HA in combination with
SSCP has been reported to detect nearly all mutations (Glavac and Dean ,1995), but this is
often not reliable enough, especially if dealing with small sample numbers where only one
mutation may be present. Many of the other more reliable techniques, such as HOT, are
laborious and involve toxic chemicals.
Part of this project attempted to produce a tool for mutation detection, by designing a fusion
protein for MutS. MutS is a bacterial mismatch binding protein involved in the methyl-
directed mismatch repair system in E. coli and S. typhimurium. Research has shown MutS
to be highly effective for in vitro detection of single base mismatches and deletions or
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insertions of up to four bases (Smith and Modrich, 1996). Although time constraints
prevented development of a soluble fusion protein, a protocol has subsequently been
published detailing production of a His6-MutS fusion protein (Feng and Winkler, 1995).
This provides a unique opportunity for exploitation in the field of routine candidate gene
screening, although more research will be required to refine the optimal working conditions
for this protein.
Linkage mapping for Bardet-Biedl syndrome, a syndromic form of RP, was also carried out
in this project. In addition to RP, other cardinal features of this condition are Polydactyly,
hypogenitalism, obesity and mental retardation, although all are highly variable both within
and between families. Further commonly associated features include renal anomalies and
syn- or brachy-dactyly. All of these clinical features were observed among the set of 29
families collected worldwide that were used in this study. Linkage has been reported to
four loci for BBS - llql3 (BBS1), 16q21 (BBS2), 3pl3-pl2 (BBS3) and 15q22.3-q23
(BBS4) (Leppert et al, 1994; Kwitek-Black et al, 1993; Sheffield et al, 1994; Carmi et al,
1995a). Carmi et al used a form of DNA pooling for the initial linkage work, by pooling
the affected members, and unaffected individuals (controls), of the pedigree and comparing
the number of alleles observed for an individual marker. Any markers that showed a shift
towards homozygosity in the affected group (and not the controls) were then investigated
with further flanking markers. This method may be suitable for use in any large inbred
families. We studied markers closely linked to all four loci in the set of BBS families,
using conventional linkage analysis. No linkage was identified for BBS3 in our set of
families, but signs of linkage were found to the three other BBS loci.
A multipoint lod score of 6.26 was achieved for the BBS] locus, assuming genetic
heterogeneity. This analysis places the locus in a region overlapping with the results of
homozygosity mapping in Puerto Rican kindreds (Cornier et al, 1995). In total, eight
families showed evidence of linkage to this locus, by combining lod scores and haplotype
analysis. For the BBS4 locus on chromosome 15, a lod score of 6.10 was reached, again
assuming genetic heterogeneity. Seven families, three of which were consanguineous,
appeared linked to this locus when lod scores and haplotypes were combined. Two of the
consanguineous families showing homozygosity for the BBS4 region contained informative
crossovers that helped us to narrow the region in which this gene must lie. In family BB18,
a crossover was identified with D15S125, which is therefore a flanking marker, as found by
Carmi et al (1995a) in the original report of linkage to this region. In family BB31, two
informative crossovers have allowed us to narrow the region even further, by showing that
D15S131 and D15SU4 are both flanking markers. Previously reported flanking markers
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D15S131 and GATA89D04 (D15S823) placed the BBS4 locus in an interval of 4.3 cM
(Haider et al, 1996). However, results in family BB31 suggest that the locus must lie in an
interval of around 1.6 cM, probably corresponding to a physical distance of less than two
megabases. This size of interval should be suitable for a positional cloning project, but it
may be possible to reduce this region by typing more markers between D15S131 and
D15S114, in the hope of identifying the site of each recombinational event more precisely.
There are currently 14 polymorphic markers reported to lie in this interval (Dib et al, 1996),
and these could be tested for homozygosity in this family.
Weak signs of linkage were also found for BBS2 on chromosome 16, with a lod score of
1.09 assuming two BBS loci. Only three families appear linked to this region when lod
scores and haplotypes are examined, but one of these (BB13) is consanguineous, and
homozygous for the three markers studied. Thus, typing further markers with this family
may identify the limits of this region of identity-by-descent, hence defining the limits within
which the BBS2 locus must lie. It is interesting to note that at least three of the BBS
families studied show no sign of linkage to any of the reported loci. While it is possible
that further work with markers surrounding the BBS3 locus may reveal linkage in these
families, preliminary results from this locus did not suggest linkage in any of the families.
These families could be linked to a fifth, as yet unidentifed, BBS locus, as suggested by
Bonneau et al (1996) and Sunden et al (1995), due to lack of linkage in some BBS families
from France, North Africa, Portugal and Canada. This level of heterogeneity is unexpected
for such a specific disorder, and as yet no clear phenotype/genotype correlations have been
found in our families.
Whilst work with transgenic mice and cultured cells containing RP mutations have
suggested possible causes of the retinal degeneration, there remains considerable debate
about the relationship between a functional deficit and the resultant degeneration. Various
suggested mechanisms include the equivalent light hypothesis, increase in intracellular
cGMP, an accumulation of misfolded protein, and abnormal photoreceptor disc structure
(reviewed by Lisman and Fain, 1995). Cell death usually occurs through two pathways -
necrotic cell death (often due to injury), which is commonly accompanied by inflammation,
or apoptosis, an internally controlled suicide program. Apoptosis affects isolated cells,
which are usually phagocytosed by neighbouring cells. The nuclear DNA is also
fragmented by endonucleases, providing a simple method of detection (Thompson, 1995).
Apoptosis has been shown to occur during normal neuronal development in all layers of the
retina, including the photoreceptors. Research with animal models of RP and transgenic
mice has suggested that photoreceptor cell death in RP is due to apoptosis (Portera-Cailliau
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et al, 1994). Indeed, increased apoptosis has been associated with other neurodegenerative
disorders such as Alzheimer's disease and cerebellar degeneration (Thompson, 1995).
However, the actual mechanism by which RP mutations re-activate apoptosis is still
unknown. Nevertheless, it seems plausible that treatments that disrupt the apoptotic
pathway could halt or slow the gradual degeneration of photoreceptors that occurs in RP.
Bcl-2 and related proteins naturally repress apoptosis, and it has been suggested that
overexpression of these proteins may slow or prevent photoreceptor degeneration. Flannery
et al (1995) have studied the offspring of transgenic mice overexpressing Bcl-2 crossed
with mice with inherited retinal degenerations, and have suggested that Bcl-2 can slow
disease progression in mice with opsin mutations. However, Joseph and Li (1996) have
since provided conflicting evidence that overexpression of bcl-2 and bcl-XL does not halt
the apoptosis in photoreceptors in mice with opsin or PDEB mutations.
Another possible future treatment for RP is the use of gene therapy. Ocular tissues are a
suitable target for this treatment, as most cells are comparatively accessible. Anatomical
boundaries within the eye allow targeted gene transfer, and no other effective therapy has
yet been developed. Bennett et al (1996) have used a recombinant replication-defective
adenovirus containing the cDNA for PDEB in rd mice, and have observed transgene
expression in the retina at least 100 days after injection. However, potential problems with
toxicity of adenovirus-mediated transfer have been avoided by Ali et al (1996) who have
studied an adeno-associated viral vector, as this vector is deleted for all virally-encoded
proteins. They have reported efficient and non-toxic gene transfer into the murine retina.
Although much more work is required to identify safe and effective gene delivery systems,
this approach may ultimately be able to arrest the degeneration seen in RP (and allied
disorders), hence preserving the sight of thousands of people.
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Bardet-Biedl syndrome (BBS) is a clinically and ge¬
netically heterogeneous autosomal recessive disorder
characterized by retinitis pigmentosa, Polydactyly,
obesity, hypogenitalism, mental retardation, and renal
anomalies. To detect linkage to BBS loci, 29 BBS fami¬
lies, of mixed but predominantly European ethnic ori¬
gin, were typed with 37 microsatellite markers on
chromosomes 2, 3, 11, 15, 16, and 17. The results show
that an estimated 36-56% of the families are linked to
the llql3 chromosomal site (BBS1) previously de¬
scribed by M. Leppert et al. (1994,Nature Genet. 7,108-
112), with the gene order cen-DHS480-5 cM-BBSl-
3 cM-DHS913/DHS987-qter. A further 32-35% of the
families are linked to the BBS4 locus, reported by R.
Carmi et al. (1995, Hum. Mol. Genet. 4, 9-13) in chromo¬
somal region 15q22.3-q23, with the gene order cen-
D15S125-5 cM-BBS4-2 cM-D15S131/D15S204-qter.
Three consanguineous BBS families are homozygous
for three adjacent chromosome 15 markers, consistent
with identity by descent for this region. In one of these
families haplotype analysis supports a localization for
BBS4 between D15S131 and D15S114, a distance of
about 2 cM. Weak evidence of linkage to the 16q21
(BBS2) region reported by A. E. Kwitek-Black et al.
(1993, Nature Genet. 5, 392-396) was observed in 24-
27% of families with the gene order cen-D16S408-2
cM-BBS2-5 cM-D16S400. A fourth group of families,
estimated at 8%, are unlinked to all three of the above
loci, showing that at least one other BBS locus remains
to be found. No evidence of linkage was found to mark¬
ers on chromosome 3, corresponding to the BBS3 locus,
reported by V. C. Sheffield et al. (1994, Hum. Mol. Genet.
* To whom correspondence should be addressed at MRC Human
Genetics Unit, Western General Hospital, Crewe Road, Edinburgh
EH4 2XU, UK.
3, 1331-1335), or on chromosome 2 or 17, arguing
against the involvement of a BBS locus in a patient
with a t(2; 17) translocation. © 1997 Academic Press
INTRODUCTION
Bardet-Biedl syndrome (BBS; MIM 209900) is an
autosomal recessive condition in which the five
cardinal features of retinal degeneration, Polydactyly,
obesity, hypogenitalism, and mental retardation are
manifest to varying degrees within and between fami¬
lies (Schachat and Maumenee, 1982; Green et al.,
1989). Renal anomalies are another common manifes¬
tation, often causing significant morbidity, so that this
is increasingly regarded as a cardinal sign (Harnett et
al., 1988; Green etal., 1989). The population prevalence
varies from 1 in 17,500 to 1 in 160,000 in different
populations (Green et al., 1989; Klein and Ammann,
1969), with high local frequencies within certain Arab
groups associated with a high frequency of consanguin¬
eous marriages (Farag and Teebi, 1989). Linkage has
been reported to distinct BBS loci in 3 large consan¬
guineous Bedouin kindreds at chromosomal regions
3pl3-pl2 (BBS3), 15q22.3-q23 (BBS4), and 16q21
(BBS2) (Sheffield et al., 1994; Carmi et al., 1995a; Kwi-
tek-Black et al., 1993) and in a heterogeneous group of
31 North American BBS families to chromosomal re¬
gion llql3 (BBS1) (Leppert et al., 1994). A clinical
study of 11 Scandinavian families with Bardet-Biedl
syndrome, all of whom are included in the present
study, emphasized the relatively broad phenotypic
manifestations of the disorderwithin and between fam¬
ilies and confirmed the increased prevalence of associ¬
ated features including dental anomalies, diabetes mel-
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litus, deafness, and small stature (Riise et al., 1997).
The most consistent clinical findings in affected indi¬
viduals consist ofa severe retinal dystrophy, often lead¬
ing to blindness by the end of the second decade; obe¬
sity; hypogenitalism, which is most evident in males;
digital anomalies such as Polydactyly, often with
brachydactyly and/or syndactyly; mental retardation;
and renal anomalies.
In this study, DNA samples were obtained from 29
families, each containing at least two affected mem¬
bers, from nine different countries, to confirm the re¬
ported linkages and to determine the relative frequen¬
cies of the different loci.
METHODS
Subjects and diagnostic criteria. The ethnic origins of the families
are shown in Table 2. The families are from the United Kingdom
(38%), Norway (21%), Denmark (14%), Switzerland (7%), Sweden
(7%), Egypt (3%), Italy (3%), Somalia (3%), and Brazil (3%). The
criteria for inclusion of families were the presence of at least 2 af¬
fected members, at least 1 of whom met the diagnostic criteria for
three of the five cardinal signs [retinal dystrophy with subnormal
ERG, Polydactyly, obesity (body mass index >28 kg/m2), hypogeni¬
talism, and mental retardation], Sibs of affected individuals were
required to meet two instead of three of the cardinal signs. The total
sample consists of 69 affected members from 29 kindreds, 2 of which
contain 2 families with affected children. Parents and unaffected
siblings (N = 78) were also sampled wherever available, making a
total sample of 147 individuals. Parental consanguinity was present
in 6 families (BB7, BB13, BB18, BB20, BB25, and BB31).
Genotyping. Subjects were sampled by venepuncture after ethical
approval and informed consent were obtained. DNA was extracted
by standard methods (Aldred et al., 1994), and polymorphic microsat-
ellites were analyzed using a semiautomated method of linkage anal¬
ysis with an automated sequencer (ALF, Pharmacia) and single fluo-
rescein-labeled primer, as described (Mansfield et al., 1994).
Linkage and heterogeneity analyses. Linkage analysis was car¬
ried out by multipoint analysis using the LINKAGE program pack¬
age (LINKMAP) (Lathrop et al., 1984). LINKMAP was used to obtain
multipoint lod scores by means of a series of three-point analyses on
adjacent loci moving along one locus at a time. A linear genetic map
over equally spaced fixed points on each chromosome was derived
from these lod scores and used for the analysis. The genetic distances
of the loci were taken from published data. Heterogeneity analysis
was carried out using either the HOMOG program package (Terwil-
liger and Ott, 1994) or a Fortran program that located the maximum
of the total lod score using the formulas employed by HOMOG. The
following markers were typed: D2S126, D2S207, D2S139, D2S138,
D2S119, D2S114, D2S141, D2S206, D2S168, D2S171, D2S134,
D2S155, D2S140, D2S160, D3S1271, D3S1276, D3S1251, D11S480,
D11S987, D11S913, D11S916, D11S527, D11S906, D11S901,
D15S125, D15S131, D15S204, D15S114, D16S408, D16S400,
D16S421, D17S799, D17S784, D17S796, D17S798, D17S807, and
D17S849.
RESULTS
Chromosome 11 (BBS1) Linkage and Heterogeneity
Analyses
The results of multipoint linkage analysis in 29
Bardet—Biedl syndrome families, using seven micro-
satellites reported to be linked to the BBS1 locus by
Leppert et al. (1994), are shown in Fig. 1. The markers
used were D11S480, D11S913, D11S987, D11S916,
D11S527, D11S906, and D11S901. The multipoint lod
scores from the combined family data provide statisti¬
cally significant evidence of linkage, with a maximum
likelihood lod score of 6.26 at a genetic location 5 cM
distal to D11S480 and 3 cM proximal to D11S913/




Heterogeneity analysis using the multipoint data
and HOMOG programs (Terwilliger and Ott, 1994) pro¬
vides statistically significant evidence of genetic heter¬
ogeneity (Table 1), with the maximum lod score of 6.26
obtained under the hypothesis of two loci, one of which
is linked (H2), being 28 times greater than the lod
score, 4.82, assuming a single linked locus (HI) (x2 =
6.64, P = 0.005). The maximum likelihood value occurs
with 56% of the families linked to chromosome 11 when
it is considered singly, or with 36% of families linked
to this locus when all four regions (11, 15, 16, and un¬
linked) are considered simultaneously (Table 1). Haplo-
type analysis was consistent with the estimated condi¬
tional probabilities of linkage in each kindred, showing
that 12 families had a probability >0.5 of linkage to
the BBS1 locus (Table 2).
Chromosome 15 (BBS4) Linkage and Heterogeneity
Analyses
The results of multipoint linkage analysis in 29
Bardet-Biedl syndrome families, using four microsat-
ellites (D15S125, D15S131, D15S204, and D15S114)
from the chromosome 15 region shown to be linked to
BBS (BBS4) by Carmi et al. (1995a), are shown in Fig.
1. The maximum likelihood multipoint lod score is 6.10
at a genetic location 5 cM distal to D15S125 and 2 cM
proximal to D15S131/D15S204 (Fig. 1). The order of
loci is cen-D15S125-5 cM-BBS4-2 cM-D15S131/
D15S204-2.5 cM-D15S114-qter.
Heterogeneity analysis was then carried out and
showed statistically significant genetic heterogeneity
(Table 1). The maximum lod score obtained under the
hypothesis of two loci (H2) is 6.10 compared with 3.84
on the hypothesis (HI) of a single linked locus (180:1,
X2 = 10.39, P = 0.0006). The maximum likelihood oc¬
curs with 35% of families linked to the above locus
when chromosome 15 linkage is considered alone, or
32% of families when all four possible loci are consid¬
ered together. Eight families show a conditional proba¬
bility >0.5 of linkage to BBS4 on the basis ofmultipoint
lod scores (Table 2), which is consistent with the haplo-
type analysis (not shown). Three of these families (BB7,
BB18, and BB31) contain the offspring of consanguine¬
ous marriages, and in each case there is marker homo¬
zygosity spanning three adjacent chromosome 15
markers (D15S125, D15S204, and D15S131), indicat¬
ing identity by descent and resulting in significantly
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FIG. 1. Multipoint lod scores in Bardet-Biedl families corresponding to different possible genetic locations (in centimorgans from the
distal short arm) for the disease locus in relation to markers from chromosomes 11, 15, and 16.
higher lod scores (1.69, 2.37, and 2.85) than in noncon-
sanguineous families. Haplotype analysis in consan¬
guineous family BB31 (Fig. 2) shows two informative
crossovers that help to localize the disease locus fur¬
ther. A crossover in affected male 31A places BBS4
proximal to D15S114; a second crossover in unaffected
female 31B places BBS4 distal to D15S131. The dis¬
tance between D15S114 and D15S131 is about 2 cM
(Dib et al., 1996).
The average lod score for the six consanguineous
families, taken at the maximum likelihood chromo¬
somal location, was 1.59 compared with 0.57 for the
remaining families (excluding only BB8, which showed
negative lod scores at each BBS locus). This empha-
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TABLE 1





(max likelihood lod score) Linkage hypothesis (y2; P value)
Chromosome 11 0.36 (0.56) 66 cM
(6.26)
H2 vs HO (x2 = 28.84;P = 0.0000)
H2 vs HI (x2 = 6.64; P = 0.005)
Chromosome 15 0.32 (0.35) 94 cM
(6.10)
H2 vs HO (x2 = 28.07, P = 0.0000);
H2 vs HI (x2 = 10.39, P = 0.0006)
Chromosome 16 0.24 (0.27) 76 cM
(1.09)
H2 vs HO (x2 = 5.02; P = 0.041)
H2 vs HI (x2 = 3.50; P = 0.031)
Note. The linkage hypotheses are H2—two disease loci, only one of which is linked to the markers; HI—one disease locus linked to the
markers; and HO—null hypothesis of no linkage. The genetic location is shown in centimorgans (cM) from the distal short arm of the
chromosome based on the location of markers described by Gyapay et al. (1994). The proportion of linked families was calculated by testing
for linkage to all three loci versus nonlinkage simultaneously or individually (in parentheses).
sizes the greater utility of consanguineous families for
mapping recessive disorders.
Chromosome 16 (BBS2) Linkage and Heterogeneity
Analyses
The results of linkage analysis in 29 BBS families,
using markers D16S408, D16S400, and D16S421,
which are close to the BBS2 locus (Kwitek-Black et al.,
1993), are shown in Fig. 1. The maximum likelihood
lod score is 1.09 under the hypothesis of genetic hetero¬
geneity (H2) (x2 = 5.02, P = 0.04), a result of borderline
significance (Table 1). Under the hypothesis of hetero¬
geneity, 27% of families are estimated to be linked to
this site when chromosome 16 linkage is considered
alone, compared with 24% when all four locations are
considered jointly. The estimated gene location is cen-
D16S408-2 cM-BBS2-5 cM-D16S400-4 cM-
D16S421-qter.
Haplotype and conditional probability analyses show
that only two families have a probability >0.5 of link¬
age to BBS2 (Table 2), although two additional families
have probabilities of linkage >0.4 for chromosome 16,
which is higher than that for any other site.
Chromosomal Exclusions
One family, BB8, shows negative lod scores at each
BBS locus, with lod scores of -2.31, -2.09, and —1.4
at the maximum likelihood locations for the chromo¬
some 11, 15, and 16 marker regions. Three other fami¬
lies show lod scores «0.10 for all three regions. These
results indicate that at least one other BBS locus re¬
mains to be mapped.
Sixteen markers distributed on chromosomes 2, 3,
and 17 were analyzed for linkage to BBS. Strongly neg¬
ative lod scores were obtained (data not shown) in each
case, excluding the BBS3 locus and a proposed site on
either chromosome 2 or 17 corresponding to the
breakpoints of a balanced translocation in a BBS pa¬
tient (Dallapiccola, 1971).
DISCUSSION
Bardet-Biedl syndrome has proved to be genetically
very heterogeneous for such a comparatively rare disor¬
der. The initial linkage ofBBS tomarkers from chromo¬
somal region 16q21 (BBS2) was made in a single inbred
Bedouin kindred by Kwitek-Black et al. (1993). Other
inbred families from the Middle East failed to show
linkage, and the disease in these families was later
mapped to loci in chromosomal regions 3pl3-pl2
(BBS3) and 15q22.3-q23 (BBS4) (Sheffield et al., 1994;
Carmi et al., 1995a). The only reported linkage study
of BBS in a mixed population of families is that of
Leppert et al. (1994), who found evidence of genetic
heterogeneity with linkage to markers from chromo¬
somal region llql3 (BBS1) in 17 of 31 North American
families, which were similar in size and ethnic origin
to those used in this study. The results of the present
study from an ethnically diverse, predominantly Euro¬
pean group of 29 families are very similar to those of
Leppert et al. (1994) with regard to the llql3 locus.
Our data confirm the BBS1 locus as the most common
site of mutation in Bardet-Biedl syndrome, with an
observed 36-56% of families having mutations at this
locus (Table 1).
The precise genetic location of BBS1 is difficult to
establish with certainty since recombination events in
individual small families, which might refine the local¬
ization, cannot be distinguished from nonlinkage due to
heterogeneity. Nevertheless, the location of BBS1 iden¬
tified in this study is very similar to that of Leppert et
al. (1994). The maximum likelihood location of the BBS1
locus is 3 cM proximal to D11S913 (Fig. 1), which com¬
pares well with the estimate of 5 cM from D11S913 in
a subset of 17 PYGM-linked families. The Utah/Houston
group found the PYGM marker to be apparently closer
than D11S913 to BBS1, although this probably occurred
only because this marker is less informative than
D11S913, which is estimated to be 3 cM distal to PYGM
(Quackenbush et al., 1995) and was found to segregate
together with the latter in 39 families (Leppert et al.,
1994). The statistical significance of our BBS1 linkage
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TABLE 2
Exclusion or Inclusion of Linkage to Bardet-Biedl
Syndrome Loci on Chromosomes 11 (BBS1), 15 (BBS4),
and 16 (BBS2) in Individual Families Based on the Con¬
ditional Probabilities of Linkage Calculated by the
HOMOG Program from Multipoint Linkage Data
Linkage Linkage
Ethnic exclusion inclusion
Family origin P < 0.10 P > 0.5
BB1 UK 15 (0.04) 11 (0.75)
BB2 UK 11 (0.03) 15 (0.52)
BB4 UK 11 (0.03) 16 (0.50)
BB5 UK 11 (0.51)
BB6 UK 15 (0.00) 11 (0.97)
16 (0.01)
BB7* UK 11 (0.00) 15 (0.98)
16 (0.01)





BB12 Norway 11 (0.54)
BB13" Norway 16 (0.10) 11 (0.72)
BB14 Norway 16 (0.01) 11 (0.54)
BB15 UK 16 (0.03) 11 (0.51)
BB17 UK 15 (0.01) 11 (0.87)
16 (0.04)
BB18" Norway 11 (0.04) 15 (0.95)
16 (0.00)
BB19 UK 16 (0.03) 15 (0.64)
BB20" Egypt 15 (0.10) 11 (0.78)
16 (0.02)
BB21 UK 15 (0.02) 11 (0.85)
16 (0.05)
BB22 Sweden 11 (0.03) 16 (0.55)
BB23 Denmark 16 (0.07) 11 (0.62)
BB24 Denmark 15 (0.02) 11 (0.61)
BB25/26" Denmark 11 (0.01)
16 (0.04)
BB27 Denmark 16 (0.03)
BB28 Norway 11 (0.08)
BB29 Italy 11 (0.01) 15 (0.97)
16 (0.01)
BB30 Sweden 11 (0.05) 15 (0.83)
16 (0.07)
BB31" Norway 11 (0.06) 15 (0.94)
16 (0.00)
BB32 Somalia 11 (0.08) 15 (0.57)
Note. The probability of linkage to the chromosome indicated is
given in parentheses.
" A consanguineous family.
data (lod score 6.26, x2 = 28.84, 2 df; P < 0.0001) pro¬
vides convincing evidence of a locus in this region. A
very large series of BBS families (—100) could provide
narrower confidence limits, but the identification of fur¬
ther consanguineous pedigrees linked to this region pro¬
vides the most promising approach. A report by Cornier
et al. (1995) describes two large inbred Puerto Rican
families that show homozygosity for chromosome 11
markers and share a common haplotype between the
PYGM and the GATA8A08 loci, which are, respectively,
approximately 2 and 12 cM proximal to D11S913.
Possible candidate loci in the llql3 region include
ROM1, estimated to be about 6 cM proximal to our
location for BBS1 (Bascom et al., 1995); the human
homologue of the Drosophila retinal degeneration lo¬
cus, rdgB (Banfi et al., 1996); and the phospholipase C
/33 gene (Lagercrantz et al., 1995). Twelve BBS families
show results consistent with linkage to the BBS1 locus
(Table 2) on which further studies of candidate genes
could be focused.
A locus for BBS on chromosome 15 was also identified
in an observed 32-35% of the 29 BBS families, using
markers shown by Carmi et al. (1995a) to be linked
to BBS4 (Table 1). The two markers showing tightest
linkage to BBS4 in the consanguineous pedigree of
Carmi et al. (1995a) were D15S131 and D15S204, nei¬
ther ofwhich showed any recombination. In the present
study, multipoint heterogeneity analysis supports a lo¬
cus for BBS4 at 2 cM proximal to these markers (Fig.
1). The statistical support for a locus on chromosome
15 in addition to one or more unlinked loci (lod score
6.10, x2 = 28.07, 2 df;P < 0.0001) confirms the reported
linkage to this chromosomal region. Eight BBS families
show results consistent with linkage to the BBS4 locus
(Table 2), 3 of which (BB7, BB18, and BB31) are homo¬
zygous for three adjacent chromosome 15 markers, in¬
dicating identity by descent spanning an estimated 7.5-
cM region (Carmi et al., 1995a; Dib et al., 1996). Haplo¬
type analysis in 1 of the 3 consanguineous families
(BB31, Fig. 2) shows two informative recombinants
placing BBS1 between the D15S131 and the D15S114
loci, a distance of about 2 cM, substantially narrowing
the location of the gene from the 9-cM interval
(D15S125-D15S114) reported by Carmi et al. (1995a).
An observed 24-27% of the families have a BBS lo¬
cus in chromosomal region 16q21 (BBS2) (Table 1). The
maximum multipoint lod score is found at a genetic
location 2 cM distal to D16S408, between this marker
and D16S400 (Fig. 1). This is similar to the findings of
Kwitek-Black et al. (1993), who found no evidence of
recombination within an 18-cM region around
D16S408 between the proximal marker D16S419 and
the distal marker D16S265. The statistical support for
this locus (x2 = 5.02, 2 df;P = 0.041) is, however, much
less convincing than that for the other two loci. This
finding must therefore be regarded as tentative con¬
firmation of the BBS2 locus at a borderline significance
level. This is borne out by the fact that only four fami¬
lies show better evidence for chromosome 16 linkage
than for other chromosomal sites (Table 2).
Are there clinical features that serve to distinguish
the different genetic forms of BBS? The first problem
is to classify such comparatively small families satis¬
factorily. Haplotype analysis and conditional probabili¬
ties of linkage derived from the heterogeneity analysis
yield similar results with regard to classifying individ¬
ual families (Table 2). A lack of recombination in small
families, many with only two affected individuals—
potentially four meioses, two of which determine the
parental linkage phase—provides a rather unsatisfac-





























FIG. 2. Marker haplotypes in consanguineous family BBS31 in
which the affected sons are homozygous for markers D15S125,
D15S131, and D15S204, indicating possible identity by descent. The
recombination events in 31A and 31B support a location for the BBS4
locus between D15S131 and D15S114, a distance of about 2 cM.
tory means of classification. However, the presence of
recombination, particularly if it involves flanking
markers, can effectively exclude a locus. On this basis,
the chromosome 11 locus (BBS1) is excluded in 11 fami¬
lies, the chromosome 15 locus (BBS4) is excluded in 6
families, and the chromosome 16 locus is excluded in
16 families. In one family from Brazil (BB8), all three
loci are excluded, consistent with the view that at least
one other BBS locus remains to be found.
The clinical features in this family do not differ from
those found in families linked to BBS1, BBS2, or BBS4.
Similarly, when two of three loci are excluded and there
is evidence for linkage to a third locus, four families
appear to be linked to BBS1 (BB6, BB17, BB20, and
BB21) and six families to BBS4 (BB7, BB18, BB25/
26, BB29, BB30, and BB31). Again, no clear clinical
distinctions are apparent between the BBS1- and
BBS4-linked families. On the basis of careful examina¬
tion of the available data, there are no reliable clinical
distinctions among the BBS1, BBS2, and BBS4 loci
or among the unlinked families. Carmi et al. (1995b)
suggested that mutations at the BBS4 locus result in
postaxial Polydactyly predominantly of the upper
limbs, whereas BBS3 (chromosome 3) mutations are
associated with postaxial Polydactyly ofhands and feet.
Similarly, early-onset morbid obesity was more evident
in a large BBS4-linked family than in BBS3 or BBS2
families. These observations could not be confirmed in
this set of families, suggesting that the findings of
Carmi et al. (1995b) could relate more to the specific
mutations or to the inbred genetic background than to
the BBS locus per se.
The genetic diversity of Bardet-Biedl syndrome begs
the question of how to identify specifically the responsi¬
ble loci in the presence of such a high degree of genetic
diversity. One possibility is to identify a patient with a
cytogenetic abnormality involving a BBS locus. A sys¬
tematic cytogenetic survey by Fannemel et al. (1993)
failed to identify chromosomal rearrangements in 22
unrelated BBS patients. The report of a BBS patient
with a balanced translocation t(2p—; 17p+) (Dallapic-
cola, 1971) suggests a possible locus in one of these re¬
gions. However, we typed 14 markers spanning the
length of chromosome 2 and 6 markers spanning chro¬
mosome 17 without finding evidence of linkage to BBS.
The most promising approach, in the absence of such a
rearrangement, is to narrow the region of search for
each BBS locus in extended consanguineous pedigrees.
These pedigrees provide large numbers of meioses that
can be tracked indirectly from the common ancestor by
homozygosity mapping, so that the identification of a
small region of homozygosity in the affected child of
distantly related parents can potentially narrow the in¬
terval to a few megabases of DNA, close enough for an
attempt at positional cloning. Even with the small con¬
sanguineous families analyzed in this study, loss of ho¬
mozygosity for 2 of the markers provides reasonable
grounds for narrowing the search interval to about 2
cM, sufficiently small for a positional cloning effort. This
provides further validation of the approach taken in this
study, namely, a systematic linkage analysis of unse-
lected BBS families with at least two affected members.
This approach not only is essential for determining the
relative frequencies of the different genetic forms but
also can provide convincing evidence for linkage to a
specific locus, particularly within consanguineous fami¬
lies, hence improving the ability to refine the gene local¬
ization. Further efforts to collect consanguineous BBS
families with only two or three affected members, which
are considerably more frequent than extended consan¬
guineous kindreds from isolate populations, would be
an effective means of fine genetic mapping these loci.
Haplotyping of apparently unrelated affected individu¬
als from a small geographic isolate is a third means of
refining the genetic mapping of BBS loci, by making
use of the large numbers ofmeioses since the presumed
common ancestor. Finally, the mutational analysis of
candidate genes in the vicinity of each locus is another
possible route to the identification of BBS genes, but
the high density of identified genes such as expressed
sequence-tagged cDNAs shows that this approach also
needs to be guided by good genetic mapping.
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